<SEC-DOCUMENT>0001493152-22-020362.txt : 20220726
<SEC-HEADER>0001493152-22-020362.hdr.sgml : 20220726
<ACCEPTANCE-DATETIME>20220726171544
ACCESSION NUMBER:		0001493152-22-020362
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		23
CONFORMED PERIOD OF REPORT:	20220722
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220726
DATE AS OF CHANGE:		20220726

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enveric Biosciences, Inc.
		CENTRAL INDEX KEY:			0000890821
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				954484725
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38286
		FILM NUMBER:		221107871

	BUSINESS ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103
		BUSINESS PHONE:		239-302-1707

	MAIL ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERI Holdings, Inc.
		DATE OF NAME CHANGE:	20150527

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SPATIALIZER AUDIO LABORATORIES INC
		DATE OF NAME CHANGE:	19950323
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:ENVB="http://enveric.com/20220722">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_ENVB_enveric.com_20220722 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20220722_20220722 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0000890821 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityCentralIndexKey">0000890821</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="envb-20220722.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-07-22to2022-07-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-22</xbrli:startDate>
        <xbrli:endDate>2022-07-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_900_edei--DocumentType_c20220722__20220722_zkOVs599GS73"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Current
Report</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of the</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_907_edei--DocumentPeriodEndDate_c20220722__20220722_zOPOaJh1jhN4"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">July 22, 2022</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90B_edei--EntityRegistrantName_c20220722__20220722_z5YP3ftP4mxe"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityRegistrantName">Enveric
Biosciences, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of Registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20220722__20220722_z91XYxUjNt4d"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityFileNumber_c20220722__20220722_zepXlHFvjT12"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityFileNumber">001-38286</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20220722__20220722_ztsyyNCOSlTb"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityTaxIdentificationNumber">95-4484725</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
                                            or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    No.)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
                                            Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20220722__20220722_z8pWVYnus8Fb"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityAddressAddressLine1">Enveric
Biosciences, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityAddressAddressLine2_c20220722__20220722_z1NscF89smfj"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityAddressAddressLine2">4851
Tamiami Trail N</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressAddressLine3_c20220722__20220722_zAnBKPfs43og"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityAddressAddressLine3">Suite 200</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20220722__20220722_zSYxBaLxXRyg"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityAddressCityOrTown">Naples</ix:nonNumeric></span>,
<span id="xdx_903_edei--EntityAddressStateOrProvince_c20220722__20220722_z3yMn4lmySAa"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span> <span id="xdx_909_edei--EntityAddressPostalZipCode_c20220722__20220722_zMSE28k3LBZb"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityAddressPostalZipCode">34103</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of principal executive offices and zip code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_903_edei--CityAreaCode_c20220722__20220722_zX2KsHJO4lbk"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:CityAreaCode">(239)</ix:nonNumeric></span> <span id="xdx_907_edei--LocalPhoneNumber_c20220722__20220722_zvKVINwVoafj"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:LocalPhoneNumber">302-1707</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
name or former address, if changed since last report.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--WrittenCommunications_c20220722__20220722_zzUytIFu7MEb"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--SolicitingMaterial_c20220722__20220722_z6VRPRYl9qQ6"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20220722__20220722_zYCbE8CJ5Et2"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20220722__20220722_zRoJvk0VkMcl"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20220722__20220722_zfBE0kCu4Wu4"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:Security12bTitle">Common
    stock, par value $0.01 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--TradingSymbol_c20220722__20220722_zwK1Jm3l9Eo5"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:TradingSymbol">ENVB</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--SecurityExchangeName_c20220722__20220722_zZCfuXcsljj9"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_906_edei--EntityEmergingGrowthCompany_c20220722__20220722_zkXme93eO6v"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry
    Into a Material Definitive Agreement</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, Enveric Biosciences, Inc. (the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Registered
Direct Securities Purchase Agreement&#8221;) with an institutional investor for the purchase and sale of 116,500 shares of the Company&#8217;s
common stock (&#8220;Common Stock&#8221;), pre-funded warrants to purchase up to 258,500 shares of Common Stock (the &#8220;RD Pre-Funded
Warrants&#8221;), and unregistered preferred investment options (the &#8220;RD Preferred Investment Options&#8221;) to purchase up to
375,000 shares of Common Stock (the &#8220;RD Offering&#8221;). The combined purchase price for one share of Common Stock and associated
RD Preferred Investment Option is $8.00 and for a RD Pre-Funded Warrant and associated RD Preferred Investment Option is $7.9999. The
RD Preferred Investment Options have an exercise price of $7.78 per share, are immediately exercisable, and will expire five and one-half
years from the date of issuance. Shares of Common Stock and RD Pre-Funded Warrants issued in the RD Offering were offered pursuant to
a &#8220;shelf&#8221; registration statement on Form S-3 (File No. 333-257690) previously filed with the Securities and Exchange Commission
(the &#8220;SEC&#8221;) on July 2, 2021 and declared effective by the SEC on July 9, 2021, and a prospectus supplement, dated July 22,
2022, to the shelf registration statement, filed with the SEC on July 26, 2022. The gross proceeds from RD Offering was approximately
$3,000,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with the RD Offering, the Company entered into a securities purchase agreement (the &#8220;PIPE Securities Purchase Agreement&#8221;)
with institutional investors for the purchase and sale of 116,000 shares of Common Stock, pre-funded warrants to purchase up to 509,000
shares of Common Stock (the &#8220;PIPE Pre-Funded Warrants&#8221;), and preferred investment options (the &#8220;PIPE Preferred Investment
Options&#8221;) to purchase up to 625,000 shares of the Common Stock in a private placement (the &#8220;PIPE&#8221;). The combined purchase
price for one share of Common Stock and associated PIPE Preferred Investment Option is $8.00 and for a PIPE Pre-Funded Warrant and associated
PIPE Preferred Investment Option is $7.9999. The PIPE Preferred Investment Options have an exercise price of $7.78 per share, are immediately
exercisable, and will expire five and one-half years from the date of issuance. The gross proceeds from the PIPE was approximately $5,000,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the investors in both offerings, the Company is
required to file a registration statement with the Securities and Exchange Commission (the &#8220;SEC&#8221;) covering the resale of
(i) the shares of the Common Stock issued in the PIPE, the shares of Common Stock issuable upon exercise of the PIPE Pre-Funded Warrants
and shares of Common Stock issuable upon exercise of the PIPE Preferred Investment Options, and (ii) the shares of Common Stock underlying
RD Preferred Investment Options, within 15 days of the date of the Registration Rights Agreement and to use best efforts to have the
registration statement declared effective as promptly as practical, and in any event within 45 days or within 75 days in the event of
a full review by the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the RD Offering and the PIPE, the Company entered into Warrant Amendment Agreements (the &#8220;Warrant Amendments&#8221;)
with the investors in both offerings to amend certain existing warrants to purchase up to an aggregate of 122,000 shares of Common Stock
that were previously issued to the investors, with an exercise price of $27.50 per share and expiration date of February 15, 2027. Pursuant
to the Warrant Amendments, the previously issued warrants were amended, effective upon the closing of the offerings, so that the amended
warrants have a reduced exercise price of $7.78 per share and expire five and one-half years following the closing of the offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RD Offering and the PIPE closed on July 26, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds received from the offerings for general working capital purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) acted as the exclusive placement agent for the RD Offering and the PIPE, pursuant
to the engagement letter with the Company, dated as of July 11, 2022. Upon closing of the offerings, the Company paid Wainwright a cash
transaction fee equal to 7.0% of the aggregate gross proceeds to us from the offerings and reimbursement of certain expenses. The Company
also issued Wainwright preferred investment options to purchase 70,000 shares of Common Stock (the &#8220;Wainwright Warrants&#8221;).
The preferred investment options issued to Wainwright have substantially the same terms as the RD Preferred Investment Options and the
PIPE Preferred Investments Options, except that Wainwright&#8217;s preferred investment options have an exercise price of $10.00 per
share and will expire five years after the commencement of sales of the offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legal opinion of Haynes and Boone, LLP relating to the legality of the issuance and sale of the securities in the RD Offering is attached
as Exhibit 5.1 to this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the Registered Direct Securities Purchase Agreement, RD Preferred Investment Options, RD Pre-Funded Warrants,
PIPE Securities Purchase Agreement, PIPE Preferred Investment Options, PIPE Pre-Funded Warrants, Registration Rights Agreement, Wainwright
Warrants and Warrant Amendments do not purport to be complete and are qualified in their entirety by the full text of the form of Registered
Direct Purchase Agreement, form of RD Preferred Investment Option, form of RD Pre-Funded Warrant, form of PIPE Securities Purchase Agreement,
form of PIPE Preferred Investment Options, form of PIPE Pre-Funded Warrants, form of Registration Rights Agreement, form of Wainwright
Warrants and form of Warrant Amendments, attached hereto as Exhibits 10.1, 4.3, 4.1, 10.2, 4.4, 4.2, 10.3, 4.5 and 10.4, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.75in">Item 3.02</td>
    <td style="font-weight: bold">Unregistered Sales of Equity Securities.</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in Item 1.01 of this Current Report on Form 8-K in relation to (i) the RD Preferred Investment Options, (ii) Common
Stock issued pursuant to the PIPE, (iii) PIPE Preferred Investment Options, (iv) Wainwright Warrants, (v) PIPE Pre-Funded Warrants, (vi)
Common Stock issuable upon exercise of the PIPE Preferred Investment Options, (vii) Common Stock issuable upon exercise of the PIPE Pre-Funded
Warrants and (viii) Common Stock issuable upon exercise of the Wainwright Warrants is incorporated herein by reference. Neither the issuance
of the (i) the RD Preferred Investment Options, (ii) Common Stock issued pursuant to the PIPE, (iii) PIPE Preferred Investment Options,
(iv) Wainwright Warrants, (v) PIPE Pre-Funded Warrants, (vi) Common Stock issuable upon exercise of the PIPE Preferred Investment Options,
(vii) Common Stock issuable upon exercise of the PIPE Pre-Funded Warrants and (vi) Common Stock issuable upon exercise of the Wainwright
Warrants was registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) or any state securities laws.
The issuance of such securities was in reliance on the exemptions from registration provided by Section 4(a)(2) under the Securities
Act and Regulation D promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    8.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
    Events.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 25, 2022, the Company issued a press release announcing the pricing of the $8 million registered direct and private placement
offerings, priced at a premium to market under NASDAQ rules. A copy of the press release is attached as Exhibit 99.1 to this Current
Report on Form 8-K and is hereby incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    Statements and Exhibits</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of RD Pre-Funded Warrant</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex4-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of PIPE Pre-Funded Warrant</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex4-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of RD Preferred Investment Option</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex4-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of PIPE Preferred Investment Option</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex4-5.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Wainwright Warrant</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Opinion of Haynes and Boone, LLP</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Registered Direct Securities Purchase Agreement</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of PIPE Securities Purchase Agreement</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Registration Rights Agreement</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant Amendment</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Haynes and Boone, LLP (contained in Exhibit 5.1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, issued July 25, 2022</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* *</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ENVERIC
    BIOSCIENCES, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
26, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Joseph Tucker</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5lv5EVOijRUWsIkXE12hXCbbZsolVj+QtTVvEZWFZZr4ZIUZiRUtdIcNpXuRwwLqplEMo8IqM5oLeka03Kfhb4E1bx8q4/v2BGXkGPTMJk8nZC7211RbLFOJZJKeRlBCPUzmF/VYEnZ6RueoSjdOqAmVK2DM1rNEpfg8JB/UiQ/W7rzoiW00mhSSMB/kDMk4k7KhVT+K7hTzPRDDqJxArpkfT1TysoxoWFda+yw7of4MvHNBJUQ== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRE-FUNDED
COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares: _______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    Date: July 26, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date: July 26, 2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its
assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and until this Warrant is
exercised in full (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Enveric Biosciences,
Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant
Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated July 22, 2022, among the Company and the purchasers
signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this
Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the
date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a
portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this
Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated
on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share,
was pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the
nominal exercise price of $0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise
of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise
price under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to
the Termination Date. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.0001, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo;
in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by
(A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
= as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and
delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in
Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either
(y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common
Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading
hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if
the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a)
hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
= the Exercise Price of this Warrant, as adjusted hereunder; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><U>&ldquo;Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&ldquo;<U>VWAP</U>&rdquo;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, for any date, the price determined by the first
of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then
listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)),
(b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices
for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share
of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities
then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery
of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant
Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by
the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading
Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement
Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share
Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the
Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000
of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise),
$10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading
Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees
to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As
used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days,
on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of
Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City
time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company
agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the
Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed
with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of
a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of
this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership
Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this
paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one
or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share
exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v)
the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another
Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or
more of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such
exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation
in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of
the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor
entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in
writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions
of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder
(without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange
for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to
this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity)
equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on
the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder
to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the
purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and
which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor
Entity shall be added to the term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of
such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo;
shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor
Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto
and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and
the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally,
had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant
and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined
in accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall
be delivered in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on
the one hand, and the Holder of this Warrant, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric Biosciences, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:
<B>Enveric Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
&nbsp;] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
&nbsp;] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless
exercise procedure set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase
shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:______________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:_______________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ex4-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRE-FUNDED
COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Shares: _______</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue Date: July 26, 2022</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Initial
Exercise Date: July 26, 2022</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its
assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and until this Warrant is
exercised in full (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Enveric Biosciences,
Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant
Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated July 22, 2022, among the Company and the
purchasers signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this
Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable of
the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this
Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated
on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share, was pre-funded
to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise
price of $0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant.
The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any
circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination
Date. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.0001, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Cashless
Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in
which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A),
where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
= as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and
delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in
Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either
(y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common
Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading
hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if
the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a)
hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
= the Exercise Price of this Warrant, as adjusted hereunder; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>&ldquo;Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant
Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this
Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Mechanics
of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust
Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such
system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the
Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations
pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in
the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is
entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest
of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the
aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery
to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice
of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect
to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for
any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company
shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per
Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date
until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant
in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by
its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and
such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed
with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of
a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of
this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership
Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this
paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in
one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the
Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares
for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or
more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or more of the voting power of the common
equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the
Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to
the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the
exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is
the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and
the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all
of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section
3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable
delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant
a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which
is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the
shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of
this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares
of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and
the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory
in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to
the term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction,
each and every provision of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead
to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor
Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity
or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents
with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the
Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f) <U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of
all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall
appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of
Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights)
are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent,
together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent
or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers
an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Transfer
Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this
Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable
state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information
requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of
this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to
Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required
to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of
this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which
results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs
and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the
Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h) <U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and
the Holder of this Warrant, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)<BR STYLE="clear: both">
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD COLSPAN="2"><B>Enveric Biosciences, Inc.</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt"></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%"></TD>
    <TD STYLE="width: 5%">Name:&#8239;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 45%"></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>Title:</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt"> </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To: <B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#8239;&#8239;] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#8239;&#8239;] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4) <U>Accredited
Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the Securities Act
of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase
shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 7%">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%; text-align: justify"></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>Address:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(Please
Print)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2">Phone Number: </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2">Email Address: </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2">Dated:   ______________</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2">Holder&rsquo;s Signature:  _____________</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2">Holder&rsquo;s Address: _____________</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>ex4-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH
THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO
AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PREFERRED INVESTMENT OPTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    Investment Option Shares: ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    Date: July 26, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date: July 26, 2022</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">THIS PREFERRED INVESTMENT OPTION
(the &ldquo;<U>Preferred Investment Option</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on January
26, 2028 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Enveric Biosciences, Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Preferred
Investment Option Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Preferred Investment
Option shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated July 22, 2022, among the Company and the purchasers signatory thereto. In addition,
&ldquo;<U>Akos</U>&rdquo; means Akos Biosciences, Inc. (formerly known as Acanna Therapeutics, Inc.), a majority owned Subsidiary, to
which the Company has previously publicly announced that the Company will transfer the Company&rsquo;s cannabinoid clinical development
pipeline assets, and &ldquo;<U>Spin Off</U>&rdquo; means the Company&rsquo;s spin-off of Akos by way of dividends to the Company&rsquo;s
shareholders, as described in the Company&rsquo;s Form 8-K filed with the Commission on May 11, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Exercise of Preferred
Investment Option</U>. Exercise of the purchase rights represented by this Preferred Investment Option may be made, in whole or in part,
at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly
executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the Preferred Investment Option Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check
drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice
of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Preferred Investment Option to the Company until the Holder has purchased all of the Preferred Investment Option Shares
available hereunder and the Preferred Investment Option has been exercised in full, in which case, the Holder shall surrender this Preferred
Investment Option to the Company for cancellation as soon as reasonably practicable of the date on which the final Notice of Exercise
is delivered to the Company. Partial exercises of this Preferred Investment Option resulting in purchases of a portion of the total number
of Preferred Investment Option Shares available hereunder shall have the effect of lowering the outstanding number of Preferred Investment
Option Shares purchasable hereunder in an amount equal to the applicable number of Preferred Investment Option Shares purchased. The Holder
and the Company shall maintain records showing the number of Preferred Investment Option Shares purchased and the date of such purchases.
The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <B>The Holder
and any assignee, by acceptance of this Preferred Investment Option , acknowledge and agree that, by reason of the provisions of this
paragraph, following the purchase of a portion of the Preferred Investment Option Shares hereunder, the number of Preferred Investment
Option Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Exercise Price</U>.
The exercise price per share of Common Stock under this Preferred Investment Option shall be <B>$7.78</B>, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Cashless Exercise</U>.
If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not
available for the resale of the Preferred Investment Option Shares by the Holder, then this Preferred Investment Option may also be exercised,
in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number
of Preferred Investment Option Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -31.5pt">(A) = as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading
Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading
Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable
Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered
within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day)
pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular
trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in">(B) = the Exercise
Price of this Preferred Investment Option, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -31.5pt">(X) = the number
of Preferred Investment Option Shares that would be issuable upon exercise of this Preferred Investment Option in accordance with the
terms of this Preferred Investment Option if such exercise were by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white"><U>&ldquo;Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;<U>VWAP</U>&rdquo;
</FONT>means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the <FONT STYLE="background-color: white">Purchasers</FONT> of a majority in interest of the Securities then outstanding and
reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Preferred Investment Option Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section
3(a)(9) of the Securities Act, the Preferred Investment Option Shares shall take on the characteristics of the Preferred Investment Options
being exercised, and the holding period of the Preferred Investment Option Shares being issued may be tacked on to the holding period
of this Preferred Investment Option. The Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Delivery of Preferred
Investment Option Shares Upon Exercise</U>. The Company shall cause the Preferred Investment Option Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in
such system and either (A) there is an effective registration statement permitting the issuance of the Preferred Investment Option Shares
to or resale of the Preferred Investment Option Shares by the Holder or (B) the Preferred Investment Option Shares are eligible for resale
by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Preferred Investment
Options), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder
or its designee, for the number of Preferred Investment Option Shares to which the Holder is entitled pursuant to such exercise to the
address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery
to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii)
the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such
date, the &ldquo;<U>Preferred Investment Option Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall
be deemed for all corporate purposes to have become the holder of record of the Preferred Investment Option Shares with respect to which
this Preferred Investment Option has been exercised, irrespective of the date of delivery of the Preferred Investment Option Shares, provided
that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Preferred Investment Option
Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Preferred Investment Option Shares subject to a
Notice of Exercise by the Preferred Investment Option Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated
damages and not as a penalty, for each $1,000 of Preferred Investment Option Shares subject to such exercise (based on the VWAP of the
Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading
Day after the Preferred Investment Option Share Delivery Date) for each Trading Day after such Preferred Investment Option Share Delivery
Date until such Preferred Investment Option Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer
agent that is a participant in the FAST program so long as this Preferred Investment Option remains outstanding and exercisable. As used
herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on
the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Delivery of New
Preferred Investment Options Upon Exercise</U>. If this Preferred Investment Option shall have been exercised in part, the Company shall,
at the request of a Holder and upon surrender of this Preferred Investment Option certificate, at the time of delivery of the Preferred
Investment Option Shares, deliver to the Holder a new Preferred Investment Option evidencing the rights of the Holder to purchase the
unpurchased Preferred Investment Option Shares called for by this Preferred Investment Option, which new Preferred Investment Option shall
in all other respects be identical with this Preferred Investment Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">iii. <U>Rescission Rights</U>.
If the Company fails to cause the Transfer Agent to transmit to the Holder the Preferred Investment Option Shares pursuant to Section
2(d)(i) by the Preferred Investment Option Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Preferred Investment Option Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Preferred Investment Option Shares in accordance
with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Preferred Investment Option Share Delivery Date,
and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s
brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Preferred Investment
Option Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay
in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Preferred Investment Option
Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the
sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of
the Preferred Investment Option and equivalent number of Preferred Investment Option Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Preferred Investment Option as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">v. <U>No Fractional
Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Preferred
Investment Option. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">vi. <U>Charges, Taxes
and Expenses</U>. Issuance of Preferred Investment Option Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Preferred Investment Option Shares, all of which taxes and expenses
shall be paid by the Company, and such Preferred Investment Option Shares shall be issued in the name of the Holder or in such name or
names as may be directed by the Holder; <U>provided</U>, <U>however</U>, that in the event that Preferred Investment Option Shares are
to be issued in a name other than the name of the Holder, this Preferred Investment Option when surrendered for exercise shall be accompanied
by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of
a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day
processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing
similar functions) required for same-day electronic delivery of the Preferred Investment Option Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">vii. <U>Closing of Books</U>.
The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Preferred Investment
Option, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Preferred Investment Option, and a Holder shall not have the
right to exercise any portion of this Preferred Investment Option, pursuant to Section 2 or otherwise, to the extent that after giving
effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the
foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall
include the number of shares of Common Stock issuable upon exercise of this Preferred Investment Option with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Preferred Investment Option beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)
exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation,
any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially
owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this
Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is
in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Preferred Investment
Option is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of
which portion of this Preferred Investment Option is exercisable shall be in the sole discretion of the Holder, and the submission of
a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Preferred Investment Option is exercisable
(in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this
Preferred Investment Option is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no
obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated
above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For
purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the
case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent
setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within
one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the
number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Preferred Investment Option, by the Holder or its Affiliates or Attribution Parties since the date as of which
such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [4.99%/9.99%]
of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable
upon exercise of this Preferred Investment Option. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this
Preferred Investment Option held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial
Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions
of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e)
to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation
herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations
contained in this paragraph shall apply to a successor holder of this Preferred Investment Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Stock Dividends
and Splits</U>. If the Company, at any time while this Preferred Investment Option is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Preferred Investment Option), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by
a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event,
and the number of shares issuable upon exercise of this Preferred Investment Option shall be proportionately adjusted such that the aggregate
Exercise Price of this Preferred Investment Option shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and
shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Subsequent Rights
Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common
Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares
of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to
such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of
Common Stock acquirable upon complete exercise of this Preferred Investment Option (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that to the extent that
the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the
Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Pro Rata Distributions</U>.
During such time as this Preferred Investment Option is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Preferred Investment Option, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Preferred Investment Option (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record
is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution
(<U>provided</U>, <U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Distribution would result
in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution
to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the
portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would
not result in the Holder exceeding the Beneficial Ownership Limitation). For purposes of clarity, the Spin Off shall not be a Distribution
for purposes of this Section 3(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Fundamental Transaction</U>.
If, at any time while this Preferred Investment Option is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly
or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of
its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their
shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50%
or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or more of the voting power of the common
equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Preferred Investment
Option, the Holder shall have the right to receive, for each Preferred Investment Option Share that would have been issuable upon such
exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation
in Section 2(e) on the exercise of this Preferred Investment Option), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Preferred Investment
Option is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise
of this Preferred Investment Option). For purposes of clarity, the Spin Off shall not be a Fundamental Transaction for purposes of this
Section 3(d). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Preferred Investment Option following such Fundamental Transaction. Notwithstanding anything to
the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s
option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later,
the date of the public announcement of the applicable contemplated Fundamental Transaction), purchase this Preferred Investment Option
from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised
portion of this Preferred Investment Option on the date of the consummation of such Fundamental Transaction; provided, however, that if
the Fundamental Transaction is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors,
Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same
proportion), at the Black Scholes Value of the unexercised portion of this Preferred Investment Option, that is being offered and paid
to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form
of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative
forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company
are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received
common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.
&ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Preferred Investment Option based on the Black Scholes Option Pricing
Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation of the applicable Fundamental
Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal
to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date,
(B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined
utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated
Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price
per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction
and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable
contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading
Day of the Holder&rsquo;s request pursuant to this Section 3(d) and (D) a remaining option time equal to the time between the date of
the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow.
The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within
the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction. The
Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Preferred Investment Option and the other Transaction
Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory
to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of
the Holder, deliver to the Holder in exchange for this Preferred Investment Option a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Preferred Investment Option which is exercisable for a corresponding number
of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable
upon exercise of this Preferred Investment Option (without regard to any limitations on the exercise of this Preferred Investment Option)
prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital
stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value
of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the
economic value of this Preferred Investment Option immediately prior to the consummation of such Fundamental Transaction), and which is
reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity
shall be added to the term &ldquo;Company&rdquo; under this Preferred Investment Option (so that from and after the occurrence or consummation
of such Fundamental Transaction, each and every provision of this Preferred Investment Option and the other Transaction Documents referring
to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally),
and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company
prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this
Preferred Investment Option and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor
Entities, jointly and severally, had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment to
Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver
to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Preferred
Investment Option Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Notice to Allow
Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock,
(B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize
the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class
or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the
Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or
substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or
property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the
Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear
upon the Preferred Investment Option Register of the Company, at least 20 calendar days prior to the applicable record or effective date
hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Preferred Investment Option constitutes, or contains, material,
non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Preferred Investment Option during the period
commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set
forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Preferred Investment Option</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of
Section 4.1 of the Purchase Agreement, this Preferred Investment Option and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Preferred Investment Option at the principal office of the Company
or its designated agent, together with a written assignment of this Preferred Investment Option substantially in the form attached hereto
duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Preferred Investment Option or Preferred
Investment Options in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such
instrument of assignment, and shall issue to the assignor a new Preferred Investment Option evidencing the portion of this Preferred Investment
Option not so assigned, and this Preferred Investment Option shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Preferred Investment Option to the Company unless the Holder has assigned
this Preferred Investment Option in full, in which case, the Holder shall surrender this Preferred Investment Option to the Company within
three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Preferred Investment
Option in full. The Preferred Investment Option, if properly assigned in accordance herewith, may be exercised by a new holder for the
purchase of Preferred Investment Option Shares without having a new Preferred Investment Option issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>New Preferred
Investment Options</U>. This Preferred Investment Option may be divided or combined with other Preferred Investment Options upon presentation
hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Preferred
Investment Options are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any
transfer which may be involved in such division or combination, the Company shall execute and deliver a new Preferred Investment Option
or Preferred Investment Options in exchange for the Preferred Investment Option or Preferred Investment Options to be divided or combined
in accordance with such notice. All Preferred Investment Options issued on transfers or exchanges shall be dated the Issue Date of this
Preferred Investment Option and shall be identical with this Preferred Investment Option except as to the number of Preferred Investment
Option Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Preferred Investment
Option Register</U>. The Company shall register this Preferred Investment Option, upon records to be maintained by the Company for that
purpose (the &ldquo;<U>Preferred Investment Option Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The
Company may deem and treat the registered Holder of this Preferred Investment Option as the absolute owner hereof for the purpose of any
exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Transfer Restrictions</U>.
If, at the time of the surrender of this Preferred Investment Option in connection with any transfer of this Preferred Investment Option,
the transfer of this Preferred Investment Option shall not be either (i) registered pursuant to an effective registration statement under
the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale
restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such
transfer, that the Holder or transferee of this Preferred Investment Option, as the case may be, comply with the provisions of Section
5.7 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Preferred Investment Option
and, upon any exercise hereof, will acquire the Preferred Investment Option Shares issuable upon such exercise, for its own account and
not with a view to or for distributing or reselling such Preferred Investment Option Shares or any part thereof in violation of the Securities
Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>No Rights as Stockholder
Until Exercise; No Settlement in Cash</U>. This Preferred Investment Option does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Preferred Investment Option Shares on a &ldquo;cashless exercise&rdquo;
pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company
be required to net cash settle an exercise of this Preferred Investment Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Loss, Theft, Destruction
or Mutilation of Preferred Investment Option</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Preferred Investment Option or any stock certificate relating to the Preferred
Investment Option Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in
the case of the Preferred Investment Option, shall not include the posting of any bond), and upon surrender and cancellation of such Preferred
Investment Option or stock certificate, if mutilated, the Company will make and deliver a new Preferred Investment Option or stock certificate
of like tenor and dated as of such cancellation, in lieu of such Preferred Investment Option or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Saturdays, Sundays,
Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein
shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 1in">The Company covenants that,
during the period the Preferred Investment Option is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Preferred Investment Option Shares upon the exercise of any purchase rights under
this Preferred Investment Option. The Company further covenants that its issuance of this Preferred Investment Option shall constitute
full authority to its officers who are charged with the duty of issuing the necessary Preferred Investment Option Shares upon the exercise
of the purchase rights under this Preferred Investment Option. The Company will take all such reasonable action as may be necessary to
assure that such Preferred Investment Option Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Preferred Investment
Option Shares which may be issued upon the exercise of the purchase rights represented by this Preferred Investment Option will, upon
exercise of the purchase rights represented by this Preferred Investment Option and payment for such Preferred Investment Option Shares
in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created
by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">Except and to the extent
as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Preferred Investment Option,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Preferred Investment Option against impairment. Without limiting the
generality of the foregoing, the Company will (i) not increase the par value of any Preferred Investment Option Shares above the amount
payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or
appropriate in order that the Company may validly and legally issue fully paid and nonassessable Preferred Investment Option Shares upon
the exercise of this Preferred Investment Option and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations
under this Preferred Investment Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">Before taking any action
which would result in an adjustment in the number of Preferred Investment Option Shares for which this Preferred Investment Option is
exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as
may be necessary from any public regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Preferred Investment Option shall be determined
in accordance with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Preferred Investment Option Shares acquired upon the exercise of this Preferred Investment Option, if
not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities
laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver and
Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver
of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this Preferred
Investment Option or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Preferred
Investment Option, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient
to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>. Any
notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance
with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Limitation of
Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Preferred Investment Option
to purchase Preferred Investment Option Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to
any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted
by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Preferred Investment Option. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Preferred Investment Option and hereby agrees to waive and
not to assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">k) <U>Successors and
Assigns</U>. Subject to applicable securities laws, this Preferred Investment Option and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Preferred Investment Option are intended to be for the benefit of any Holder from time to time of this
Preferred Investment Option and shall be enforceable by the Holder or holder of Preferred Investment Option Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>.
This Preferred Investment Option may be modified or amended or the provisions hereof waived with the written consent of the Company, on
the one hand, and the Holder of this Preferred Investment Option, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Preferred Investment Option shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Preferred Investment Option shall be prohibited by or invalid under applicable law,
such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Preferred Investment Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">n) <U>Headings</U>.
The headings used in this Preferred Investment Option are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Preferred Investment Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Preferred Investment Option to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
    Biosciences, Inc. </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:
<B>Enveric Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Preferred Investment Option Shares of the Company pursuant to the terms of the attached
Preferred Investment Option (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
    &nbsp;] in lawful money of the United States; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
    &nbsp;] if permitted the cancellation of such number of Preferred Investment Option Shares as is necessary, in accordance with the
    formula set forth in subsection 2(c), to exercise this Preferred Investment Option with respect to the maximum number of Preferred
    Investment Option Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Preferred Investment Option Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Investment Option Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing Preferred
Investment Option, execute this form and supply required information. Do not use this form to exercise the Preferred Investment Option
to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Preferred Investment Option and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:____________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:_____________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>5
<FILENAME>ex4-4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH
THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO
AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PREFERRED INVESTMENT OPTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    Investment Option Shares: ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    Date: July 26, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date: July 26, 2022</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">THIS PREFERRED INVESTMENT OPTION
(the &ldquo;<U>Preferred Investment Option</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on January
26, 2028 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Enveric Biosciences, Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Preferred
Investment Option Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Preferred Investment
Option shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated July 22, 2022, among the Company and the purchasers signatory thereto. In addition,
&ldquo;<U>Akos</U>&rdquo; means Akos Biosciences, Inc. (formerly known as Acanna Therapeutics, Inc.), a majority owned Subsidiary, to
which the Company has previously publicly announced that the Company will transfer the Company&rsquo;s cannabinoid clinical development
pipeline assets, and &ldquo;<U>Spin Off</U>&rdquo; means the Company&rsquo;s spin-off of Akos by way of dividends to the Company&rsquo;s
shareholders, as described in the Company&rsquo;s Form 8-K filed with the Commission on May 11, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Exercise of Preferred
Investment Option</U>. Exercise of the purchase rights represented by this Preferred Investment Option may be made, in whole or in part,
at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly
executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the Preferred Investment Option Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check
drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice
of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Preferred Investment Option to the Company until the Holder has purchased all of the Preferred Investment Option Shares
available hereunder and the Preferred Investment Option has been exercised in full, in which case, the Holder shall surrender this Preferred
Investment Option to the Company for cancellation as soon as reasonably practicable of the date on which the final Notice of Exercise
is delivered to the Company. Partial exercises of this Preferred Investment Option resulting in purchases of a portion of the total number
of Preferred Investment Option Shares available hereunder shall have the effect of lowering the outstanding number of Preferred Investment
Option Shares purchasable hereunder in an amount equal to the applicable number of Preferred Investment Option Shares purchased. The Holder
and the Company shall maintain records showing the number of Preferred Investment Option Shares purchased and the date of such purchases.
The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <B>The Holder
and any assignee, by acceptance of this Preferred Investment Option , acknowledge and agree that, by reason of the provisions of this
paragraph, following the purchase of a portion of the Preferred Investment Option Shares hereunder, the number of Preferred Investment
Option Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Exercise Price</U>.
The exercise price per share of Common Stock under this Preferred Investment Option shall be <B>$7.78</B>, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Cashless Exercise</U>.
If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not
available for the resale of the Preferred Investment Option Shares by the Holder, then this Preferred Investment Option may also be exercised,
in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number
of Preferred Investment Option Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -31.5pt">(A) = as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading
Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading
Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable
Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered
within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day)
pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular
trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in">(B) = the Exercise
Price of this Preferred Investment Option, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -31.5pt">(X) = the number
of Preferred Investment Option Shares that would be issuable upon exercise of this Preferred Investment Option in accordance with the
terms of this Preferred Investment Option if such exercise were by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white"><U>&ldquo;Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;<U>VWAP</U>&rdquo;
</FONT>means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the <FONT STYLE="background-color: white">Purchasers</FONT> of a majority in interest of the Securities then outstanding and
reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Preferred Investment Option Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section
3(a)(9) of the Securities Act, the Preferred Investment Option Shares shall take on the characteristics of the Preferred Investment Options
being exercised, and the holding period of the Preferred Investment Option Shares being issued may be tacked on to the holding period
of this Preferred Investment Option. The Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Delivery of Preferred
Investment Option Shares Upon Exercise</U>. The Company shall cause the Preferred Investment Option Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in
such system and either (A) there is an effective registration statement permitting the issuance of the Preferred Investment Option Shares
to or resale of the Preferred Investment Option Shares by the Holder or (B) the Preferred Investment Option Shares are eligible for resale
by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Preferred Investment
Options), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder
or its designee, for the number of Preferred Investment Option Shares to which the Holder is entitled pursuant to such exercise to the
address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery
to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii)
the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such
date, the &ldquo;<U>Preferred Investment Option Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall
be deemed for all corporate purposes to have become the holder of record of the Preferred Investment Option Shares with respect to which
this Preferred Investment Option has been exercised, irrespective of the date of delivery of the Preferred Investment Option Shares, provided
that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Preferred Investment Option
Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Preferred Investment Option Shares subject to a
Notice of Exercise by the Preferred Investment Option Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated
damages and not as a penalty, for each $1,000 of Preferred Investment Option Shares subject to such exercise (based on the VWAP of the
Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading
Day after the Preferred Investment Option Share Delivery Date) for each Trading Day after such Preferred Investment Option Share Delivery
Date until such Preferred Investment Option Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer
agent that is a participant in the FAST program so long as this Preferred Investment Option remains outstanding and exercisable. As used
herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on
the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Delivery of New
Preferred Investment Options Upon Exercise</U>. If this Preferred Investment Option shall have been exercised in part, the Company shall,
at the request of a Holder and upon surrender of this Preferred Investment Option certificate, at the time of delivery of the Preferred
Investment Option Shares, deliver to the Holder a new Preferred Investment Option evidencing the rights of the Holder to purchase the
unpurchased Preferred Investment Option Shares called for by this Preferred Investment Option, which new Preferred Investment Option shall
in all other respects be identical with this Preferred Investment Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">iii. <U>Rescission Rights</U>.
If the Company fails to cause the Transfer Agent to transmit to the Holder the Preferred Investment Option Shares pursuant to Section
2(d)(i) by the Preferred Investment Option Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Preferred Investment Option Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Preferred Investment Option Shares in accordance
with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Preferred Investment Option Share Delivery Date,
and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s
brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Preferred Investment
Option Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay
in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Preferred Investment Option
Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the
sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of
the Preferred Investment Option and equivalent number of Preferred Investment Option Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Preferred Investment Option as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">v. <U>No Fractional
Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Preferred
Investment Option. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">vi. <U>Charges, Taxes
and Expenses</U>. Issuance of Preferred Investment Option Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Preferred Investment Option Shares, all of which taxes and expenses
shall be paid by the Company, and such Preferred Investment Option Shares shall be issued in the name of the Holder or in such name or
names as may be directed by the Holder; <U>provided</U>, <U>however</U>, that in the event that Preferred Investment Option Shares are
to be issued in a name other than the name of the Holder, this Preferred Investment Option when surrendered for exercise shall be accompanied
by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of
a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day
processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing
similar functions) required for same-day electronic delivery of the Preferred Investment Option Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">vii. <U>Closing of Books</U>.
The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Preferred Investment
Option, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Preferred Investment Option, and a Holder shall not have the
right to exercise any portion of this Preferred Investment Option, pursuant to Section 2 or otherwise, to the extent that after giving
effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the
foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall
include the number of shares of Common Stock issuable upon exercise of this Preferred Investment Option with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Preferred Investment Option beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)
exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation,
any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially
owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this
Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is
in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Preferred Investment
Option is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of
which portion of this Preferred Investment Option is exercisable shall be in the sole discretion of the Holder, and the submission of
a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Preferred Investment Option is exercisable
(in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this
Preferred Investment Option is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no
obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated
above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For
purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the
case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent
setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within
one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the
number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Preferred Investment Option, by the Holder or its Affiliates or Attribution Parties since the date as of which
such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [4.99%/9.99%]
of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable
upon exercise of this Preferred Investment Option. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this
Preferred Investment Option held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial
Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions
of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e)
to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation
herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations
contained in this paragraph shall apply to a successor holder of this Preferred Investment Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Stock Dividends
and Splits</U>. If the Company, at any time while this Preferred Investment Option is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Preferred Investment Option), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by
a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event,
and the number of shares issuable upon exercise of this Preferred Investment Option shall be proportionately adjusted such that the aggregate
Exercise Price of this Preferred Investment Option shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and
shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Subsequent Rights
Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common
Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares
of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to
such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of
Common Stock acquirable upon complete exercise of this Preferred Investment Option (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that to the extent that
the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the
Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Pro Rata Distributions</U>.
During such time as this Preferred Investment Option is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Preferred Investment Option, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Preferred Investment Option (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record
is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution
(<U>provided</U>, <U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Distribution would result
in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution
to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the
portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would
not result in the Holder exceeding the Beneficial Ownership Limitation). For purposes of clarity, the Spin Off shall not be a Distribution
for purposes of this Section 3(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Fundamental Transaction</U>.
If, at any time while this Preferred Investment Option is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly
or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of
its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their
shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50%
or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or more of the voting power of the common
equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Preferred Investment
Option, the Holder shall have the right to receive, for each Preferred Investment Option Share that would have been issuable upon such
exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation
in Section 2(e) on the exercise of this Preferred Investment Option), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Preferred Investment
Option is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise
of this Preferred Investment Option). For purposes of clarity, the Spin Off shall not be a Fundamental Transaction for purposes of this
Section 3(d). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Preferred Investment Option following such Fundamental Transaction. Notwithstanding anything to
the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s
option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later,
the date of the public announcement of the applicable contemplated Fundamental Transaction), purchase this Preferred Investment Option
from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised
portion of this Preferred Investment Option on the date of the consummation of such Fundamental Transaction; provided, however, that if
the Fundamental Transaction is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors,
Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same
proportion), at the Black Scholes Value of the unexercised portion of this Preferred Investment Option, that is being offered and paid
to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form
of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative
forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company
are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received
common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.
&ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Preferred Investment Option based on the Black Scholes Option Pricing
Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation of the applicable Fundamental
Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal
to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date,
(B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined
utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated
Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price
per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction
and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable
contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading
Day of the Holder&rsquo;s request pursuant to this Section 3(d) and (D) a remaining option time equal to the time between the date of
the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow.
The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within
the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction. The
Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Preferred Investment Option and the other Transaction
Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory
to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of
the Holder, deliver to the Holder in exchange for this Preferred Investment Option a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Preferred Investment Option which is exercisable for a corresponding number
of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable
upon exercise of this Preferred Investment Option (without regard to any limitations on the exercise of this Preferred Investment Option)
prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital
stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value
of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the
economic value of this Preferred Investment Option immediately prior to the consummation of such Fundamental Transaction), and which is
reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity
shall be added to the term &ldquo;Company&rdquo; under this Preferred Investment Option (so that from and after the occurrence or consummation
of such Fundamental Transaction, each and every provision of this Preferred Investment Option and the other Transaction Documents referring
to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally),
and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company
prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this
Preferred Investment Option and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor
Entities, jointly and severally, had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment to
Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver
to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Preferred
Investment Option Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Notice to Allow
Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock,
(B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize
the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class
or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the
Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or
substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or
property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the
Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear
upon the Preferred Investment Option Register of the Company, at least 20 calendar days prior to the applicable record or effective date
hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Preferred Investment Option constitutes, or contains, material,
non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Preferred Investment Option during the period
commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set
forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Preferred Investment Option</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of
Section 4.1 of the Purchase Agreement, this Preferred Investment Option and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Preferred Investment Option at the principal office of the Company
or its designated agent, together with a written assignment of this Preferred Investment Option substantially in the form attached hereto
duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Preferred Investment Option or Preferred
Investment Options in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such
instrument of assignment, and shall issue to the assignor a new Preferred Investment Option evidencing the portion of this Preferred Investment
Option not so assigned, and this Preferred Investment Option shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Preferred Investment Option to the Company unless the Holder has assigned
this Preferred Investment Option in full, in which case, the Holder shall surrender this Preferred Investment Option to the Company within
three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Preferred Investment
Option in full. The Preferred Investment Option, if properly assigned in accordance herewith, may be exercised by a new holder for the
purchase of Preferred Investment Option Shares without having a new Preferred Investment Option issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>New Preferred
Investment Options</U>. This Preferred Investment Option may be divided or combined with other Preferred Investment Options upon presentation
hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Preferred
Investment Options are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any
transfer which may be involved in such division or combination, the Company shall execute and deliver a new Preferred Investment Option
or Preferred Investment Options in exchange for the Preferred Investment Option or Preferred Investment Options to be divided or combined
in accordance with such notice. All Preferred Investment Options issued on transfers or exchanges shall be dated the Issue Date of this
Preferred Investment Option and shall be identical with this Preferred Investment Option except as to the number of Preferred Investment
Option Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Preferred Investment
Option Register</U>. The Company shall register this Preferred Investment Option, upon records to be maintained by the Company for that
purpose (the &ldquo;<U>Preferred Investment Option Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The
Company may deem and treat the registered Holder of this Preferred Investment Option as the absolute owner hereof for the purpose of any
exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Transfer Restrictions</U>.
If, at the time of the surrender of this Preferred Investment Option in connection with any transfer of this Preferred Investment Option,
the transfer of this Preferred Investment Option shall not be either (i) registered pursuant to an effective registration statement under
the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale
restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such
transfer, that the Holder or transferee of this Preferred Investment Option, as the case may be, comply with the provisions of Section
5.7 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Preferred Investment Option
and, upon any exercise hereof, will acquire the Preferred Investment Option Shares issuable upon such exercise, for its own account and
not with a view to or for distributing or reselling such Preferred Investment Option Shares or any part thereof in violation of the Securities
Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>No Rights as Stockholder
Until Exercise; No Settlement in Cash</U>. This Preferred Investment Option does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Preferred Investment Option Shares on a &ldquo;cashless exercise&rdquo;
pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company
be required to net cash settle an exercise of this Preferred Investment Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Loss, Theft, Destruction
or Mutilation of Preferred Investment Option</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Preferred Investment Option or any stock certificate relating to the Preferred
Investment Option Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in
the case of the Preferred Investment Option, shall not include the posting of any bond), and upon surrender and cancellation of such Preferred
Investment Option or stock certificate, if mutilated, the Company will make and deliver a new Preferred Investment Option or stock certificate
of like tenor and dated as of such cancellation, in lieu of such Preferred Investment Option or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Saturdays, Sundays,
Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein
shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 1in">The Company covenants that,
during the period the Preferred Investment Option is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Preferred Investment Option Shares upon the exercise of any purchase rights under
this Preferred Investment Option. The Company further covenants that its issuance of this Preferred Investment Option shall constitute
full authority to its officers who are charged with the duty of issuing the necessary Preferred Investment Option Shares upon the exercise
of the purchase rights under this Preferred Investment Option. The Company will take all such reasonable action as may be necessary to
assure that such Preferred Investment Option Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Preferred Investment
Option Shares which may be issued upon the exercise of the purchase rights represented by this Preferred Investment Option will, upon
exercise of the purchase rights represented by this Preferred Investment Option and payment for such Preferred Investment Option Shares
in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created
by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">Except and to the extent
as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Preferred Investment Option,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Preferred Investment Option against impairment. Without limiting the
generality of the foregoing, the Company will (i) not increase the par value of any Preferred Investment Option Shares above the amount
payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or
appropriate in order that the Company may validly and legally issue fully paid and nonassessable Preferred Investment Option Shares upon
the exercise of this Preferred Investment Option and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations
under this Preferred Investment Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">Before taking any action
which would result in an adjustment in the number of Preferred Investment Option Shares for which this Preferred Investment Option is
exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as
may be necessary from any public regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Preferred Investment Option shall be determined
in accordance with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Preferred Investment Option Shares acquired upon the exercise of this Preferred Investment Option, if
not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities
laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver and
Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver
of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this Preferred
Investment Option or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Preferred
Investment Option, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient
to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>. Any
notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance
with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Limitation of
Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Preferred Investment Option
to purchase Preferred Investment Option Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to
any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted
by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Preferred Investment Option. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Preferred Investment Option and hereby agrees to waive and
not to assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">k) <U>Successors and
Assigns</U>. Subject to applicable securities laws, this Preferred Investment Option and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Preferred Investment Option are intended to be for the benefit of any Holder from time to time of this
Preferred Investment Option and shall be enforceable by the Holder or holder of Preferred Investment Option Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>.
This Preferred Investment Option may be modified or amended or the provisions hereof waived with the written consent of the Company, on
the one hand, and the Holder of this Preferred Investment Option, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Preferred Investment Option shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Preferred Investment Option shall be prohibited by or invalid under applicable law,
such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Preferred Investment Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">n) <U>Headings</U>.
The headings used in this Preferred Investment Option are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Preferred Investment Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Preferred Investment Option to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
    Biosciences, Inc. </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:
<B>Enveric Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Preferred Investment Option Shares of the Company pursuant to the terms of the attached
Preferred Investment Option (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
    &nbsp;] in lawful money of the United States; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
    &nbsp;] if permitted the cancellation of such number of Preferred Investment Option Shares as is necessary, in accordance with the
    formula set forth in subsection 2(c), to exercise this Preferred Investment Option with respect to the maximum number of Preferred
    Investment Option Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Preferred Investment Option Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Investment Option Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing Preferred
Investment Option, execute this form and supply required information. Do not use this form to exercise the Preferred Investment Option
to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Preferred Investment Option and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:____________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:_____________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>6
<FILENAME>ex4-5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.5</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLACEMENT
AGENT PREFERRED INVESTMENT OPTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    Investment Option Shares: ______</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Issue
    Date: July 26, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date: July 26, 2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PLACEMENT AGENT PREFERRED INVESTMENT OPTION (the &ldquo;<U>Preferred Investment Option</U>&rdquo;) certifies that, for value received,
_____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise
and the conditions hereinafter set forth, at any time on or after the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;)
and on or prior to 5:00 p.m. (New York City time) on July 22, 2027 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to
subscribe for and purchase from Enveric Biosciences, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares
(as subject to adjustment hereunder, the &ldquo;<U>Preferred Investment Option Shares</U>&rdquo;) of Common Stock. The purchase price
of one share of Common Stock under this Preferred Investment Option shall be equal to the Exercise Price, as defined in Section 2(b).
This Preferred Investment Option is being issued pursuant to that certain engagement letter, dated as of July 11, 2022, by and between
the Company and H.C. Wainwright &amp; Co., LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated July 22, 2022, among the Company and the
purchasers signatory thereto. In addition, &ldquo;<U>Akos</U>&rdquo; means Akos Biosciences, Inc. (formerly known as Acanna
Therapeutics, Inc.), a majority owned Subsidiary, to which the Company has previously publicly announced that the Company will
transfer the Company&rsquo;s cannabinoid clinical development pipeline assets, and &ldquo;<U>Spin Off</U>&rdquo; means the
Company&rsquo;s spin-off of Akos by way of dividends to the Company&rsquo;s shareholders, as described in the Company&rsquo;s Form
8-K filed with the Commission on May 11, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Exercise
of Preferred Investment Option</U>. Exercise of the purchase rights represented by this Preferred Investment Option may be made, in
whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to
the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed
hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading
Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid,
the Holder shall deliver the aggregate Exercise Price for the Preferred Investment Option Shares specified in the applicable Notice
of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified
in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor
shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Preferred Investment Option to the
Company until the Holder has purchased all of the Preferred Investment Option Shares available hereunder and the Preferred
Investment Option has been exercised in full, in which case, the Holder shall surrender this Preferred Investment Option to the
Company for cancellation as soon as reasonably practicable of the date on which the final Notice of Exercise is delivered to the
Company. Partial exercises of this Preferred Investment Option resulting in purchases of a portion of the total number of Preferred
Investment Option Shares available hereunder shall have the effect of lowering the outstanding number of Preferred Investment Option
Shares purchasable hereunder in an amount equal to the applicable number of Preferred Investment Option Shares purchased. The Holder
and the Company shall maintain records showing the number of Preferred Investment Option Shares purchased and the date of such
purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <B>The
Holder and any assignee, by acceptance of this Preferred Investment Option , acknowledge and agree that, by reason of the provisions
of this paragraph, following the purchase of a portion of the Preferred Investment Option Shares hereunder, the number of Preferred
Investment Option Shares available for purchase hereunder at any given time may be less than the amount stated on the face
hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Exercise
Price</U>. The exercise price per share of Common Stock under this Preferred Investment Option shall be <B>$10.00</B>, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the resale of the Preferred Investment Option Shares by the Holder, then this Preferred Investment Option
may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled
to receive a number of Preferred Investment Option Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
= as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and
delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in
Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either
(y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common
Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading
hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if
the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a)
hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
= the Exercise Price of this Preferred Investment Option, as adjusted hereunder; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
= the number of Preferred Investment Option Shares that would be issuable upon exercise of this Preferred Investment Option in accordance
with the terms of this Preferred Investment Option if such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><U>&ldquo;Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&ldquo;<U>VWAP</U>&rdquo;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, for any date, the price determined by the first
of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then
listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)),
(b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices
for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share
of Common Stock as determined by an independent appraiser selected in good faith by the <FONT STYLE="background-color: white">Purchasers
</FONT>of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of
which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Preferred Investment Option Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with
Section 3(a)(9) of the Securities Act, the Preferred Investment Option Shares shall take on the characteristics of the Preferred Investment
Options being exercised, and the holding period of the Preferred Investment Option Shares being issued may be tacked on to the holding
period of this Preferred Investment Option. The Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Mechanics
of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. <U>Delivery
of Preferred Investment Option Shares Upon Exercise</U>. The Company shall cause the Preferred Investment Option Shares purchased hereunder
to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance
account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company
is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Preferred
Investment Option Shares to or resale of the Preferred Investment Option Shares by the Holder or (B) the Preferred Investment Option
Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise
of the Preferred Investment Options), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register
in the name of the Holder or its designee, for the number of Preferred Investment Option Shares to which the Holder is entitled pursuant
to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading
Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price
to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the
Notice of Exercise (such date, the &ldquo;<U>Preferred Investment Option Share Delivery Date</U>&rdquo;). Upon delivery of the Notice
of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Preferred Investment Option
Shares with respect to which this Preferred Investment Option has been exercised, irrespective of the date of delivery of the Preferred
Investment Option Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received
by the Preferred Investment Option Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Preferred Investment
Option Shares subject to a Notice of Exercise by the Preferred Investment Option Share Delivery Date, the Company shall pay to the Holder,
in cash, as liquidated damages and not as a penalty, for each $1,000 of Preferred Investment Option Shares subject to such exercise (based
on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the third Trading Day after the Preferred Investment Option Share Delivery Date) for each Trading Day after such Preferred Investment
Option Share Delivery Date until such Preferred Investment Option Shares are delivered or Holder rescinds such exercise. The Company
agrees to maintain a transfer agent that is a participant in the FAST program so long as this Preferred Investment Option remains outstanding
and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a
number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery
of the Notice of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. <U>Delivery
of New Preferred Investment Options Upon Exercise</U>. If this Preferred Investment Option shall have been exercised in part, the Company
shall, at the request of a Holder and upon surrender of this Preferred Investment Option certificate, at the time of delivery of the
Preferred Investment Option Shares, deliver to the Holder a new Preferred Investment Option evidencing the rights of the Holder to purchase
the unpurchased Preferred Investment Option Shares called for by this Preferred Investment Option, which new Preferred Investment Option
shall in all other respects be identical with this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Preferred Investment Option Shares pursuant
to Section 2(d)(i) by the Preferred Investment Option Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Preferred Investment Option Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Preferred Investment Option Shares in accordance
with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Preferred Investment Option Share Delivery Date,
and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s
brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Preferred Investment
Option Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay
in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Preferred Investment Option
Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the
sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of
the Preferred Investment Option and equivalent number of Preferred Investment Option Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Preferred Investment Option as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Preferred Investment Option. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise,
the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Preferred Investment Option Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Preferred Investment Option Shares, all of which taxes and expenses
shall be paid by the Company, and such Preferred Investment Option Shares shall be issued in the name of the Holder or in such name or
names as may be directed by the Holder; <U>provided</U>, <U>however</U>, that in the event that Preferred Investment Option Shares are
to be issued in a name other than the name of the Holder, this Preferred Investment Option when surrendered for exercise shall be accompanied
by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of
a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for
same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation
performing similar functions) required for same-day electronic delivery of the Preferred Investment Option Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Preferred
Investment Option, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Preferred Investment Option, and a Holder shall not have
the right to exercise any portion of this Preferred Investment Option, pursuant to Section 2 or otherwise, to the extent that after giving
effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the
foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties
shall include the number of shares of Common Stock issuable upon exercise of this Preferred Investment Option with respect to which such
determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the
remaining, nonexercised portion of this Preferred Investment Option beneficially owned by the Holder or any of its Affiliates or Attribution
Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including,
without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation
contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding
sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange
Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to
the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the
determination of whether this Preferred Investment Option is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Preferred Investment Option is exercisable shall be in the
sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether
this Preferred Investment Option is exercisable (in relation to other securities owned by the Holder together with any Affiliates and
Attribution Parties) and of which portion of this Preferred Investment Option is exercisable, in each case subject to the Beneficial
Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition,
a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares
of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent
periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C)
a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon
the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the
number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Preferred Investment Option, by the Holder
or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The
&ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Preferred Investment Option. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that
the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock upon exercise of this Preferred Investment Option held by the Holder and the
provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until
the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof)
which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor
holder of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Preferred Investment Option is outstanding: (i) pays a stock dividend
or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Preferred Investment Option), (ii) subdivides outstanding shares of Common Stock into a larger number of shares,
(iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)
issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if
any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Preferred Investment Option shall be proportionately
adjusted such that the aggregate Exercise Price of this Preferred Investment Option shall remain unchanged. Any adjustment made pursuant
to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Preferred Investment Option (without regard to any
limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which
a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record
holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>,
that to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership
of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held
in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Pro
Rata Distributions</U>. During such time as this Preferred Investment Option is outstanding, if the Company shall declare or make any
dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return
of capital or otherwise, other than cash (including, without limitation, any distribution of nstock or other securities, property or
options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)
(a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Preferred Investment Option, then, in each such case, the
Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the
Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Preferred Investment Option (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of
Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, that to the extent that
the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares
of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation). For purposes of clarity, the Spin Off shall not be a Distribution for purposes of this Section 3(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Fundamental
Transaction</U>. If, at any time while this Preferred Investment Option is outstanding, (i) the Company, directly or indirectly, in one
or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any
Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or
substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer
or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to
sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the
outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock
or 50% or more of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon
any subsequent exercise of this Preferred Investment Option, the Holder shall have the right to receive, for each Preferred Investment
Option Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at
the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Preferred Investment Option), the
number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and
any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Preferred Investment Option is exercisable immediately prior to such
Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Preferred Investment Option). For purposes
of clarity, the Spin Off shall not be a Fundamental Transaction for purposes of this Section 3(d). For purposes of any such exercise,
the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount
of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion
the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise
of this Preferred Investment Option following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of
a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at
any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public
announcement of the applicable contemplated Fundamental Transaction), purchase this Preferred Investment Option from the Holder by paying
to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Preferred
Investment Option on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction
is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, Holder shall only be entitled
to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black
Scholes Value of the unexercised portion of this Preferred Investment Option, that is being offered and paid to the holders of Common
Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any
combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration
in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or
paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of
the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black
Scholes Value</U>&rdquo; means the value of this Preferred Investment Option based on the Black Scholes Option Pricing Model obtained
from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for
pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time
between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing
a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental
Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being
offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii)
the highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable contemplated
Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of
the Holder&rsquo;s request pursuant to this Section 3(d) and (D) a remaining option time equal to the time between the date of the public
announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment
of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later
of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction. The Company
shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;)
to assume in writing all of the obligations of the Company under this Preferred Investment Option and the other Transaction Documents
in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to
the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of
the Holder, deliver to the Holder in exchange for this Preferred Investment Option a security of the Successor Entity evidenced by a
written instrument substantially similar in form and substance to this Preferred Investment Option which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Preferred Investment Option (without regard to any limitations on the exercise of this Preferred
Investment Option) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such
shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of
protecting the economic value of this Preferred Investment Option immediately prior to the consummation of such Fundamental Transaction),
and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the
Successor Entity shall be added to the term &ldquo;Company&rdquo; under this Preferred Investment Option (so that from and after the
occurrence or consummation of such Fundamental Transaction, each and every provision of this Preferred Investment Option and the other
Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor
Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise
every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations
of the Company prior thereto under this Preferred Investment Option and the other Transaction Documents with the same effect as if the
Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f) <U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Preferred Investment Option Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of
all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall
appear upon the Preferred Investment Option Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Preferred Investment Option constitutes, or contains, material,
non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Preferred Investment Option during the period
commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly
set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Preferred Investment Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of
Section 4.1 of the Purchase Agreement, this Preferred Investment Option and all rights hereunder (including, without limitation, any
registration rights) are transferable, in whole or in part, upon surrender of this Preferred Investment Option at the principal office
of the Company or its designated agent, together with a written assignment of this Preferred Investment Option substantially in the form
attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the
making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Preferred Investment
Option or Preferred Investment Options in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Preferred Investment Option evidencing the portion
of this Preferred Investment Option not so assigned, and this Preferred Investment Option shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Preferred Investment Option to the Company
unless the Holder has assigned this Preferred Investment Option in full, in which case, the Holder shall surrender this Preferred Investment
Option to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning
this Preferred Investment Option in full. The Preferred Investment Option, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Preferred Investment Option Shares without having a new Preferred Investment Option issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>New
Preferred Investment Options</U>. This Preferred Investment Option may be divided or combined with other Preferred Investment Options
upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations
in which new Preferred Investment Options are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with
Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Preferred
Investment Option or Preferred Investment Options in exchange for the Preferred Investment Option or Preferred Investment Options to
be divided or combined in accordance with such notice. All Preferred Investment Options issued on transfers or exchanges shall be dated
the Issue Date of this Preferred Investment Option and shall be identical with this Preferred Investment Option except as to the number
of Preferred Investment Option Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Preferred
Investment Option Register</U>. The Company shall register this Preferred Investment Option, upon records to be maintained by the Company
for that purpose (the &ldquo;<U>Preferred Investment Option Register</U>&rdquo;), in the name of the record Holder hereof from time to
time. The Company may deem and treat the registered Holder of this Preferred Investment Option as the absolute owner hereof for the purpose
of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Transfer
Restrictions</U>. If, at the time of the surrender of this Preferred Investment Option in connection with any transfer of this Preferred
Investment Option, the transfer of this Preferred Investment Option shall not be either (i) registered pursuant to an effective registration
statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume
or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition
of allowing such transfer, that the Holder or transferee of this Preferred Investment Option, as the case may be, comply with the provisions
of Section 5.7 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Preferred Investment Option
and, upon any exercise hereof, will acquire the Preferred Investment Option Shares issuable upon such exercise, for its own account and
not with a view to or for distributing or reselling such Preferred Investment Option Shares or any part thereof in violation of the Securities
Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Preferred Investment Option does not entitle the Holder to any
voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i),
except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Preferred Investment Option Shares on
a &ldquo;cashless exercise&rdquo; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv)
herein, in no event shall the Company be required to net cash settle an exercise of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Loss,
Theft, Destruction or Mutilation of Preferred Investment Option</U>. The Company covenants that upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Preferred Investment Option or any stock certificate
relating to the Preferred Investment Option Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory
to it (which, in the case of the Preferred Investment Option, shall not include the posting of any bond), and upon surrender and cancellation
of such Preferred Investment Option or stock certificate, if mutilated, the Company will make and deliver a new Preferred Investment
Option or stock certificate of like tenor and dated as of such cancellation, in lieu of such Preferred Investment Option or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Preferred Investment Option is outstanding, it will reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the Preferred Investment Option Shares upon the exercise of
any purchase rights under this Preferred Investment Option. The Company further covenants that its issuance of this Preferred Investment
Option shall constitute full authority to its officers who are charged with the duty of issuing the necessary Preferred Investment Option
Shares upon the exercise of the purchase rights under this Preferred Investment Option. The Company will take all such reasonable action
as may be necessary to assure that such Preferred Investment Option Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Preferred Investment Option Shares which may be issued upon the exercise of the purchase rights represented by this Preferred
Investment Option will, upon exercise of the purchase rights represented by this Preferred Investment Option and payment for such Preferred
Investment Option Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes,
liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Preferred
Investment Option, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Preferred Investment Option against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Preferred Investment Option
Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action
as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Preferred Investment
Option Shares upon the exercise of this Preferred Investment Option and (iii) use commercially reasonable efforts to obtain all such
authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the
Company to perform its obligations under this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Preferred Investment Option Shares for which this Preferred Investment
Option is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto,
as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Preferred Investment Option shall be determined
in accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f) <U>Restrictions</U>.
The Holder acknowledges that the Preferred Investment Option Shares acquired upon the exercise of this Preferred Investment Option, if
not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities
laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of
this Preferred Investment Option or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision
of this Preferred Investment Option, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those
of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h) <U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
to with the address of the Holder in the Warrant Register.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Preferred Investment Option
to purchase Preferred Investment Option Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise
to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability
is asserted by the Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Preferred Investment Option. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Preferred Investment Option and hereby agrees to waive and
not to assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Preferred Investment Option and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Preferred Investment Option are intended to be for the benefit of any Holder from time to time
of this Preferred Investment Option and shall be enforceable by the Holder or holder of Preferred Investment Option Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l) <U>Amendment</U>.
This Preferred Investment Option may be modified or amended or the provisions hereof waived with the written consent of the Company,
on the one hand, and the Holder of this Preferred Investment Option, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m) <U>Severability</U>.
Wherever possible, each provision of this Preferred Investment Option shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Preferred Investment Option shall be prohibited by or invalid under applicable law,
such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n) <U>Headings</U>.
The headings used in this Preferred Investment Option are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;<BR STYLE="clear: both">
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Preferred Investment Option to be executed by its officer thereunto duly authorized as of
the date first above indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 45%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To: <B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) The
undersigned hereby elects to purchase ________ Preferred Investment Option Shares of the Company pursuant to the terms of the attached
Preferred Investment Option (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;&nbsp;] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;&nbsp;] if permitted the cancellation of such number of Preferred Investment Option Shares as is necessary, in accordance with the formula
set forth in subsection 2(c), to exercise this Preferred Investment Option with respect to the maximum number of Preferred Investment
Option Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) Please
issue said Preferred Investment Option Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Investment Option Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4) <U>Accredited
Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the Securities Act
of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Preferred Investment Option, execute this form and supply required information. Do not use this form to exercise
the Preferred Investment Option to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Preferred Investment Option and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>______________________________________</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>_____________________________________</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
                                            Print)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">______________________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">______________________________________</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:<U>_______________________________</U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:<U> ______________________________</U></FONT>__</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>7
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
26, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4851
Tamiami Trail N, Suite 200</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naples,
FL 34103</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel for Enveric Biosciences, Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection
with the filing with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) pursuant to Rule 424(b) under
the Securities Act of 1933, as amended (the &ldquo;<B><I>Act</I></B>&rdquo;) of the Company&rsquo;s prospectus supplement, dated July
22, 2022 ( the &ldquo;<B><I>Prospectus Supplement</I></B>&rdquo;), forming part of the registration statement on Form S-3, initially
filed by the Company with the Securities and Exchange Commission on July 2, 2021, and declared effective on July 9, 2021 (the &ldquo;<B><I>Registration
Statement</I></B>&rdquo;). The Prospectus Supplement relates to the proposed sale of (i) 116,500 shares (the &ldquo;<B><I>Shares</I></B>&rdquo;)
of the Company&rsquo;s common stock, par value $0.01 per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;) and (ii) pre-funded warrants
(the &ldquo;<B><I>Pre-Funded Warrants</I></B>&rdquo;) to purchase up to 258,500 shares of Common Stock (the &ldquo;<B><I>Pre-Funded Warrant
Shares</I></B>&rdquo;, and together with the Shares and the Pre-Funded Warrants, the &ldquo;<B><I>Securities</I></B>&rdquo;), pursuant
to that certain Securities Purchase Agreement, dated July 22, 2022, by and between the Company and the investor named therein (the &ldquo;<B><I>Registered
Direct Securities Purchase Agreement</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
rendering the opinions expressed herein, we have examined and relied upon the originals, or copies certified or otherwise identified
to our satisfaction, of (i) the Company&rsquo;s Amended and Restated Certificate of Incorporation and bylaws, each as amended and/or
restated to date (&ldquo;<B><I>Company Charter Documents</I></B>&rdquo;); (ii) certain resolutions of the Board of Directors of the Company
approving the filing of the Registration Statement and Base Prospectus (as defined below) and certain other matters set forth therein;
(iii) certain resolutions of the Pricing Committee of the Board of Directors of the Company related to the filing of the Prospectus Supplement,
the authorization and issuance of the Securities and related matters; (iv) the Registration Statement, including the prospectus, and
all exhibits thereto; (v) the Prospectus Supplement and the prospectus included in the Registration Statement dated July 9, 2021 (the
&ldquo;<B><I>Base Prospectus</I></B>&rdquo; and together with the Prospectus Supplement, the &ldquo;<B><I>Prospectus</I></B>&rdquo;);
(vi) the Registered Direct Securities Purchase Agreement; (vii) a specimen of the Company&rsquo;s Common Stock certificate; (viii) a
certificate executed by an officer of the Company, dated as of the date hereof and (ix) such other corporate records of the Company,
as we have deemed necessary or appropriate for the purposes of the opinions hereafter expressed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
to questions of fact material to the opinions expressed below, we have, without independent verification of their accuracy, relied to
the extent we deem reasonably appropriate upon the representations and warranties of the Company contained in such documents, records,
certificates, instruments or representations furnished or made available to us by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
making the foregoing examination, we have assumed (i) the genuineness of all signatures; (ii) the authenticity of all documents submitted
to us as originals; (iii) the conformity to original documents of all documents submitted to us as certified or photostatic copies; (iv)
that all agreements or instruments we have examined are the valid, binding and enforceable obligations of the parties thereto; and (v)
that all factual information on which we have relied was accurate and complete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
26, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
2</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also assumed that, at the time of the issuance of the Securities: (i) the resolutions of the Board of Directors of the Company and
the Pricing Committee of the Board of Directors of the Company referred to above will not have been modified or rescinded; (ii) the Company
will receive consideration for the issuance of the Securities and that is at least equal to the par value of the Common Stock; (iii)
the Registered Direct Securities Purchase Agreement will have been duly authorized and validly executed and delivered by the parties
thereto (other than the Company) and will be enforceable obligations of the parties thereto (other than the Company); and (vi) all requirements
of the General Corporation Law of the State of Delaware (the &ldquo;<B><I>DGCL</I></B>&rdquo;) and the Company Charter Documents will
be complied with when the Shares are issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the foregoing and subject to the assumptions and qualifications stated herein, we are of the opinion that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
the Shares, upon payment and delivery in accordance with the Registered Direct Securities Purchase Agreement and the Prospectus, will
be validly issued, fully paid and non-assessable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
when the Pre-Funded Warrants have been duly executed by the Company and the Pre-Funded Warrants have been issued and sold pursuant to
the Prospectus, against payment in full of the consideration payable therefor, the Pre-Funded Warrants will constitute valid and legally
binding obligations of the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
the Pre-Funded Warrant Shares have been duly authorized and, upon the valid exercise in accordance with the terms of the Pre-Funded Warrants
and payment in full of the consideration payable therefor, the Pre-Funded Warrant Shares will be validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion as an Exhibit 5.1 to the Company&rsquo;s Current Report on Form 8-K to be filed with the
Commission. We further consent to the reference to our firm under the caption &ldquo;Legal Matters&rdquo; in the Prospectus on the date
hereof constituting a part of the Registration Statement. In giving this consent, we are not admitting that we are within the category
of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder. This opinion
is given as of the date hereof and we assume no obligation to update or supplement such opinion after the date hereof to reflect any
facts or circumstances that may thereafter come to our attention or any changes that may thereafter occur. The opinions expressed herein
are limited exclusively to the DGCL and we have not considered, and express no opinion on, any other laws or the laws of any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion with the Commission as Exhibit 5.1 to the Registration Statement and to the reference to
our firm under the heading &ldquo;Legal Matters&rdquo; in the Prospectus. In giving such consent, we do not hereby admit that we are
in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission
thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Haynes and Boone, LLP</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haynes
and Boone, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>8
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-transform: uppercase; text-align: right; text-indent: -0.5in"><B>E<FONT STYLE="text-transform: lowercase">XHIBIT
</FONT>10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of July 22, 2022, between Enveric Biosciences, Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including
its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to (i) an effective registration statement under the Securities
Act (as defined below) as to the Shares and the Pre-Funded Warrants and (ii) an exemption from the registration requirements of Section
5 of the Securities Act contained in Section 4(a)(2) thereof and/or Regulation D thereunder as to the Preferred Investment Options, the
Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company,
securities of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second (2<SUP>nd</SUP>)
Trading Day following the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Haynes and Boone, LLP, with offices located at 30 Rockefeller Plaza, 26<SUP>th</SUP> Floor, New York, New York
10112.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effective
Date</U>&rdquo; means the earliest of the date that (a) the initial registration statement to be filed by the Company in connection with
the Private Placement has been declared effective by the Commission, (b) all of the securities issued in the Private Placement have been
sold pursuant to Rule 144 or may be sold pursuant to Rule 144 without the requirement for the Company to be in compliance with the current
public information required under Rule 144 and without volume or manner-of-sale restrictions, (c) following the one year anniversary
of the Closing Date provided that a holder of all of the securities issued in the Private Placement is not an Affiliate of the Company,
or (d) all of the securities issued in the Private Placement may be sold pursuant to an exemption from registration under Section 4(a)(1)
of the Securities Act without volume or manner-of-sale restrictions and Company Counsel has delivered to such holders a standing written
unqualified opinion that resales may then be made by such holders of the securities issued in the Private Placement pursuant to such
exemption which opinion shall be in form and substance reasonably acceptable to such holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant
to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority
of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) securities
upon the exercise or exchange of or conversion of any Securities issued hereunder, warrants to the Placement Agent in connection with
the transactions pursuant to this Agreement and any securities upon exercise of warrants to the Placement Agent and/or other securities
exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided
that (other than with respect to the Warrant Amendment (as such term is defined below)) such securities have not been amended since the
date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price
of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, (c) securities
issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided
that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that
require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.11(a) herein,
and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries,
an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company
additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities
primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, and (d) securities of
the Company issued pursuant to a concurrent private placement (the &ldquo;<U>Private Placement</U>&rdquo;) and amendment to certain existing
warrants held by the Purchasers (the &ldquo;<U>Warrant Amendment</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Legend
Removal Date</U>&rdquo; shall have the meaning ascribed to such term in Section 4.1(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $8.00 (less $0.0001 for each Pre-Funded Warrant), subject to adjustment for reverse and forward
stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agent</U>&rdquo; means H.C. Wainwright &amp; Co., LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preferred
Investment Options</U>&rdquo; means, collectively, the Preferred Investment Options delivered to the Purchasers at the Closing in accordance
with Section 2.2(a) hereof, which Preferred Investment Options shall be exercisable immediately upon issuance and have a term of exercise
equal to 5.5 years, in the form of <U>Exhibit A-2</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preferred
Investment Option Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Preferred Investment Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing in
accordance with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately and will expire when exercised in full,
in the form of <U>Exhibit A-1</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the
Commission and delivered by the Company to each Purchaser at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission file No. 333-257690 which registers the sale of the Shares
and Pre-Funded Warrants to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Warrants and the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified
below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds (minus, if applicable, a Purchaser&rsquo;s aggregate exercise price of the
Pre-Funded Warrants, which amounts shall be paid as and when such Pre-Funded Warrants are exercised for cash).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth in the SEC Reports, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any other documents or agreements
executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means American Stock Transfer &amp; Trust LLC the current transfer agent of the Company, with a mailing address of 6201
15th Ave, Brooklyn, NY 11219, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.11(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in The Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Preferred Investment Options and the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASE
AND SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the
execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly,
agree to purchase, up to an aggregate of $3.0 million of Shares and Warrants. Notwithstanding anything herein to the contrary, to the
extent that a Purchaser determines, in its sole discretion, that such Purchaser&rsquo;s Subscription Amount (together with such Purchaser&rsquo;s
Affiliates and any Person acting as a group together with such Purchaser or any of such Purchaser&rsquo;s Affiliates) would cause such
Purchaser&rsquo;s beneficial ownership of the shares of Common Stock to exceed the Beneficial Ownership Limitation, or as such Purchaser
may otherwise choose, such Purchaser may elect to purchase Pre-Funded Warrants in lieu of the Shares as determined pursuant to Section
2.2(a). The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, at the election of the Purchaser at Closing, 9.99%)
of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the Securities on the Closing
Date. In each case, the election to receive Pre-Funded Warrants is solely at the option of the Purchaser. Each Purchaser&rsquo;s Subscription
Amount as set forth on the signature page hereto executed by such Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo;
settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares, Pre-Funded Warrants and
Preferred Investment Option as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items
set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and
2.3, the Closing shall take place remotely by electronic transfer of the Closing documentation. Notwithstanding anything herein to the
contrary, if at any time on or after the time of execution of this Agreement by the Company and an applicable Purchaser, through, and
including the time immediately prior to the Closing (the &ldquo;<U>Pre-Settlement Period</U>&rdquo;), such Purchaser sells to any Person
all, or any portion, of the Shares to be issued hereunder to such Purchaser at the Closing (collectively, the &ldquo;<U>Pre-Settlement
Shares</U>&rdquo;), such Purchaser shall, automatically hereunder (without any additional required actions by such Purchaser or the Company),
be deemed to be unconditionally bound to purchase, such Pre-Settlement Shares to such Purchaser at the Closing; provided, that the Company
shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the Company&rsquo;s receipt of the purchase price
of such Pre-Settlement Shares hereunder; and provided further that the Company hereby acknowledges and agrees that the forgoing shall
not constitute a representation or covenant by such Purchaser as to whether or not during the Pre-Settlement Period such Purchaser shall
sell any shares of Common Stock to any Person and that any such decision to sell any shares of Common Stock by such Purchaser shall solely
be made at the time such Purchaser elects to effect any such sale, if any. Notwithstanding the foregoing, with respect to any Notice(s)
of Exercise (as defined in the Pre-Funded Warrants) delivered on or prior to 12:00 p.m. (New York City time) on the Closing Date, which
may be delivered at any time after the time of execution of this Agreement, the Company agrees to deliver the Pre-Funded Warrant Shares
subject to such notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Warrant Share Delivery
Date (as defined in the Pre-Funded Warrants) for purposes thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">(a)
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a legal opinion of Company Counsel, directed to the Placement Agent and the Purchasers, in a form reasonably acceptable to the Placement
Agent and Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
subject to Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
subject to Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an
expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) Shares equal to
such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
if applicable, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal
to the difference between (A) such Purchaser&rsquo;s Subscription Amount divided by the Per Pre-Funded Warrant Purchase Price and (B)
the number of Shares otherwise issuable to such Purchaser that would cause such Purchaser&rsquo;s Beneficial Ownership to be more than
the Beneficial Ownership Limitation with an exercise price equal to $0.0001 per share of Common Stock, subject to adjustment therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
a Preferred Investment Option registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to
100% of the sum of such Purchaser&rsquo;s Shares and Pre-Funded Warrant Shares, with an exercise price equal to $7.78, subject to adjustment
therein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
such Purchaser&rsquo;s Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the
Company or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Closing Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects)
on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in
which case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality,
in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless
as of a specific date therein in which case they shall be accurate in all respects or, to the extent representations or warranties are
qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
there shall have been no Material Adverse Effect with respect to the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPRESENTATIONS
AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. Except as set forth in the SEC Reports, the Company hereby makes the following
representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Subsidiaries</U>. All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. Except as set forth
in the SEC Reports, the Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free
and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully
paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries,
all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could
not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in
any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material
Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking
to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no
further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith
other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been
(or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) application(s)
to each applicable Trading Market for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required
thereby, and (iv) the filing of Form D with the Commission and such filings as are required to be made under applicable state securities
laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Issuance of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with
the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed
by the Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and
nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the
maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the
Registration Statement in conformity with the requirements of the Securities Act, which became effective on July 9, 2021, including the
Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration Statement
is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending
or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or,
to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission,
shall file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto
became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed
and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading;
and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued
and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and
will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. The Company was at the time of the filing of the Registration
Statement eligible to use Form S-3. The Company is eligible to use Form S-3 under the Securities Act and it meets the transaction requirements
with respect to the aggregate market value of securities being sold pursuant to this offering and during the twelve (12) months prior
to this offering, as set forth in General Instruction I.B.6 of Form S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth in the SEC Reports, including the number
of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof. The Company has not
issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of
employee stock options under the Company&rsquo;s stock option plans, the issuance of shares of Common Stock to employees pursuant to
the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding
as of the date of the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive
right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except
as a result of the purchase and sale of the Securities and as set forth in the SEC Reports, there are no outstanding options, warrants,
scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible
into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the
capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is
or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance
and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any
Person (other than the Purchasers). Except as set forth in the SEC Reports, there are no outstanding securities or instruments of the
Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument
upon an issuance of securities by the Company or any Subsidiary. Except as set forth in the SEC Reports, there are no outstanding securities
or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such
Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar
plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and
nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued
in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization
of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders
agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a
party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and
the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received
a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act,
as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The Company has been subject to Rule 144(i) under the Securities Act; it has filed all reports and other
materials required to be filed by Section 13 or 15(d) of the Exchange Act, as applicable, during the preceding 48 months. The financial
statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the
rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been
prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved
(&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited
financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position
of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the
periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, except as set forth in the SEC Reports, (i) there has been no event, occurrence or development that has had or
that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings
made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth in the SEC Reports, no event,
liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect
to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that
would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made
that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Litigation</U>. Except as set forth in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation
pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties
before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth in the SEC Reports, (i) adversely affects or challenges
the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable
decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director
or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities
laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission
has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary
under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Environmental Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating
to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or
toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and
(iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of
which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which
the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None
of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights
has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date
of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included
within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe
upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge
of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any
of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company
nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase
in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Transactions With Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of the Company
or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to
any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to
or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director
or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other
employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements
of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries
maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance
with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with
management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets
at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and
designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it
files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s
rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of
the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act
(such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange
Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations
as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as
such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely
to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Certain Fees</U>. Except for fees payable by the Company to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions
are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no
obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated
in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Registration Rights</U>. Other than pursuant to the registration rights agreement to be entered into in connection with the Private
Placement and as set forth in the SEC Reports, no Person has any right to cause the Company or any Subsidiary to effect the registration
under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in
the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently
eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is
current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such
electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the
laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of
the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or
counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise
disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation
in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, is true and correct
and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company
during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of
the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes
or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set
forth in Section 3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of the
Preferred Investment Options or Preferred Investment Option Shares under the Securities Act, or (ii) any applicable shareholder approval
provisions of any Trading Market on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt
by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its
business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)
the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature
(taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any
facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. <U>A</U>ll outstanding secured and unsecured Indebtedness of the Company
or any Subsidiary, or for which the Company or any Subsidiary has commitments is set forth in the SEC Reports. For the purposes of this
Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other
than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations
in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance
sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions
in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to
be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)
has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material
taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>Accountants</U>. The Company&rsquo;s accounting firm is set forth in the SEC Reports. To the knowledge and belief of the Company,
such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with
respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<FONT STYLE="text-underline-style: double"><U>Acknowledgment Regarding Purchaser&rsquo;s Trading Activity. Anything in this Agreement
or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(f) and 4.13 hereof), it is understood and acknowledged by
the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing
or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company
or to hold the Securities for any specified term; (ii) past or future open market or other transactions by any Purchaser, specifically
including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private
placement transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser,
and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or indirectly, presently
may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with
or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction. The Company further understands and
acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the Securities
are outstanding, including, without limitation, during the periods that the value of the Warrant Shares deliverable with respect to Securities
are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders' equity interests
in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned
hedging activities do not constitute a breach of any of the Transaction Documents.</U></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>Regulation M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement
of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under
the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure
to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter
or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and
promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws
or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical
hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company
or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of
its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries,
and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of
the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations
of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United
States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving
or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>Cybersecurity</U>. (i)(x) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any
Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data (including the data of its respective
customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively,
&ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of
any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and
Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders,
rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations
relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use,
access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)
the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material
confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company
and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>Form S-3 Eligibility</U>. The Company is eligible to register the resale of the Preferred Investment Option Shares for resale by the
Purchaser on Form S-3 promulgated under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer,
agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity
of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
<U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)
<U>Private Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, no
registration under the Securities Act is required for the offer and sale of the Preferred Investment Options or the Preferred Investment
Option Shares by the Company to the Purchasers as contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)
<U>No General Solicitation</U>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Preferred
Investment Options or Preferred Investment Option Shares by any form of general solicitation or general advertising. The Company has
offered the Preferred Investment Options and Preferred Investment Option Shares for sale only to the Purchasers and certain other &ldquo;accredited
investors&rdquo; within the meaning of Rule 501 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)
<U>No Disqualification Events</U>. With respect to the Preferred Investment Options and Preferred Investment Option Shares to be offered
and sold hereunder in reliance on Rule 506 under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer,
any director, executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or
more of the Company&rsquo;s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that
term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an &ldquo;<U>Issuer
Covered Person</U>&rdquo;) is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described in Rule 506(d)(1)(i) to (viii)
under the Securities Act (a &ldquo;<U>Disqualification Event</U>&rdquo;), except for a Disqualification Event covered by Rule 506(d)(2)
or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification
Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the
Purchasers a copy of any disclosures provided thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)
<U>Other Covered Persons</U>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person)
that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any
Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)
<U>Notice of Disqualification Events</U>. The Company will notify the Purchasers and the Placement Agent in writing, prior to the Closing
Date of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time,
reasonably be expected to become a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and
warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case
they shall be accurate as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and
in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance
by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to
which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof,
will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except:
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or
otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the
ordinary course of its business. Such Purchaser understands that the Preferred Investment Options and the Preferred Investment Option
Shares are &ldquo;restricted securities&rdquo; and have not been registered under the Securities Act or any applicable state securities
law and is acquiring such Securities as principal for his, her or its own account and not with a view to or for distributing or reselling
such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention
of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or
indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities in violation
of the Securities Act or any applicable state securities law (this representation and warranty not limiting such Purchaser&rsquo;s right
to sell such Securities pursuant to a registration statement or otherwise in compliance with applicable federal and state securities
laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Purchaser Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each
date on which it exercises any Warrants, it will be an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3),
(a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the
Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the
opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that
is necessary to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither
the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect
to the Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes
any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public
information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of the
Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to
such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has
not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser
first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material
terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing,
in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other
than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers,
directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>General Solicitation</U>. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other
communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or
presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER
AGREEMENTS OF THE PARTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Removal of Legends</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Preferred Investment Options and Preferred Investment Option Shares may only be disposed of in compliance with state and federal
securities laws. In connection with any transfer of Preferred Investment Options or Preferred Investment Option Shares other than pursuant
to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as
contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected
by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory
to the Company, to the effect that such transfer does not require registration of such transferred Preferred Investment Options under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Preferred Investment Options
or Preferred Investment Option Shares in the following form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL
INSTITUTION THAT IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY
SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered
broker-dealer or grant a security interest in some or all of the Preferred Investment Options or Preferred Investment Option Shares to
a financial institution that is an &ldquo;accredited investor&rdquo; as defined in Rule 501(a) under the Securities Act and, if required
under the terms of such arrangement, such Purchaser may transfer pledged or secured Preferred Investment Options or Preferred Investment
Option Shares to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal
opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall
be required of such pledge. At the appropriate Purchaser&rsquo;s expense, the Company will execute and deliver such reasonable documentation
as a pledgee or secured party of Preferred Investment Options and Preferred Investment Option Shares may reasonably request in connection
with a pledge or transfer of the Preferred Investment Options or Preferred Investment Option Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Certificates evidencing the Preferred Investment Option Shares shall not contain any legend (including the legend set forth in Section
4.1(b) hereof): (i) while a registration statement covering the resale of such security is effective under the Securities Act, or (ii)
following any sale of such Preferred Investment Option Shares pursuant to Rule 144 (assuming cashless exercise of the Preferred Investment
Options), or (iii) if such Preferred Investment Option Shares are eligible for sale under Rule 144 (assuming cashless exercise of the
Preferred Investment Options), or (iv) if such legend is not required under applicable requirements of the Securities Act (including
judicial interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal
opinion to the Transfer Agent or the Purchaser promptly if required by the Transfer Agent to effect the removal of the legend hereunder,
or if requested by a Purchaser, respectively. If all or any portion of a Preferred Investment Option is exercised at a time when there
is an effective registration statement to cover the resale of the Preferred Investment Option Shares, or if such Preferred Investment
Option Shares may be sold under Rule 144 (assuming cashless exercise of the Preferred Investment Options) or if such legend is not otherwise
required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff
of the Commission) then such Preferred Investment Option Shares shall be issued free of all legends. The Company agrees that following
such time as such legend is no longer required under this Section 4.1(c), the Company will, no later than the earlier of (i) two (2)
Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery
by a Purchaser to the Company or the Transfer Agent of a certificate representing Preferred Investment Option Shares, as applicable,
issued with a restrictive legend (such date, the &ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or cause to be delivered to such
Purchaser a certificate representing such shares that is free from all restrictive and other legends. The Company may not make any notation
on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4. Preferred
Investment Option Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting
the account of the Purchaser&rsquo;s prime broker with the Depository Trust Company System as directed by such Purchaser. As used herein,
&ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s
primary Trading Market with respect to the Common Stock as in effect on the date of delivery of a certificate representing Preferred
Investment Option Shares issued with a restrictive legend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
In addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash, (i) as partial liquidated
damages and not as a penalty, for each $1,000 of Preferred Investment Option Shares (based on the VWAP of the Common Stock on the date
such Securities are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4.1(c), $10
per Trading Day (increasing to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day
after the Legend Removal Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver
(or cause to be delivered) to a Purchaser by the Legend Removal Date a certificate representing the Securities so delivered to the Company
by such Purchaser that is free from all restrictive and other legends and (b) if after the Legend Removal Date such Purchaser purchases
(in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of all or
any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the
number of shares of Common Stock, that such Purchaser anticipated receiving from the Company without any restrictive legend, then an
amount equal to the excess of such Purchaser&rsquo;s total purchase price (including brokerage commissions and other out-of-pocket expenses,
if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &ldquo;<FONT STYLE="font-weight: normal"><U>Buy-In
Price</U></FONT>&rdquo;) over the product of (A) such number of Preferred Investment Option Shares that the Company was required to deliver
to such Purchaser by the Legend Removal Date multiplied by (B) the lowest closing sale price of the Common Stock on any Trading Day during
the period commencing on the date of the delivery by such Purchaser to the Company of the applicable Preferred Investment Option Shares
(as the case may be) and ending on the date of such delivery and payment under this Section 4.1(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares shall be issued free of legends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Furnishing of Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Until the earlier of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to timely
file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company
after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
At any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of the
Preferred Investment Option Shares (assuming cashless exercise) may be sold without the requirement for the Company to be in compliance
with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, if the Company (i) shall fail for any reason
to satisfy the current public information requirement under Rule 144(c) or (ii) has ever been an issuer described in Rule 144(i)(1)(i)
or becomes an issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a &ldquo;<U>Public
Information Failure</U>&rdquo;) then, in addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser,
in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Preferred
Investment Option Shares, an amount in cash equal to two percent (2.0%) of the aggregate Exercise Price of such Purchaser&rsquo;s Preferred
Investment Options on the day of a Public Information Failure and on every thirtieth (30<SUP>th</SUP>) day (pro rated for periods totaling
less than thirty days) thereafter until the earlier of (a) the date such Public Information Failure is cured and (b) such time that such
public information is no longer required for the Purchasers to transfer the Preferred Investment Option Shares pursuant to Rule 144.
The payments to which a Purchaser shall be entitled pursuant to this Section 4.2(b) are referred to herein as &ldquo;<U>Public Information
Failure Payments</U>.&rdquo; Public Information Failure Payments shall be paid on the earlier of (i) the last day of the calendar month
during which such Public Information Failure Payments are incurred and (ii) the third (3<SUP>rd</SUP>) Business Day after the event or
failure giving rise to the Public Information Failure Payments is cured. In the event the Company fails to make Public Information Failure
Payments in a timely manner, such Public Information Failure Payments shall bear interest at the rate of 1.5% per month (prorated for
partial months) until paid in full. Nothing herein shall limit such Purchaser&rsquo;s right to pursue actual damages for the Public Information
Failure, and such Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would
require the registration under the Securities Act of the sale of the Preferred Investment Options or Preferred Investment Option Shares
or that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market
such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained
before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material
terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits
thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company
represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers
by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including,
without limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In addition,
effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations
under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors,
employees, Affiliates or agents, including, without limitation, the Placement Agent, on the one hand, and any of the Purchasers or any
of their Affiliates on the other hand, shall terminate and be no further force or effect. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser
shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the
Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of
the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any
press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law,
in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication.
Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser
in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except
(a) as required by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to
the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with
prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by
the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Non-Public Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such
information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company,
any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public
information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall
not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees,
Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of
their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, not to trade
on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant
to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant
in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Use of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes
and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than payment of trade payables
in the ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption of any Common Stock or Common Stock
Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Indemnification of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or
incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company
in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or
any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect
to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such
Purchaser Party&rsquo;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings
such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws
or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct)
or (c) in connection with any registration statement of the Company providing for the resale by the Purchasers of the Preferred Investment
Option Shares issued and issuable upon exercise of the Preferred Investment Options, the Company will indemnify each Purchaser Party,
to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including,
without limitation, reasonable attorneys&rsquo; fees) and expenses, as incurred, arising out of or relating to (i) any untrue or alleged
untrue statement of a material fact contained in such registration statement, any prospectus or any form of prospectus or in any amendment
or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material
fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or supplement thereto,
in the light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that such
untrue statements or omissions are based solely upon information regarding such Purchaser Party furnished in writing to the Company by
such Purchaser Party expressly for use therein, or (ii) any violation or alleged violation by the Company of the Securities Act, the
Exchange Act or any state securities law, or any rule or regulation thereunder in connection therewith. If any action shall be brought
against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly
notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably
acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate
in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent
that (x) the employment thereof has been specifically authorized by the Company in writing, (y) the Company has failed after a reasonable
period of time to assume such defense and to employ counsel or (z) in such action there is, in the reasonable opinion of counsel, a material
conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company
shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to
any Purchaser Party under this Agreement (1) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written
consent, which shall not be unreasonably withheld or delayed; or (2) to the extent, but only to the extent that a loss, claim, damage
or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or agreements
made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.8
shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received
or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser
Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
<U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep
available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
<U>Listing of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock
on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all
of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such
Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will
then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of
the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take
all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects
with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees
to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing
corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing
corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
<U>Subsequent Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From the date hereof until 60 days after the Effective Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement
to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration
statement or any amendment or supplement thereto, in each case other than the Prospectus Supplement or the filing of a registration statement
or any amendment thereto with respect to the Preferred Investment Option Shares and the Private Placement and the Warrant Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
From the date hereof until the one year anniversary of the Effective Date, the Company shall be prohibited from effecting or entering
into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a
combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction
in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or
include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other
price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the
initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset
at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events
directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction
under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the
Company may issue securities at a future determined price; <U>provided</U>, <U>however</U>, that, after six months following the Effective
Date, the issuance of shares of Common Stock in an &ldquo;at the market&rdquo; offering with the Placement Agent as sales agent shall
not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude
any such issuance, which remedy shall be in addition to any right to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction
shall be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
<U>Equal Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration
is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate
right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat
the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the
purchase, disposition or voting of Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13
<U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that
neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at
such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as
described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction (other than as disclosed
to its legal and other representatives). N<FONT STYLE="color: windowtext">otwithstanding the foregoing and notwithstanding anything contained
in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty
or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions
contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no
Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable
securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to
the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade
in the securities of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees,
Affiliates or agent, including, without limitation, the Placement Agent, after the issuance of the initial press release as described
in Section 4.4. </FONT>Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate
portfolio managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the
investment decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth
above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase
the Securities covered by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14
<FONT STYLE="color: windowtext"><U>Exercise Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality
of the procedures required of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions
shall be required of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required
in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with
the terms, conditions and time periods set forth in the Transaction Documents.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15
<FONT STYLE="color: windowtext"><U>Form D; Blue Sky Filings</U>. The Company agrees to timely file a Form D with respect to the Preferred
Investment Options and Preferred Investment Option Shares as required under Regulation D and to provide a copy thereof, promptly upon
request of any Purchaser. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain
an exemption for, or to qualify the Preferred Investment Options and Preferred Investment Option Shares for, sale to the Purchasers at
the Closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States, and shall provide evidence
of such actions promptly upon request of any Purchaser.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without
any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including,
without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice
delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus
Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior
agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such
documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is
delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New
York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
<U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares and Pre-Funded
Warrants based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case
of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification
or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted
Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement
of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the
rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior
written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon
each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7
<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the
transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8
<U>No Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties of
the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for the
benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision
hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall
be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10
<U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11
<U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13
<U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that in the case of a rescission
of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded
exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and
the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Warrant (including, issuance
of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14
<U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15
<U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction
Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that
a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16
<U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17
<U>Independent Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as
a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way
acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of
this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to
communicate with the Company through EGS. EGS does not represent any of the Purchasers and only represents the Placement Agent. The Company
has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because
it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in
this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and
the Purchasers collectively and not between and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18
<U>Liquidated Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts
have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19
<U>Saturdays, Sundays, Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20
<U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each
and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21
<B><U>WAIVER OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY,
THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
    Biosciences, Inc. </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
    for Notice:</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; layout-grid-mode: line; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; layout-grid-mode: line; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; layout-grid-mode: line; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="4" STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    a copy to (which shall not constitute notice):</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">ENVB</FONT> SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser: ________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Purchaser</I>: _________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory:_________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Warrants to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount: $_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:
_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
Warrants: _______________ Beneficial Ownership Blocker o 4.99% or o 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
Investment Options: _____________ Beneficial Ownership Blocker o 4.99% or o 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN
Number: _______________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>9
<FILENAME>ex10-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>E<FONT STYLE="font-variant: small-caps; text-transform: lowercase">xhibit
</FONT>10.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of July 22, 2022, between Enveric Biosciences, Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including
its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively, the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act (as defined below),
and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly,
desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <FONT STYLE="background-color: white"><U>provided</U>, <U>however</U>, for clarification, commercial
banks shall not be deemed to be authorized or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;,
&ldquo;non-essential employee&rdquo; or any other similar orders or restrictions or the closure of any physical branch locations at the
direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial
banks in The City of New York are generally open for use by customers on such day</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Haynes and Boone, LLP, with offices located at 30 Rockefeller Plaza, 26<SUP>th</SUP> Floor, New York, New York
10112.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effective
Date</U>&rdquo; means the earliest of the date that (a) the initial Registration Statement registering for resale all Shares and Warrant
Shares has been declared effective by the Commission, (b) all of the Shares and Warrant Shares have been sold pursuant to Rule 144 or
may be sold pursuant to Rule 144 without the requirement for the Company to be in compliance with the current public information required
under Rule 144 and without volume or manner-of-sale restrictions, (c) following the one year anniversary of the Closing Date provided
that a holder of Shares or Warrant Shares is not an Affiliate of the Company, or (d) all of the Shares and Warrant Shares may be sold
pursuant to an exemption from registration under Section 4(a)(1) of the Securities Act without volume or manner-of-sale restrictions
and Company Counsel has delivered to such holders a standing written unqualified opinion that resales may then be made by such holders
of the Shares and Warrant Shares pursuant to such exemption which opinion shall be in form and substance reasonably acceptable to such
holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant
to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority
of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) warrants
to the Placement Agent in connection with the transactions pursuant to this Agreement and any securities upon exercise of warrants to
the Placement Agent, securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities
exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided
that (other than with respect to the Warrant Amendment (as such term is defined below)) such securities have not been amended since the
date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price
of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, (c) securities
issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided
that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that
require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.11(a) herein,
and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries,
an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company
additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities
primarily for the purpose of raising capital or to an entity whose primary business is investing in securities and (d) securities of
the Company issued pursuant to a concurrent registered direct offering and private placement of the preferred investment options issued
in the registered direct offering (the &ldquo;<U>Registered Direct</U>&rdquo;) and amendment to certain existing warrants held by the
Purchasers (the &ldquo;<U>Warrant Amendment</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(kk).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(kk).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(bb).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Legend
Removal Date</U>&rdquo; shall have the meaning ascribed to such term in Section 4.1(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $8.00 (less $0.0001 for each Pre-Funded Warrant), subject to adjustment for reverse and forward
stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(jj).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agent</U>&rdquo; means H.C. Wainwright &amp; Co., LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preferred
Investment Options</U>&rdquo; means, collectively, the Preferred Investment Options delivered to the Purchasers at the Closing in accordance
with Section 2.2(a) hereof, which Preferred Investment Options shall be exercisable immediately upon issuance and have a term of exercise
equal to 5.5 years, in the form of <U>Exhibit A-2</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preferred
Investment Option Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Preferred Investment Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing in
accordance with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately and will expire when exercised in full,
in the form of <U>Exhibit A-1</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Public
Information Failure</U>&rdquo; shall have the meaning ascribed to such term in Section 4.2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Public
Information Failure Payments</U>&rdquo; shall have the meaning ascribed to such term in Section 4.2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Rights Agreement</U>&rdquo; means the Registration Rights Agreement, dated on or about the date hereof, among the Company and the Purchasers,
in the form of <U>Exhibit B</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means a registration statement meeting the requirements set forth in the Registration Rights Agreement and covering
the resale by the Purchasers of the Shares and the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Warrants and the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in; color: blue"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified
below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds (minus, if applicable, a Purchaser&rsquo;s aggregate exercise price of the
Pre-Funded Warrants, which amounts shall be paid as and when such Pre-Funded Warrants are exercised for cash).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth in the SEC Reports and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, the Registration Rights Agreement, all exhibits and schedules thereto and hereto
and any other documents or agreements executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means American Stock Transfer &amp; Trust LLC the current transfer agent of the Company, with a mailing address of 6201
15th Ave, Brooklyn, NY 11219, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Preferred Investment Options and the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASE
AND SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the
execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly,
agree to purchase, up to an aggregate of $5.0 million of Shares and Warrants. Notwithstanding anything herein to the contrary, to the
extent that a Purchaser determines, in its sole discretion, that such Purchaser&rsquo;s Subscription Amount (together with such Purchaser&rsquo;s
Affiliates and any Person acting as a group together with such Purchaser or any of such Purchaser&rsquo;s Affiliates) would cause such
Purchaser&rsquo;s beneficial ownership of the shares of Common Stock to exceed the Beneficial Ownership Limitation, or as such Purchaser
may otherwise choose, such Purchaser may elect to purchase Pre-Funded Warrants in lieu of the Shares as determined pursuant to Section
2.2(a). The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, at the election of the Purchaser at Closing, 9.99%)
of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the Securities on the Closing
Date. In each case, the election to receive Pre-Funded Warrants is solely at the option of the Purchaser. Each Purchaser shall deliver
to the Company, via wire transfer or a certified check, immediately available funds equal to such Purchaser&rsquo;s Subscription Amount
as set forth on the signature page hereto executed by such Purchaser, and the Company shall deliver to each Purchaser its respective
Shares, Pre-Funded Warrants and Preferred Investment Option, as determined pursuant to Section 2.2(a), and the Company and each Purchaser
shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions
set forth in Sections 2.2 and 2.3, the Closing shall take place remotely by electronic transfer of the Closing documentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a legal opinion of Company Counsel, directed to the Placement Agent and the Purchasers, in a form reasonably acceptable to the Placement
Agent and Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis, a certificate
evidencing a number of Shares equal to such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price, registered
in the name of such Purchaser, or, at the election of such Purchaser, evidence of the issuance of such Purchaser&rsquo;s Shares hereunder
as held in DRS book-entry form by the Transfer Agent and registered in the name of such Purchaser, which evidence shall be reasonably
satisfactory to such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
a Preferred Investment Option registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to
100% of the sum of such Purchaser&rsquo;s Shares and Pre-Funded Warrant Shares, with an exercise price equal to $7.78, subject to adjustment
therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
if applicable, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal
to the difference between (A) such Purchaser&rsquo;s Subscription Amount divided by the Per Pre-Funded Warrant Purchase Price and (B)
the number of Shares otherwise issuable to such Purchaser that would cause such Purchaser&rsquo;s Beneficial Ownership to be more than
the Beneficial Ownership Limitation with an exercise price equal to $0.0001 per share of Common Stock, subject to adjustment therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
the Registration Rights Agreement duly executed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
such Purchaser&rsquo;s Subscription Amount by wire transfer to the account specified in writing by the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the Registration Rights Agreement duly executed by such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Closing Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects)
on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in
which case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality,
in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless
as of a specific date therein in which case they shall be accurate in all material respects or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
there shall have been no Material Adverse Effect with respect to the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPRESENTATIONS
AND WARRANTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. Except as set forth in the SEC Reports, the Company hereby makes the following
representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Subsidiaries</U>. All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. Except as set forth
SEC Reports, the Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and
clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully
paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries,
all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could
not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in
any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material
Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking
to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no
further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith
other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been
(or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission pursuant to the Registration Rights Agreement,
(iii) the notice and/or application(s) to each applicable Trading Market for the issuance and sale of the Securities and the listing
of the Shares and Warrant Shares for trading thereon in the time and manner required thereby, and (iv) the filing of Form D with the
Commission and such filings as are required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Issuance of the Securities</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company
other than restrictions on transfer provided for in the Transaction Documents. The Warrant Shares, when issued in accordance with the
terms of the Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the
Company other than restrictions on transfer provided for in the Transaction Documents. The Company has reserved from its duly authorized
capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth in the SEC Reports, including the number
of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof. The Company has not
issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of
employee stock options under the Company&rsquo;s stock option plans, the issuance of shares of Common Stock to employees pursuant to
the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding
as of the date of the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive
right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except
as a result of the purchase and sale of the Securities and as set forth in the SEC Reports, there are no outstanding options, warrants,
scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible
into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the
capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is
or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance
and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any
Person (other than the Purchasers). Except as set forth in the SEC Reports, there are no outstanding securities or instruments of the
Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument
upon an issuance of securities by the Company or any Subsidiary. Except as set forth in the SEC Reports, there are no outstanding securities
or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such
Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar
plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and
nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued
in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization
of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders
agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a
party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein
as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received a valid extension of such time of filing and has filed any
such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material
respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained
any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading. The Company has been subject to
Rule 144(i) under the Securities Act; it has filed all reports and other materials required to be filed by Section 13 or 15(d) of the
Exchange Act, as applicable, during the preceding 48 months. The financial statements of the Company included in the SEC Reports comply
in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto
as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted
accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise
specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes
required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries
as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited
statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included
within the SEC Reports, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result
in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables
and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be
reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company
has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property
to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company
has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The
Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of
the Securities contemplated by this Agreement or as set forth in the SEC Reports, no event, liability, fact, circumstance, occurrence
or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or
their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed
by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed
at least 1 Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Litigation</U>. Except as set forth in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation
pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties
before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth in SEC Reports, (i) adversely affects or challenges the
legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable
decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director
or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities
laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission
has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary
under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree, or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Environmental Laws</U>.&#9;The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws
relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface
or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants,
or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise
relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials,
as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters,
orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;);
(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i),
(ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and the payment of which
is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which
the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None
of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights
has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date
of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included
within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe
upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge
of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any
of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company
nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase
in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Transactions with Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of the Company
or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to
any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to
or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director
or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other
employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements
of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries
maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance
with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with
management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets
at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and
designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it
files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s
rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of
the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act
(such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange
Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations
as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as
such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely
to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Certain Fees</U>. Except for fees payable by the Company to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions
are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no
obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated
in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Private Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, no
registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated
hereby. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Registration Rights</U>. Other than each of the Purchasers and as set forth in the SEC Reports, no Person has any right to cause the
Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in
the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently
eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is
current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such
electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the
laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of
the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or
counsel with any information that it believes constitutes or might constitute material, non-public information. The Company understands
and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All
of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective
businesses and the transactions contemplated hereby is true and correct and does not contain any untrue statement of a material fact
or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which
they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement
taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the circumstances under which they were made and when made, not
misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to
the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of any
such securities under the Securities Act, or (ii) any applicable shareholder approval provisions of any Trading Market on which any of
the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt
by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its
business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)
the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature
(taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any
facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. All outstanding secured and unsecured Indebtedness of the Company or
any Subsidiary, or for which the Company or any Subsidiary has commitments is set forth in the SEC Reports. For the purposes of this
Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other
than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations
in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance
sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions
in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to
be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)
has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material
taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>No General Solicitation</U>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Securities
by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers and
certain other &ldquo;accredited investors&rdquo; within the meaning of Rule 501 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>Foreign Corrupt Practices.</U> Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<U>Accountants</U>. The Company&rsquo;s accounting firm is set forth in SEC Reports . To the knowledge and belief of the Company, such
accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with respect
to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>No Disagreements with Accountants and Lawyers.</U>&#9;There are no disagreements of any kind presently existing, or reasonably anticipated
by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company and the Company
is current with respect to any fees owed to its accountants and lawyers which could affect the Company&rsquo;s ability to perform any
of its obligations under any of the Transaction Documents. &#9;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Acknowledgment Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Sections 3.2(g) and 4.13 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been
asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the
Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified
term, (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales
or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company&rsquo;s publicly-traded securities, (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo;
transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the
Common Stock and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party
in any &ldquo;derivative&rdquo; transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage
in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the
periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities
(if any) could reduce the value of the existing stockholders&rsquo; equity interests in the Company at and after the time that the hedging
activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any
of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>Regulation M Compliance.</U> The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement
of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under
the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure
to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter
or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and
promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws
or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical
hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company
or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of
its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries,
and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of
the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations
of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United
States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving
or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll) <U>Form
S-3 Eligibility</U>. The Company is eligible to register the resale of the Securities for resale by the Purchaser on Form S-3 promulgated
under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm) <U>Stock
Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn) <U>Cybersecurity</U>.
(i)(x) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s information
technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers,
vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;)
and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition that would reasonably
be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are
presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator
or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems
and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as
would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented
and maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous
operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and
disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo) <U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp) <U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning
of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq) <U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of
1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal
Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or
Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr) <U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss) <U>No
Disqualification Events</U>. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under the Securities
Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company
participating in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s outstanding voting equity securities,
calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with
the Company in any capacity at the time of sale (each, an &ldquo;<U>Issuer Covered Person</U>&rdquo; and, together, &ldquo;<U>Issuer
Covered Persons</U>&rdquo;) is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described in Rule 506(d)(1)(i) to (viii)
under the Securities Act (a &ldquo;<U>Disqualification Event</U>&rdquo;), except for a Disqualification Event covered by Rule 506(d)(2)
or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification
Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the
Purchasers a copy of any disclosures provided thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt) <U>Other
Covered Persons</U>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person) that
has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(uu) <U>Notice
of Disqualification Events</U>. The Company will notify the Purchasers and the Placement Agent in writing, prior to the Closing Date
of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become
a Disqualification Event relating to any Issuer Covered Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2 <U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the
date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate
as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such
Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a
party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except (i) as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Own
Account</U>. Such Purchaser understands that the Securities are &ldquo;restricted securities&rdquo; and have not been registered under
the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account and not with
a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state
securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable
state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the
distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty
not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with
applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which
it exercises any Warrants, it will be an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8),
(a)(9), (a)(12), or (a)(13) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) <U>General
Solicitation</U>. Such Purchaser is not, to such Purchaser&rsquo;s knowledge, purchasing the Securities as a result of any advertisement,
article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over
television or radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) <U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither the Placement
Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the Securities
nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes any representation
as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public information
with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of the Securities
to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) <U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or
sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first
received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms
of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the
case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other
portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets
managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to
other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers, directors,
partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures
made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing,
for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV.<BR>
OTHER AGREEMENTS OF THE PARTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 <U>Transfer
Restrictions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The
Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities
other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection
with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion
of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably
satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities under the
Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and
the Registration Rights Agreement and shall have the rights and obligations of a Purchaser under this Agreement and the Registration
Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities in the following
form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON
AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY
NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE
SECURITIES LAWS. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER
LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR
OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered
broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an &ldquo;accredited investor&rdquo;
as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such Purchaser may transfer
pledged or secured Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company
and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no
notice shall be required of such pledge. At the appropriate Purchaser&rsquo;s expense, the Company will execute and deliver such reasonable
documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities,
including, if the Securities are subject to registration pursuant to the Registration Rights Agreement, the preparation and filing of
any required prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act
to appropriately amend the list of Selling Stockholders (as defined in the Registration Rights Agreement) thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Certificates
evidencing the Shares and Warrant Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof), (i)
while a registration statement (including the Registration Statement) covering the resale of such security is effective under the Securities
Act, (ii) following any sale of such Shares or Warrant Shares pursuant to Rule 144 (assuming cashless exercise of the Warrants), (iii)
if such Shares or Warrant Shares are eligible for sale under Rule 144 (assuming cashless exercise of the Warrants), or (iv) if such legend
is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by
the staff of the Commission). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent or the Purchaser promptly
after the Effective Date if required by the Transfer Agent to effect the removal of the legend hereunder, or if requested by a Purchaser,
respectively. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the
resale of the Warrant Shares, or if such Shares or Warrant Shares may be sold under Rule 144 and the Company is then in compliance with
the current public information required under Rule 144 (assuming cashless exercise of the Warrants), or if the Shares or Warrant Shares
may be sold under Rule 144 without the requirement for the Company to be in compliance with the current public information required under
Rule 144 as to such Shares or Warrant Shares or if such legend is not otherwise required under applicable requirements of the Securities
Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then such Warrant Shares shall be issued
free of all legends. The Company agrees that following the Effective Date or at such time as such legend is no longer required under
this Section 4.1(c), it will, no later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the
Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate
representing Shares or Warrant Shares, as the case may be, issued with a restrictive legend (such date, the &ldquo;<U>Legend Removal
Date</U>&rdquo;), deliver or cause to be delivered to such Purchaser a certificate representing such shares that is free from all restrictive
and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions
on transfer set forth in this Section 4. Certificates for Securities subject to legend removal hereunder shall be transmitted by the
Transfer Agent to the Purchaser by crediting the account of the Purchaser&rsquo;s prime broker with the Depository Trust Company System
as directed by such Purchaser. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period,
expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on
the date of delivery of a certificate representing Shares or Warrant Shares, as the case may be, issued with a restrictive legend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) In
addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash, (i) as partial liquidated
damages and not as a penalty, for each $1,000 of Shares or Warrant Shares (based on the VWAP of the Common Stock on the date such Securities
are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4.1(c), $10 per Trading Day
(increasing to $20 per Trading Day five (5) Trading Days after the Legend Removal Date) for each Trading Day after the Legend Removal
Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered)
to a Purchaser by the Legend Removal Date a certificate representing the Securities so delivered to the Company by such Purchaser that
is free from all restrictive and other legends and (b) if after the Legend Removal Date such Purchaser purchases (in an open market transaction
or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of shares
of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock
that such Purchaser anticipated receiving from the Company without any restrictive legend, then, an amount equal to the excess of such
Purchaser&rsquo;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common
Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &ldquo;<FONT STYLE="font-weight: normal"><U>Buy-In
Price</U></FONT>&rdquo;) over the product of (A) such number of Shares or Warrant Shares that the Company was required to deliver to
such Purchaser by the Legend Removal Date multiplied by (B) the lowest closing sale price of the Common Stock on any Trading Day during
the period commencing on the date of the delivery by such Purchaser to the Company of the applicable Shares or Warrant Shares (as the
case may be) and ending on the date of such delivery and payment under this clause (ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) Each
Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell any Securities
pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or
an exemption therefrom, and that if Securities are sold pursuant to a Registration Statement, they will be sold in compliance with the
plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Securities
as set forth in this Section 4.1 is predicated upon the Company&rsquo;s reliance upon this understanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 <U>Furnishing
of Information; Public Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Until
the earlier of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to maintain the
registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect
thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to
the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) At
any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of the Securities
may be sold without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation
pursuant to Rule 144, if the Company (i) shall fail for any reason to satisfy the current public information requirement under Rule 144(c)
or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an issuer in the future, and the Company shall fail to satisfy
any condition set forth in Rule 144(i)(2) (a &ldquo;<U>Public Information Failure</U>&rdquo;) then, in addition to such Purchaser&rsquo;s
other available remedies, the Company shall pay to a Purchaser, in cash, as partial liquidated damages and not as a penalty, by reason
of any such delay in or reduction of its ability to sell the Securities, an amount in cash equal to two percent (2.0%) of the aggregate
Subscription Amount of such Purchaser&rsquo;s Securities on the day of a Public Information Failure and on every thirtieth (30<SUP>th</SUP>)
day (pro rated for periods totaling less than thirty days) thereafter until the earlier of (a) the date such Public Information Failure
is cured and (b) such time that such public information is no longer required for the Purchasers to transfer the Shares and Warrant Shares
pursuant to Rule 144. The payments to which a Purchaser shall be entitled pursuant to this Section 4.2(b) are referred to herein as &ldquo;<U>Public
Information Failure Payments</U>.&rdquo; Public Information Failure Payments shall be paid on the earlier of (i) the last day of the
calendar month during which such Public Information Failure Payments are incurred and (ii) the third (3<SUP>rd</SUP>) Business Day after
the event or failure giving rise to the Public Information Failure Payments is cured. In the event the Company fails to make Public Information
Failure Payments in a timely manner, such Public Information Failure Payments shall bear interest at the rate of 1.5% per month (prorated
for partial months) until paid in full. Nothing herein shall limit such Purchaser&rsquo;s right to pursue actual damages for the Public
Information Failure, and such Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 <U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in
Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the
registration under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale of the Securities
for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing
of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4 <U>Securities
Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of
the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto,
with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents
to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the
Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without
limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In addition, effective
upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations
under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors,
agents, employees, Affiliates or agents, including, without limitation, the Placement Agent, on the one hand, and any of the Purchasers
or any of their Affiliates on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms
that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and
each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby,
and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the
prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with
respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is
required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement
or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name
of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such
Purchaser, except (a) as required by federal securities law in connection with (i) any registration statement contemplated by the Registration
Rights Agreement and (ii) the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is required
by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted
under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5 <U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser
is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser
could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents
or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6 <U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting on its
behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such
information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company,
any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public
information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall
not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees,
Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of
their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, not to trade
on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant
to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant
in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7 <U>Use
of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and shall
not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than payment of trade payables in the
ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption of any Common Stock or Common Stock Equivalents,
(c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8 <U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning
of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members,
partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack
of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any and all
losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result
of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents, (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their
respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the
transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party&rsquo;s
representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may
have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser
Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct), or (c) in connection with
any registration statement of the Company providing for the resale by the Purchasers of the Warrant Shares issued and issuable upon exercise
of the Warrants, the Company will indemnify each Purchaser Party, to the fullest extent permitted by applicable law, from and against
any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys&rsquo; fees) and expenses,
as incurred, arising out of or relating to (i) any untrue or alleged untrue statement of a material fact contained in such registration
statement, any prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising
out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements
therein (in the case of any prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading,
except to the extent, but only to the extent, that such untrue statements or omissions are based solely upon information regarding such
Purchaser Party furnished in writing to the Company by such Purchaser Party expressly for use therein, or (ii) any violation or alleged
violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder in
connection therewith. If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant
to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume
the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the
right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel
shall be at the expense of such Purchaser Party except to the extent that (x) the employment thereof has been specifically authorized
by the Company in writing, (y) the Company has failed after a reasonable period of time to assume such defense and to employ counsel
or (z) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position
of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses
of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (1) for any settlement
by a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed;
or (2) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach
of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction
Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course
of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in
addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company
may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9 <U>Reservation
of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at
all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue
Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10 <U>Listing
of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on the Trading
Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares
and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market.
The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include
in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares
and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action
reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with
the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain
the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation,
including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation
in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11 <U>Subsequent
Equity Sales.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) From
the date hereof until 60 days after the Effective Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement
to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration
statement or any amendment or supplement thereto, in each case other than as contemplated pursuant to the Registration Rights Agreement,
and other than a prospectus supplement to be filed in connection with the Registered Direct or the filing of a registration statement
or any amendment thereto with respect to the Warrant Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) From
the date hereof until the one year anniversary of the Effective Date, the Company shall be prohibited from effecting or entering into
an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination
of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which
the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include
the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price
that is based upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock at any time after the initial
issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some
future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly
or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction
under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the
Company may issue securities at a future determined price; <U>provided</U>, <U>however</U>, that, after six months following the Effective
Date, the issuance of shares of Common Stock in an &ldquo;at the market&rdquo; offering with the Placement Agent as sales agent shall
not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude
any such issuance, which remedy shall be in addition to any right to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Notwithstanding
the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be
an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12 <U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is
also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right
granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers
as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition
or voting of Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13 <U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it,
nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short
Sales, of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such
time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions
contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4,
such Purchaser will maintain the confidentiality of the existence and terms of this transaction (other than as disclosed to its legal
and other representatives). Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary, the
Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not
engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement
are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted
or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and
after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the
Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agent, including
, without limitation, the Placement Agent after the issuance of the initial press release as described in Section 4.4. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the
portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect
to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14 <U>Form
D; Blue Sky Filings</U>. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and
to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably
determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers at the Closing under
applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States, and shall provide evidence of such actions promptly
upon request of any Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15 <U>Acknowledgment
of Dilution</U>. The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common
Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges that its obligations under
the Transaction Documents, including, without limitation, its obligation to issue the Shares and Warrant Shares pursuant to the Transaction
Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the
effect of any such dilution or any claim the Company may have against any Purchaser and regardless of the dilutive effect that such issuance
may have on the ownership of the other stockholders of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16 <U>Exercise
Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers
in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the Purchasers
to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall
any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to exercise
the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms, conditions
and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V.<BR>
MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1 <U>Termination</U>.
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect whatsoever
on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been
consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>, that no such
termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2 <U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses
of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without
limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered
by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3 <U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4 <U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via facsimile
at the facsimile number or email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30
p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication
is delivered via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading
Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of
mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice
is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5 <U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in
the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares and Pre-Funded Warrants
based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver,
by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver
disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser
(or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of
this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the
rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior
written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon
each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6 <U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7 <U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser
(other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns
or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities,
by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8 <U>No
Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties of the
Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for the benefit
of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof
be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9 <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents),
and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.
If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the
obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing
party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10 <U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11 <U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo;
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12 <U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13 <U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any
of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document
and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in
whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that, in the case of a rescission
of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded
exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and
the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Warrant (including, issuance
of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14 <U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of
and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company
of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15 <U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and
hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law
would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16 <U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a
Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or
any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or
are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17 <U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For
reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through
EGS. EGS does not represent any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers
with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so
by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction
Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between
and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18 <U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents
is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have
been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19 <U>Saturdays,
Sundays, Holidays, etc.</U>&#9;If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20 <U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to
share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21 <B><U>WAIVER
OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES
EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective
authorized signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
    Biosciences, Inc.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
    for Notice:</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">With
    a copy to (which shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">ENVB</FONT> SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser: ________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Purchaser</I>: __________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ____________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: _____________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory: ______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Securities to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount: $_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:
_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
Warrants: _______________ Beneficial Ownership Blocker &#9744;  4.99% or &#9744;  9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
Investment Option: _____________ Beneficial Ownership Blocker &#9744;  4.99% or &#9744;  9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN
Number: _______________________</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>10
<FILENAME>ex10-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.3</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REGISTRATION
RIGHTS AGREEMENT</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Registration Rights Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is made and entered into as of __________, 2022, between Enveric
Biosciences, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each of the several purchasers signatory hereto (each
such purchaser, a &ldquo;<U>Purchaser</U>&rdquo; and, collectively, the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser
(the &ldquo;<U>Purchase Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and each Purchaser hereby agrees as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Definitions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capitalized
terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the
Purchase Agreement.</B> As used in this Agreement, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Advice</U>&rdquo;
shall have the meaning set forth in Section 6(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effectiveness
Date</U>&rdquo; means, with respect to the Initial Registration Statement required to be filed hereunder, the 45<SUP>th</SUP> calendar
day following the date hereof (or, in the event of a &ldquo;full review&rdquo; by the Commission, the 75<SUP>th</SUP> calendar day following
the date hereof) and with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section
3(c), the 45<SUP>th</SUP> calendar day following the date on which an additional Registration Statement is required to be filed hereunder
(or, in the event of a &ldquo;full review&rdquo; by the Commission, the 75<SUP>th</SUP> calendar day following the date such additional
Registration Statement is required to be filed hereunder); <U>provided</U>, <U>however</U>, that in the event the Company is notified
by the Commission that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review
and comments, the Effectiveness Date as to such Registration Statement shall be the fifth Trading Day following the date on which the
Company is so notified if such date precedes the dates otherwise required above, provided, further, if such Effectiveness Date falls
on a day that is not a Trading Day, then the Effectiveness Date shall be the next succeeding Trading Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effectiveness
Period</U>&rdquo; shall have the meaning set forth in Section 2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Event</U>&rdquo;
shall have the meaning set forth in Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Event
Date</U>&rdquo; shall have the meaning set forth in Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Filing
Date</U>&rdquo; means, with respect to the Initial Registration Statement required hereunder, the 15<SUP>th</SUP> calendar day following
the date hereof and, with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section
3(c), the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related
to the Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Holder</U>&rdquo;
or &ldquo;<U>Holders</U>&rdquo; means the holder or holders, as the case may be, from time to time of Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indemnified
Party</U>&rdquo; shall have the meaning set forth in Section 5(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indemnifying
Party</U>&rdquo; shall have the meaning set forth in Section 5(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Initial
Registration Statement</U>&rdquo; means the initial Registration Statement filed pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Losses</U>&rdquo;
shall have the meaning set forth in Section 5(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Plan
of Distribution</U>&rdquo; shall have the meaning set forth in Section 2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the
Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the
offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to
the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference
in such Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registrable
Securities</U>&rdquo; means, as of any date of determination, (a) all Shares, (b) all Warrant Shares then issued and issuable upon exercise
of the Warrants, including the Preferred Investment Option Shares (as such term is defined in the securities purchase agreement entered
into in connection with the Registered Direct) then issued and issuable upon exercise of the Preferred Investment Options (as such term
is defined in the securities purchase agreement entered into in connection with the Registered Direct) issued by the Company to the Purchaser
in connection with the Registered Direct (assuming on such date the Warrants are exercised in full without regard to any exercise limitations
therein), (c) any additional shares of Common Stock issued and issuable in connection with any anti-dilution provisions in the Warrants,
including the Preferred Investment Options (as such term is defined in the securities purchase agreement entered into in connection with
the Registered Direct) issued by the Company to the Purchaser in connection with the Registered Direct (without giving effect to any
limitations on exercise set forth in the Warrants) and (d) any securities issued or then issuable upon any stock split, dividend or other
distribution, recapitalization or similar event with respect to the foregoing; <U>provided, however</U>, that any such Registrable Securities
shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another,
Registration Statement hereunder with respect thereto) for so long as (a) a Registration Statement with respect to the sale of such Registrable
Securities is declared effective by the Commission under the Securities Act and such Registrable Securities have been disposed of by
the Holder in accordance with such effective Registration Statement, (b) such Registrable Securities have been previously sold in accordance
with Rule 144, or (c) such securities become eligible for resale without volume or manner-of-sale restrictions and without current public
information pursuant to Rule 144 as set forth in a written opinion letter to such effect, addressed, delivered and acceptable to the
Transfer Agent and the affected Holders (assuming that such securities and any securities issuable upon exercise, conversion or exchange
of which, or as a dividend upon which, such securities were issued or are issuable, were at no time held by any Affiliate of the Company,
as reasonably determined by the Company, upon the advice of counsel to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional registration
statements contemplated by Section 2(c) or Section 3(c), including (in each case) the Prospectus, amendments and supplements to any such
registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated
by reference or deemed to be incorporated by reference in any such registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
415</U>&rdquo; means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Selling
Stockholder Questionnaire</U>&rdquo; shall have the meaning set forth in Section 3(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Guidance</U>&rdquo; means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements
or requests of the Commission staff and (ii) the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Shelf Registration</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale
of all of the Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made
on a continuous basis pursuant to Rule 415. Each Registration Statement filed hereunder shall be on Form S-3 (except if the Company
is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on
another appropriate form in accordance herewith, subject to the provisions of Section 2(e)) and shall contain (unless otherwise
directed by at least 85% in interest of the Holders) substantially the &ldquo;<U>Plan of Distribution</U>&rdquo; attached hereto as <U>Annex
A</U> and substantially the &ldquo;<U>Selling Stockholder</U>&rdquo; section attached hereto as <U>Annex B</U>; <U>provided</U>, <U>however</U>,
that no Holder shall be required to be named as an &ldquo;underwriter&rdquo; without such Holder&rsquo;s express prior written
consent. Subject to the terms of this Agreement, the Company shall use its best efforts to cause a Registration Statement filed
under this Agreement (including, without limitation, under Section 3(c)) to be declared effective under the Securities Act as
promptly as possible after the filing thereof, but in any event no later than the applicable Effectiveness Date, and shall use its
best efforts to keep such Registration Statement continuously effective under the Securities Act until the date that all Registrable
Securities covered by such Registration Statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold
without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance
with the current public information requirement under Rule 144, as determined by the counsel to the Company pursuant to a written
opinion letter to such effect, addressed and acceptable to the Transfer Agent and the affected Holders (the &ldquo;<U>Effectiveness
Period</U>&rdquo;). The Company shall telephonically request effectiveness of a Registration Statement as of 5:00 p.m. (New York
City time) on a Trading Day. The Company shall immediately notify the Holders via e-mail of the effectiveness of a Registration
Statement on the same Trading Day that the Company telephonically confirms effectiveness with the Commission, which shall be the
date requested for effectiveness of such Registration Statement. The Company shall, by 9:30 a.m. (New York City time) on the Trading
Day after the effective date of such Registration Statement, file a final Prospectus with the Commission as required by Rule 424.
Failure to so notify the Holder within one (1) Trading Day of such notification of effectiveness or failure to file a final
Prospectus as foresaid shall be deemed an Event under Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Notwithstanding the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the
Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a
single registration statement, the Company agrees to promptly inform each of the Holders thereof and use its commercially reasonable
efforts to file amendments to the Initial Registration Statement as required by the Commission, covering the maximum number of
Registrable Securities permitted to be registered by the Commission, on Form S-3 or such other form available to register for resale
the Registrable Securities as a secondary offering, subject to the provisions of Section 2(e); with respect to filing on Form S-3 or
other appropriate form, and subject to the provisions of Section 2(d) with respect to the payment of liquidated damages; <U>provided</U>, <U>however</U>,
that prior to filing such amendment, the Company shall be obligated to use diligent efforts to advocate with the Commission for the
registration of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, Compliance and
Disclosure Interpretation 612.09.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Notwithstanding any other provision of this Agreement and subject to the payment of liquidated damages pursuant to Section 2(d), if
the Commission or any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular
Registration Statement as a secondary offering (and notwithstanding that the Company used diligent efforts to advocate with the Commission
for the registration of all or a greater portion of Registrable Securities), unless otherwise directed in writing by a Holder as to its
Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement will be reduced as follows:</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>First,
                                            the Company shall reduce or eliminate any securities to be included other than Registrable
                                            Securities;</U></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Second,
                                            the Company shall reduce Registrable Securities represented by Preferred Investment Option
                                            Shares (applied, in the case that some Preferred Investment Option Shares may be registered,
                                            to the Holders on a pro rata basis based on the total number of unregistered Preferred Investment
                                            Option Shares held by such Holders); and</U></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Third,
                                            the Company shall reduce Registrable Securities represented by Shares and Pre-Funded Warrants
                                            (applied, in the case that some Shares and Pre-Funded Warrants may be registered, to the
                                            Holders on a pro rata basis based on the total number of unregistered Shares and Pre-Funded
                                            Warrants held by such Holders).</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>In
the event of a cutback hereunder, the Company shall give the Holder at least three (3) Trading Days prior written notice along with the
calculations as to such Holder&rsquo;s allotment. In the event the Company amends the Initial Registration Statement in accordance with
the foregoing, the Company will use its best efforts to file with the Commission, as promptly as allowed by Commission or SEC Guidance
provided to the Company or to registrants of securities in general, one or more registration statements on Form S-3 or such other form
available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration Statement,
as amended.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
If: (i) the Initial Registration Statement is not filed on or prior to its Filing Date (if the Company files the Initial
Registration Statement without affording the Holders the opportunity to review and comment on the same as required by Section 3(a)
herein or the Company subsequent withdraws the filing of the Registration Statement, the Company shall be deemed to have not
satisfied this clause as of the Filing Date (i)), or (ii) the Company fails to file with the Commission a request for acceleration
of a Registration Statement in accordance with Rule 461 promulgated by the Commission pursuant to the Securities Act, within five
Trading Days of the date that the Company is notified (orally or in writing, whichever is earlier) by the Commission that such
Registration Statement will not be &ldquo;reviewed&rdquo; or will not be subject to further review, or (iii) prior to the effective
date of a Registration Statement, the Company fails to file a pre-effective amendment and otherwise respond in writing to comments
made by the Commission in respect of such Registration Statement within ten (10) calendar days after the receipt of comments by or
notice from the Commission that such amendment is required in order for such Registration Statement to be declared effective, or
(iv) a Registration Statement registering for resale all of the Registrable Securities is not declared effective by the Commission
by the Effectiveness Date of the Initial Registration Statement (provided if the Registration Statement does not allow for the
resale of Registrable Securities at prevailing market prices (ie. only allows for fixed price sales), the Company shall have been
deemed to have not satisfied this clause) or (v) after the effective date of a Registration Statement, such Registration Statement
ceases for any reason to remain continuously effective as to all Registrable Securities included in such Registration Statement, or
the Holders are otherwise not permitted to utilize the Prospectus therein to resell such Registrable Securities, for more than ten
(10) consecutive calendar days or more than an aggregate of fifteen (15) calendar days (which need not be consecutive calendar days)
during any 12-month period (any such failure or breach being referred to as an &ldquo;<U>Event</U>&rdquo;, and for purposes of
clauses (i) and (iv), the date on which such Event occurs, and for purpose of clause (ii) the date on which such five (5) Trading
Day period is exceeded, and for purpose of clause (iii) the date which such ten (10) calendar day period is exceeded, and for
purpose of clause (v) the date on which such ten (10) or fifteen (15) calendar day period, as applicable, is exceeded being referred
to as &ldquo;<U>Event Date</U>&rdquo;), then, in addition to any other rights the Holders may have hereunder or under applicable
law, on each such Event Date and on each monthly anniversary of each such Event Date (if the applicable Event shall not have been
cured by such date) until the applicable Event is cured, the Company shall pay to each Holder an amount in cash, as partial
liquidated damages and not as a penalty, equal to the product of 1.0% multiplied by the aggregate Subscription Amount paid by such
Holder pursuant to the Purchase Agreement. The parties agree that the maximum aggregate liquidated damages payable to a Holder under
this Agreement shall be 5.0% of the aggregate Subscription Amount paid by such Holder pursuant to the Purchase Agreement. If the
Company fails to pay any partial liquidated damages pursuant to this Section in full within seven days after the date payable, the
Company will pay interest thereon at a rate of 18% per annum (or such lesser maximum amount that is permitted to be paid by
applicable law) to the Holder, accruing daily from the date such partial liquidated damages are due until such amounts, plus all
such interest thereon, are paid in full. The partial liquidated damages pursuant to the terms hereof shall apply on a daily pro rata
basis for any portion of a month prior to the cure of an Event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
If Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register
the resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities on
Form S-3 as soon as such form is available, provided that the Company shall maintain the effectiveness of the Registration Statement
then in effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared
effective by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Notwithstanding anything to the contrary contained herein, in no event shall the Company be permitted to name any Holder or
affiliate of a Holder as any underwriter without the prior written consent of such Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Registration Procedures</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Company&rsquo;s registration obligations hereunder, the Company shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Not less than five (5) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day prior
to the filing of any related Prospectus or any amendment or supplement thereto (including any document that would be incorporated or
deemed to be incorporated therein by reference), the Company shall (i) furnish to each Holder copies of all such documents proposed
to be filed, which documents (other than those incorporated or deemed to be incorporated by reference) will be subject to the review
of such Holders, and (ii) cause its officers and directors, counsel and independent registered public accountants to respond to such
inquiries as shall be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable
investigation within the meaning of the Securities Act. The Company shall not file a Registration Statement or any such Prospectus
or any amendments or supplements thereto to which the Holders of a majority of the Registrable Securities shall reasonably object in
good faith, provided that, the Company is notified of such objection in writing no later than five (5) Trading Days after the
Holders have been so furnished copies of a Registration Statement or one (1) Trading Day after the Holders have been so furnished
copies of any related Prospectus or amendments or supplements thereto. Each Holder agrees to furnish to the Company a completed
questionnaire in the form attached to this Agreement as <U>Annex C </U>(a &ldquo;<U>Selling Stockholder Questionnaire</U>&rdquo;) on
a date that is not less than two (2) Trading Days prior to the Filing Date or by the end of the fourth (4<SUP>th</SUP>) Trading Day
following the date on which such Holder receives draft materials in accordance with this Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
(i) Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and the
Prospectus used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the
applicable Registrable Securities for the Effectiveness Period and prepare and file with the Commission such additional Registration
Statements in order to register for resale under the Securities Act all of the Registrable Securities, (ii) cause the related
Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so
supplemented or amended, to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably possible to any comments received
from the Commission with respect to a Registration Statement or any amendment thereto and provide as promptly as reasonably possible
to the Holders true and complete copies of all correspondence from and to the Commission relating to a Registration Statement
(provided that, the Company shall excise any information contained therein which would constitute material non-public information
regarding the Company or any of its Subsidiaries), and (iv) comply in all material respects with the applicable provisions of the
Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration
Statement during the applicable period in accordance (subject to the terms of this Agreement) with the intended methods of
disposition by the Holders thereof set forth in such Registration Statement as so amended or in such Prospectus as so
supplemented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common
Stock then registered in a Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case
prior to the applicable Filing Date, an additional Registration Statement covering the resale by the Holders of not less than the
number of such Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Notify the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be
accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as
reasonably possible (and, in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested by
any such Person) confirm such notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus or any
Prospectus supplement or post-effective amendment to a Registration Statement is proposed to be filed, (B) when the Commission
notifies the Company whether there will be a &ldquo;review&rdquo; of such Registration Statement and whenever the Commission
comments in writing on such Registration Statement, and (C) with respect to a Registration Statement or any post-effective
amendment, when the same has become effective, (ii) of any request by the Commission or any other federal or state governmental
authority for amendments or supplements to a Registration Statement or Prospectus or for additional information, (iii) of the
issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a
Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose, (iv)
of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from
qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding
for such purpose, (v) of the occurrence of any event or passage of time that makes the financial statements included in a
Registration Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any
document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any
revisions to a Registration Statement, Prospectus or other documents so that, in the case of a Registration Statement or the
Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading, and (vi) of the occurrence or existence of any pending corporate development with respect to the Company that the
Company believes may be material and that, in the determination of the Company, makes it not in the best interest of the Company to
allow continued availability of a Registration Statement or Prospectus; <U>provided</U>, <U>however</U>, that in no event shall any
such notice contain any information which would constitute material, non-public information regarding the Company or any of its
Subsidiaries, and the Company agrees that the Holders shall not have any duty of confidentiality to the Company or any of its
Subsidiaries and shall not have any duty to the Company or any of its Subsidiaries not to trade on the basis of such
information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Use its best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending the
effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of
the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Furnish to each Holder, without charge, at least one conformed copy of each such Registration Statement and each amendment thereto,
including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the
extent requested by such Person, and all exhibits to the extent requested by such Person (including those previously furnished or
incorporated by reference) promptly after the filing of such documents with the Commission, provided that any such item which is
available on the EDGAR system (or successor thereto) need not be furnished in physical form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement
thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such
Prospectus and any amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Prior to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or
cooperate with the selling Holders in connection with the registration or qualification (or exemption from the registration or
qualification) of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such
jurisdictions within the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or
exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to
enable the disposition in such jurisdictions of the Registrable Securities covered by each Registration Statement, provided that the
Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the
Company to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process
in any such jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
If requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates representing
Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free, to
the extent permitted by the Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to be in such
denominations and registered in such names as any such Holder may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Upon the occurrence of any event contemplated by Section 3(d), as promptly as reasonably possible under the circumstances taking
into account the Company&rsquo;s good faith assessment of any adverse consequences to the Company and its stockholders of the
premature disclosure of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration
Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference,
and file any other required document so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will
contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which they were made, not misleading. <FONT STYLE="text-underline-style: double; letter-spacing: 0pt"><U>If
the Company notifies the Holders in accordance with clauses (iii) through (vi) of Section 3(d) above to suspend the use of any
Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall suspend use of such Prospectus. The
Company will use its best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company
shall be entitled to exercise its right under this Section 3(j) to suspend the availability of a Registration Statement and
Prospectus, subject to the payment of partial liquidated damages otherwise required pursuant to Section 2(d), for a period not to
exceed 60 calendar days (which need not be consecutive days) in any 12-month period</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
Otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the Commission under the
Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus,
including any supplement or amendment thereof, with the Commission pursuant to Rule 424 under the Securities Act, promptly inform
the Holders in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in
Rule 172 and, as a result thereof, the Holders are required to deliver a Prospectus in connection with any disposition of
Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable
Securities hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
The Company shall use its best efforts to maintain eligibility for use of Form S-3 (or any successor form thereto) for the
registration of the resale of Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
The Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common
Stock beneficially owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and
dispositive control over the shares. During any periods that the Company is unable to meet its obligations hereunder with respect to
the registration of the Registrable Securities solely because any Holder fails to furnish such information within three Trading Days
of the Company&rsquo;s request, any liquidated damages that are accruing at such time as to such Holder only shall be tolled and any
Event that may otherwise occur solely because of such delay shall be suspended as to such Holder only, until such information is
delivered to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Registration Expenses</U>. All fees and expenses incident to the performance of or compliance
with, this Agreement by the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration
Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing
fees (including, without limitation, fees and expenses of the Company&rsquo;s counsel and independent registered public accountants)
(A) with respect to filings made with the Commission, (B) with respect to filings required to be made with any Trading Market on which
the Common Stock is then listed for trading, and (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed
to by the Company in writing (including, without limitation, fees and disbursements of counsel for the Company in connection with Blue
Sky qualifications or exemptions of the Registrable Securities), (ii) printing expenses (including, without limitation, expenses of printing
certificates for Registrable Securities), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for
the Company, (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other
Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement. In addition,
the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated
by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting
duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities
on any securities exchange as required hereunder. In no event shall the Company be responsible for any broker or similar commissions
of any Holder or, except to the extent provided for in the Transaction Documents, any legal fees or other costs of the Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Indemnification
by the Company</U>. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder,
the officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as
principal as a result of a pledge or any failure to perform under a margin call of Common Stock), investment advisors and employees
(and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or
any other title) of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act
or Section 20 of the Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees (and any other
Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other
title) of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses,
claims, damages, liabilities, costs (including, without limitation, reasonable attorneys&rsquo; fees) and expenses (collectively,
&ldquo;<U>Losses</U>&rdquo;), as incurred, arising out of or relating to (1) any untrue or alleged untrue statement of a material
fact contained in a Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in
any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be
stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the
circumstances under which they were made) not misleading or (2) any violation or alleged violation by the Company of the Securities
Act, the Exchange Act or any state securities law, or any rule or regulation thereunder, in connection with the performance of its
obligations under this Agreement, except to the extent, but only to the extent, that (i) such untrue statements or omissions are
based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein, or
to the extent that such information relates to such Holder or such Holder&rsquo;s proposed method of distribution of Registrable
Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement, such
Prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for this
purpose) or (ii) in the case of an occurrence of an event of the type specified in Section 3(d)(iii)-(vi), the use by such Holder of
an outdated, defective or otherwise unavailable Prospectus after the Company has notified such Holder in writing that the Prospectus
is outdated, defective or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the Advice
contemplated in Section 6(c). The Company shall notify the Holders promptly of the institution, threat or assertion of any
Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware. Such
indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified person and
shall survive the transfer of any Registrable Securities by any of the Holders in accordance with Section 6(f).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Indemnification
by Holders</U>. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers,
agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of
the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted by
applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely upon: any untrue or alleged
untrue statement of a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement
thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact
required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in
light of the circumstances under which they were made) not misleading (i) to the extent, but only to the extent, that such untrue
statement or omission is contained in any information so furnished in writing by such Holder to the Company expressly for inclusion
in such Registration Statement or such Prospectus or (ii) to the extent, but only to the extent, that such information relates to
such Holder&rsquo;s information provided in the Selling Stockholder Questionnaire or the proposed method of distribution of
Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration
Statement (it being understood that the Holder has approved Annex A hereto for this purpose), such Prospectus or in any amendment or
supplement thereto. In no event shall the liability of a selling Holder be greater in amount than the dollar amount of the proceeds
(net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the amount of any damages such
Holder has otherwise been required to pay by reason of such untrue statement or omission) received by such Holder upon the sale of
the Registrable Securities included in the Registration Statement giving rise to such indemnification obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Conduct
of Indemnification Proceedings</U>. If any Proceeding shall be brought or asserted against any Person entitled to indemnity
hereunder (an &ldquo;<U>Indemnified Party</U>&rdquo;), such Indemnified Party shall promptly notify the Person from whom indemnity
is sought (the &ldquo;<U>Indemnifying Party</U>&rdquo;) in writing, and the Indemnifying Party shall have the right to assume the
defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees
and expenses incurred in connection with defense thereof, provided that the failure of any Indemnified Party to give such notice
shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the
extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or
further review) that such failure shall have materially and adversely prejudiced the Indemnifying Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but
the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party
has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense of such
Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to
any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to
the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if the same counsel were to represent
such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing
that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to
assume the defense thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying
Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which
consent shall not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified
Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes
an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to
the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section)
shall be paid to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying Party, provided
that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such
actions for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject
to appeal or further review) not to be entitled to indemnification hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>Contribution</U>.
If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold an Indemnified
Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified
Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in
connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable
considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other
things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged
omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or
Indemnified Party, and the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct or prevent
such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include,
subject to the limitations set forth in this Agreement, any reasonable attorneys&rsquo; or other fees or expenses incurred by such
party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the
indemnification provided for in this Section was available to such party in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata
allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately
preceding paragraph. In no event shall the contribution obligation of a Holder of Registrable Securities be greater in amount than the
dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the
amount of any damages such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have
to the Indemnified Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Remedies</U>.
In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement, each Holder or
the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement,
including recovery of damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company and
each Holder agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it
of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in
respect of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)<U>
No Piggyback on Registrations; Prohibition on Filing Other Registration Statements</U>. Except the shares of Common Stock issuable
upon exercise of the warrants issued to the Placement Agent in the transactions contemplated by the Purchase Agreement (if any),
neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto) may include securities
of the Company in any Registration Statements other than the Registrable Securities. The Company shall not file any other
registration statements until all Registrable Securities are registered pursuant to a Registration Statement that is declared
effective by the Commission, provided that this Section 6(b) shall not prohibit the Company from filing amendments to registration
statements filed prior to the date of this Agreement so long as no new securities are registered on any such existing registration
statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Discontinued Disposition</U>. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from
the Company of the occurrence of any event of the kind described in Section 3(d)(iii) through (vi), such Holder will forthwith discontinue
disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the &ldquo;<U>Advice</U>&rdquo;)
by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will
use its best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company agrees and acknowledges
that any periods during which the Holder is required to discontinue the disposition of the Registrable Securities hereunder shall be
subject to the provisions of Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Amendments and Waivers</U>. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified
or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing
and signed by the Company and the Holders of 50.1% or more of the then outstanding Registrable Securities (for purposes of clarification,
this includes any Registrable Securities issuable upon exercise or conversion of any Security), provided that, if any amendment, modification
or waiver disproportionately and adversely impacts a Holder (or group of Holders), the consent of such disproportionately impacted Holder
(or group of Holders) shall be required. If a Registration Statement does not register all of the Registrable Securities pursuant to
a waiver or amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered for each
Holder shall be reduced pro rata among all Holders and each Holder shall have the right to designate which of its Registrable Securities
shall be omitted from such Registration Statement. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof
with respect to a matter that relates exclusively to the rights of a Holder or some Holders and that does not directly or indirectly
affect the rights of other Holders may be given only by such Holder or Holders of all of the Registrable Securities to which such waiver
or consent relates; <U>provided</U>, <U>however</U>, that the provisions of this sentence may not be amended, modified, or supplemented
except in accordance with the provisions of the first sentence of this Section 6(d). No consideration shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration also is offered
to all of the parties to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered
as set forth in the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Successors and Assigns</U>. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns
of each of the parties and shall inure to the benefit of each Holder. The Company may not assign (except by merger) its rights or obligations
hereunder without the prior written consent of all of the Holders of the then outstanding Registrable Securities. Each Holder may assign
their respective rights hereunder in the manner and to the Persons as permitted under Section 5.7 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>No Inconsistent Agreements</U>. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the
Company or any of its Subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities,
that would have the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts with the provisions
hereof. Neither the Company nor any of its Subsidiaries has previously entered into any agreement granting any registration rights with
respect to any of its securities to any Person that have not been satisfied in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Execution and Counterparts</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall
be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to
the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered
by e-mail delivery of a &ldquo;.pdf&rdquo; format data file or any electronic signature complying with the U.S. federal ESIGN Act of
2000 (e.g., www.docusign.com), such signature shall create a valid and binding obligation of the party executing (or on whose behalf
such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be
determined in accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Cumulative Remedies</U>. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Headings</U>. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be
deemed to limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Independent Nature of Holders&rsquo; Obligations and Rights</U>. The obligations of each Holder hereunder are several and not joint
with the obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations
of any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action
taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint venture
or any other kind of group or entity, or create a presumption that the Holders are in any way acting in concert or as a group or entity
with respect to such obligations or the transactions contemplated by this Agreement or any other matters, and the Company acknowledges
that the Holders are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations
or transactions. Each Holder shall be entitled to protect and enforce its rights, including without limitation the rights arising out
of this Agreement, and it shall not be necessary for any other Holder to be joined as an additional party in any proceeding for such
purpose. The use of a single agreement with respect to the obligations of the Company contained was solely in the control of the Company,
not the action or decision of any Holder, and was done solely for the convenience of the Company and not because it was required or requested
to do so by any Holder. It is expressly understood and agreed that each provision contained in this Agreement is between the Company
and a Holder, solely, and not between the Company and the Holders collectively and not between and among Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
    Biosciences, Inc. </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGE OF HOLDERS FOLLOWS]</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
PAGE OF HOLDERS TO ENVB RRA]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Holder: __________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Holder</I>: __________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: __________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Annex
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Plan
of Distribution</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Selling Stockholder (the &ldquo;<U>Selling Stockholders</U>&rdquo;) of the securities and any of their pledgees, assignees and successors-in-interest
may, from time to time, sell any or all of their securities covered hereby on the principal Trading Market or any other stock exchange,
market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices.
A Selling Stockholder may use any one or more of the following methods when selling securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
    brokerage transactions and transactions in which the broker-dealer solicits purchasers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
    trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block
    as principal to facilitate the transaction;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
    by a broker-dealer as principal and resale by the broker-dealer for its account;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    exchange distribution in accordance with the rules of the applicable exchange;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately
    negotiated transactions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement
    of short sales;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated
    price per security;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
    the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    combination of any such methods of sale; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other method permitted pursuant to applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933,
as amended (the &ldquo;<U>Securities Act</U>&rdquo;), if available, rather than under this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker-dealers
engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or
markdown in compliance with FINRA Rule 2121.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they
assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan
or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the
delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo;
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company
has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders
without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for
the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar
effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule
of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable
state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is
complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously
engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M,
prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the
Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the
common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders
and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including
by compliance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Annex
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SELLING
SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock being offered by the selling shareholders are those previously issued to the selling shareholders, and those issuable to
the selling shareholders, upon exercise of the warrants. For additional information regarding the issuances of those shares of common
stock and warrants, see &ldquo;Private Placement of Shares of Common Stock and Warrants&rdquo; above. We are registering the shares of
common stock in order to permit the selling shareholders to offer the shares for resale from time to time. Except for the ownership of
the shares of common stock and the warrants, the selling shareholders have not had any material relationship with us within the past
three years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below lists the selling shareholders and other information regarding the beneficial ownership of the shares of common stock by
each of the selling shareholders. The second column lists the number of shares of common stock beneficially owned by each selling shareholder,
based on its ownership of the shares of common stock and warrants, as of ________, 2022, assuming exercise of the warrants held by the
selling shareholders on that date, without regard to any limitations on exercises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
third column lists the shares of common stock being offered by this prospectus by the selling shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the terms of a registration rights agreement with the selling shareholders, this prospectus generally covers the resale
of the sum of (i) the number of shares of common stock issued to the selling shareholders in the &ldquo;Private Placement of Shares of
Common Stock and Warrants&rdquo; described above and (ii) the maximum number of shares of common stock issuable upon exercise of the
related warrants, determined as if the outstanding warrants were exercised in full as of the trading day immediately preceding the date
this registration statement was initially filed with the SEC, each as of the trading day immediately preceding the applicable date of
determination and all subject to adjustment as provided in the registration right agreement, without regard to any limitations on the
exercise of the warrants. The fourth column assumes the sale of all of the shares offered by the selling shareholders pursuant to this
prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the warrants, a selling shareholder may not exercise the warrants to the extent such exercise would cause such selling shareholder,
together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99%
or 9.99%, as applicable, of our then outstanding common stock following such exercise, excluding for purposes of such determination shares
of common stock issuable upon exercise of such warrants which have not been exercised. The number of shares in the second and fourth
columns do not reflect this limitation. The selling shareholders may sell all, some or none of their shares in this offering. See &ldquo;Plan
of Distribution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>&nbsp;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 20%; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U></U></B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U></U></B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of Selling Shareholder</B></FONT></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of shares of</B></FONT></P>
                                                                                <P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
                                            Stock Owned</B></FONT></P>
                                                                                <P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prior
                                            to Offering</B></FONT></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximum
                                            Number of</B></FONT></P>
                                                                                <P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>shares
                                            of Common Stock</B></FONT></P>
                                                                                <P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>to
                                            be Sold Pursuant to this Prospectus</B></FONT></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of shares of Common Stock Owned After Offering</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Annex
C</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Enveric
Biosciences, Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
Stockholder Notice and Questionnaire</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned beneficial owner of common stock (the &ldquo;<U>Registrable Securities</U>&rdquo;) of Enveric Biosciences, Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), understands that the Company has filed or intends to file with the Securities and Exchange
Commission (the &ldquo;<U>Commission</U>&rdquo;) a registration statement (the &ldquo;<U>Registration Statement</U>&rdquo;) for the registration
and resale under Rule 415 of the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), of the Registrable Securities,
in accordance with the terms of the Registration Rights Agreement (the &ldquo;<U>Registration Rights Agreement</U>&rdquo;) to which this
document is annexed. A copy of the Registration Rights Agreement is available from the Company upon request at the address set forth
below. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
legal consequences arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly,
holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences
of being named or not being named as a selling stockholder in the Registration Statement and the related prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned beneficial owner (the &ldquo;<U>Selling Stockholder</U>&rdquo;) of Registrable Securities hereby elects to include the Registrable
Securities owned by it in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUESTIONNAIRE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Full
    Legal Name of Selling Stockholder</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Full
    Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Full
    Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote
    or dispose of the securities covered by this Questionnaire):</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Address for Notices to Selling Stockholder:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contact
    Person:</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Broker-Dealer Status:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Are
    you a broker-dealer?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    &#9744; No &#9744;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(b)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">If
    &ldquo;yes&rdquo; to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to
    the Company?</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    &#9744;  No &#9744;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    &ldquo;no&rdquo; to Section 3(b), the Commission&rsquo;s staff has indicated that you should be identified as an underwriter in the
    Registration Statement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Are
    you an affiliate of a broker-dealer?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    &#9744;  No &#9744;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business,
    and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or
    indirectly, with any person to distribute the Registrable Securities?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    &#9744;  No &#9744;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    &ldquo;no&rdquo; to Section 3(d), the Commission&rsquo;s staff has indicated that you should be identified as an underwriter in the
    Registration Statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Beneficial Ownership of Securities of the Company Owned by the Selling Stockholder.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Except
as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than
the securities issuable pursuant to the Purchase Agreement.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
    and Amount of other securities beneficially owned by the Selling Stockholder:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Relationships with the Company:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Except
as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5%
of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with
the Company (or its predecessors or affiliates) during the past three years.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
any exceptions here:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned agrees to promptly notify the Company of any material inaccuracies or changes in the information provided herein that may
occur subsequent to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall
not be required to notify the Company of any changes to the number of securities held or owned by the undersigned or its affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and
the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto.
The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment
of the Registration Statement and the related prospectus and any amendments or supplements thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either
in person or by its duly authorized agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________    </FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
    Owner: </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">_____________________________________</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">___________________________________</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLEASE
EMAIL A .PDF COPY OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE TO:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 27; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>11
<FILENAME>ex10-4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
22, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder
of Warrants to Purchase Common Stock issued on February 15, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendment to Existing Warrants</U></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Holder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference
is hereby made to the concurrent private placement and registered direct offering on or about the date hereof (the &ldquo;<U>Offering</U>&rdquo;)
by Enveric Biosciences, Inc. (the &ldquo;<U>Company</U>&rdquo;) of its securities (collectively, the &ldquo;<U>Securities</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter confirms that, in consideration for the Holder&rsquo;s participation in the Offering and purchase of Securities in the Offering
(the &ldquo;<U>Purchase Commitment</U>&rdquo;), the Company hereby amends, effective as of the closing of the Offering, the Holder&rsquo;s
existing warrants to purchase up to [____] shares of common Stock at an exercise price of $27.50 per share issued on February 15, 2022
(collectively, the &ldquo;<U>Existing Warrants</U>&rdquo;), by (i) reducing the Exercise Price (as defined therein) of the Existing Warrants
to $7.78 per share, and (ii) amending the expiration date of the Existing Warrants to five and one-half (5.5) years following the closing
of the Offering (the &ldquo;<U>Warrant Amendment</U>&rdquo;). The Warrant Amendment shall be effective upon the closing the Offering
and the satisfaction of the other terms and conditions referenced below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Amendment is subject to the consummation of the Offering and the Holder&rsquo;s satisfaction of the Purchase Commitment. In the
event that either (i) the Offering is not consummated, or (ii) the Holder does not satisfy the Purchase Commitment, the Warrant Amendment
shall be null and void and the provisions of the Existing Warrants in effect prior to the date hereof shall remain in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as expressly set forth herein, the terms and provisions of the Existing Warrants shall remain in full force and effect after the execution
of this letter and shall not be in any way changed, modified or superseded except by the terms set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
and after the effectiveness of the Warrant Amendment, the Company agrees to promptly deliver to the Holder, upon request, amended Existing
Warrants that reflect the Warrant Amendments in exchange for the surrender for cancellation of the Holder&rsquo;s Existing Warrants to
be amended as provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page Follows]</I></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this agreement to be duly executed by their respective authorized signatories as of the
date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Enveric Biosciences, Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 45%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Holder: ________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
of Authorized Signatory of Holder: __________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ____________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>[SIGNATURE PAGE TO WARRANT
AMENDMENT AGREEMENT]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>12
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enveric
Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cambridge,
MA., July 25, 2022 &ndash; Enveric Biosciences, Inc. (NASDAQ: ENVB) (&ldquo;Enveric&rdquo; or the &ldquo;Company&rdquo;), a neuroscience-focused
biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has entered into
a definitive agreement with an institutional investor for the purchase and sale of 375,000 shares of the Company&rsquo;s common stock
(or pre-funded warrants in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In addition,
the Company has agreed to issue to the investor in the registered direct offering unregistered preferred investment options (the &ldquo;preferred
investment options&rdquo;) to purchase up to 375,000 additional shares of the Company&rsquo;s common stock. The purchase price for one
share of common stock (or pre-funded warrant) and one preferred investment option to purchase one share of common stock is $8.00. The
preferred investment options have an exercise price of $7.78 per share, will be immediately exercisable, and will expire five and one-half
years from the date of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with the registered direct offering, the Company entered into definitive agreements with institutional investors for the purchase and
sale of 625,000 shares of common stock (or pre-funded warrants in lieu thereof) and preferred investment options to purchase up to 625,000
shares of the Company&rsquo;s common stock in a private placement priced at-the-market under Nasdaq rules. The purchase price
for one share of common stock (or pre-funded warrant) and one preferred investment option to purchase one share of common stock is $8.00.
The preferred investment options have an exercise price of $7.78 per share, will be immediately exercisable, and will expire five and
one-half years from the date of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co. is acting as the exclusive placement agent for the offerings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross proceeds to the Company from the offerings are expected to be $8 million, before deducting placement agent fees and other offering
expenses payable by the Company. The Company intends to use the net proceeds from the offerings for working capital and general corporate
purposes. The closing of the offerings is expected to occur on or about July 26, 2022, subject to the satisfaction of customary closing
conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also has agreed that certain existing warrants to purchase up to an aggregate of 122,000 shares of common stock of the Company
that were previously issued to the investors, with an exercise price of $27.50 per share and expiration date of February 15, 2027, will
be amended effective upon the closing of the offerings so that the amended warrants will have a reduced exercise price of $7.78 per share
and will expire five and one-half years following the closing of the offerings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock, pre-funded warrants and shares of common stock underlying the pre-funded warrants (but excluding the shares of
common stock and pre-funded warrants to be issued in the private placement and the preferred investment options and the shares of common
stock underlying the preferred investment options) being offered by the Company in the registered direct offering are being offered pursuant
to a &ldquo;shelf&rdquo; registration statement on Form S-3 (File No. 333-257690) previously filed with the Securities and Exchange Commission
(the &ldquo;SEC&rdquo;) on July 2, 2021, and declared effective by the SEC on July 9, 2021. The offering of the common stock and pre-funded
warrants in the registered direct offering is made only by means of a prospectus, including a prospectus supplement, forming a part of
the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the securities being offered
will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available,
on the SEC&rsquo;s website at http://www.sec.gov. and may also be obtained by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue,
3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preferred investment options to purchase common stock, pre-funded warrants and the shares of common stock offered under the private placement,
as well as the preferred investment options being issued to investors in the registered directed offering, are being offered in a transaction
not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
or applicable state securities laws. Accordingly, those securities may not be reoffered or resold in the United States except pursuant
to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable
state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
a registration rights agreement with the investors, the Company is required to file a registration statement with the SEC covering the
resale of the shares of the common stock and shares of common stock underlying the pre-funded warrants to be issued in the private placement
and the shares of common stock underlying the preferred investment options to be issued in both offerings, within 15 days and to use
best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event within 45 days
or within 75 days in the event of a full review by the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Enveric Biosciences</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc. (NASDAQ: ENVB) is a neuroscience-focused pharmaceutical company developing next-generation, psychedelic-inspired mental
health medicines. Enveric&rsquo;s robust pipeline supports drug development from the clinic to commercialization aimed to help millions
of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For additional information,
please visit www.enveric.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These
statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking
statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology
such as &ldquo;plans,&rdquo;&ldquo; expects&rdquo; or &ldquo;does not expect,&rdquo; &ldquo;proposed,&rdquo; &ldquo;is expected,&rdquo;
&ldquo;budgets,&rdquo; &ldquo;scheduled,&rdquo; &ldquo;estimates,&rdquo; &ldquo;forecasts,&rdquo; &ldquo;intends,&rdquo; &ldquo;anticipates&rdquo;
or &ldquo;does not anticipate,&rdquo; or &ldquo;believes,&rdquo; or variations of such words and phrases, or by the use of words or phrases
which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist
of not purely historical statements, including any statements regarding beliefs, plans, expectations, or intentions regarding the future.
Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available
to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain
factors, including, but not limited to, the satisfaction of the customary conditions to the closing of the registered direct offering
and the private placement; the consummation of the offerings; the Company&rsquo;s intended use of proceeds from the offerings; our ability
to retain our listing on the Nasdaq Capital Market; the ability of the company to successfully spin-off its cannabinoid assets; the ability
to achieve the value creation contemplated by technical developments; the impact of the novel coronavirus (COVID-19) on Enveric&rsquo;s
ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric&rsquo;s ability to conduct its
business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products
are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of
therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability
to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms;
Enveric&rsquo;s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the
size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights
related to Enveric&rsquo;s products, including patent protection. A discussion of these and other factors, including risks and uncertainties
with respect to Enveric, is set forth in Enveric&rsquo;s filings with the Securities and Exchange Commission (SEC), including the Company&rsquo;s
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contacts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valter
Pinto</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KCSA
Strategic Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">212.896.1254</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">valter@kcsa.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media
Contacts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allison
Soss</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KCSA
Strategic Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">212.896.1267</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">asoss@kcsa.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>envb-20220722.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaKA+bP9z5Z8+ekhvWBzbZlaHyMjUUlpByBnuT9GIbAJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:ENVB="http://enveric.com/20220722" elementFormDefault="qualified" targetNamespace="http://enveric.com/20220722">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://enveric.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="envb-20220722_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="envb-20220722_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>envb-20220722_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>envb-20220722_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://enveric.com/role/Cover" xlink:href="envb-20220722.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140538348941072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 22,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Enveric
Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000890821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4484725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Enveric
Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4851
Tamiami Trail N<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Naples<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">34103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">302-1707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENVB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="envb-20220722.xsd" xlink:type="simple"/>
    <context id="From2022-07-22to2022-07-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2022-07-22</startDate>
            <endDate>2022-07-22</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-07-22to2022-07-22">0000890821</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-07-22to2022-07-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-07-22to2022-07-22">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-07-22to2022-07-22">2022-07-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-07-22to2022-07-22">Enveric Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-07-22to2022-07-22">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-07-22to2022-07-22">001-38286</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-07-22to2022-07-22">95-4484725</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-07-22to2022-07-22">Enveric Biosciences, Inc.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-07-22to2022-07-22">4851 Tamiami Trail N</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="From2022-07-22to2022-07-22">Suite 200</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="From2022-07-22to2022-07-22">Naples</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-07-22to2022-07-22">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-07-22to2022-07-22">34103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-07-22to2022-07-22">(239)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-07-22to2022-07-22">302-1707</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-07-22to2022-07-22">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-07-22to2022-07-22">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-07-22to2022-07-22">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-07-22to2022-07-22">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-07-22to2022-07-22">Common     stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-07-22to2022-07-22">ENVB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-07-22to2022-07-22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-07-22to2022-07-22">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>18
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M CB_DM*\[MC7 >7;G-&_4$L#!!0    ( /.)^E2?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M 5!+ 0(4 Q0    ( /.)^E0'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ \XGZ5 UNS+CN    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ \XGZ5)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " #SB?I4R(7A<'0$  #9$0  &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ \XGZ5)^@&_"Q @  X@P   T              ( !MPP  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " #SB?I4EXJ[',     3 @  "P
M@ &3#P  7W)E;',O+G)E;'-02P$"% ,4    " #SB?I4JL0B%C,!   B @
M#P              @ %\$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M\XGZ5"0>FZ*M    ^ $  !H              ( !W!$  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ \XGZ5&60>9(9 0  SP,  !,
M             ( !P1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  "Q0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>envb-20220722.xsd</File>
    <File>envb-20220722_lab.xml</File>
    <File>envb-20220722_pre.xml</File>
    <File>ex10-1.htm</File>
    <File>ex10-2.htm</File>
    <File>ex10-3.htm</File>
    <File>ex10-4.htm</File>
    <File>ex4-1.htm</File>
    <File>ex4-2.htm</File>
    <File>ex4-3.htm</File>
    <File>ex4-4.htm</File>
    <File>ex4-5.htm</File>
    <File>ex5-1.htm</File>
    <File>ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>23
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "envb-20220722_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "envb-20220722_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "envb-20220722.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ENVB",
   "nsuri": "http://enveric.com/20220722",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-07-22to2022-07-22",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://enveric.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-07-22to2022-07-22",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>24
<FILENAME>0001493152-22-020362-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-020362-xbrl.zip
M4$L#!!0    ( /.)^E1DN^[I*@,  *@+   1    96YV8BTR,#(R,#<R,BYX
M<V2U5=MRVC 0?6YG^@^J7SNV,9E<()!,2)J4%M),"$DF+QW97D"-D%Q)YI*O
MK^0+=RC0UD_2[CEG=Z5=N7(^ZE,T "$)9U7+<PH6 A;PD+!NU6JW[(O69;UN
MH?.S#^^1_BH?;1M=$Z!A&5WQP*ZS#C]%M[@/970## 167)RB1TQC8^'7A()
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M0H<PDL3*!L9#MAF/V)2EEPFEXBZ"9R1B">%W=I:L(P%2\Y+D&]J0$3/(&E*
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M3,Z@PAA\%;PSR/'MA0$-T&XR=$0$A-X F] -AR(2%:$?4!F,&M&>SL^R0Q9
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MK6K9$U4-6XU^U\#42GJDW<3CT11&,H&-F*AYFL,.F"DXJ ]P:\KXKI:PS7B
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MKWSQ^,"L2:OD\4$O@%Z9E@=Q?$CB;5Y#HW=Y=>$7N,%R,E]NX;$URFN3_]Z
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M&)Q%=^XTC?/WX8']@'K)V9MD_&S3EBCSME81P@0M#!ZD5%[_"ZU#_PGOO:G
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M55E%"Q@T=L@5 DRAZ=$\C>XP(M%XTI81^4BI46X*=AS!\%?<G(/\$3+]';I
M$793/*E@<R:+%7<):X-Q0KC5.YA26@?I:ETBBQ97,]&,8!QII<L,#*BZA1YM
MT<OME3[Z@$3U=T.B^M,FJK\;$M5__43UP#?_.?CF]XMP_O+LXO+LZNSU]?3Z
M_,WK*^:=_W5Z>3E]?7U^=O4E+,/^P@,_RW'_6-CG+WL"SK]N"S@S1_W9>R2P
M\)F4Q5*[.CL-+LF*KGS> N'09 O-R]N,1W?$O#N</9\GJ?/%H3CW,[F(T%40
M6P3<ITD:&1*Q8(K!XKD4/)?,&HH%9/)'Y?R@'2ZFM.(.4>X5>4+J[)3YXA9C
MUOS\C)'ZN?Z+&XAKLNIHG=;@"E7,RJY=,@QB4\] ;AAH@1YF\M@[4ZGQB#BN
M,Q51;AX?_2I5^&R*DMOG"#4RI: <ZG=;1]H:2/=QN%(W\,83F(]S-_QXWF1(
M[XK]!=$ISA]%5:4J=KGP&APIWG*-,=$U986ID86TE2RQ :<0 <^XCR^52#"W
M)WMKUG<_#,Y;<.4(VV5Z;SF4! *M)57CHO%L^"RN/($P#1'@JY46 :?[<& :
MQ=M,69)6V(P"[-YD #;LP:0)V "ZYXW; 15E^'\XR1E'NJN#S]AON/ U7;DK
M>6E%%=5PU,%6ISJS- =-OT9ES_$NRY0@K5=5 J*M=Z%ZGU:U[A6JFY&:K6UK
M9+/HUNB]WV 754EJ"/-3:GVAGRH10K?/:VBA&)1:J]):!>OB%EMPT/Z7&-4&
M-Q>H/1H,5E;BG==EL5;<+H:N!;4@"3RX.(9S?H.A-;QRUE385X4 F]*CAAO6
M) TR;QW"NTJ%HMNN;LY[=SQRU%1*K3QNTD*"7GA-HN91D]5:0VKJ<"11JC0N
MI=4[(<9ATWNE(%*$WFG&FM);KC"8;7A]83T*X>NVJ\=!-5!A)5(YZX8 E?2M
M:)]%0B/6%A(2#9M-QZ7C=7%6#26@TD(P'MDF Q73D"G8+4'[-?-1P_*GHV^>
M@*1N'VCIDR&#-H\V[XC3J_3"Z0#$1M=@]Z6UF'X4LOO=W2]!KF(\)[#7@>)C
M]I9BFV0E1FF&S^,\;E4X*T#'J2_N(9&FTX%:8;T=%I-CTKC)$B>B7)0N&]M,
M4;=<S>P&;Q^%) 6M,DD/J'5O*Y!I8IV\K9 WCK#-M"$%V:!R6.U81;,TD\"I
M1([U<3(>Z?,D###7??>#>& D>[BZ.B/.NRDT;R+$U3> #8N)"B8VXNKJ%-LQ
M9I< AM0 (V=!NET6&4?$*6=Z]]#;/&1Z63 0R_EUPF![86.=%*-FX9AQP%=%
MO%&X1UTX&:NXUOJ:XSJ8R&:'MRE+K0>.S#R6.$JGZ, U]G)T'ID4-ZM"#@/=
MZQKM#HKNIYKGGTD+-&&]MY.08.L=R2GE,*AW=XF:K@8QE[\JI=Z15T3""-<K
MN=JYE&]-^C?PU2\U"'<VUV"7[,&D)S';)5,6 SYTG@5GK(1P%W1MDJ5H2GN<
M&Z.C5[#0"4<_!+V1PAS>L/^:U4J09=P"1YJ7< <;,/2SR+"J>B7U;:.(SZ%^
MBYL<%F,%6:NAJ3O:P$))18_I9@ ,2;UWG[N'#*^GO0X=0GIU\&H^ S%IU5ZI
MP%LHW6M$#WZV<3.(: /(._E#.M1COE,?H('N@<1Z%YOT]9D7>3$>Z68G\HNT
MLI@I?SKLTCXOP,W!>[T@_[4HJRU)9'8=X81($-CKPWEQ/F1'\D_Y#VTP(477
M-OCOI1[:=(WV6I15*,Q;WM?6%\7M5-"0P0PAGF2X0!NCPL>C"0R,>BT:P;A-
M72C'P4ZN8$Z2$])S)X$-"0 U<I1\OWG9Q3RD)]+FT6UC\'*R+>BZ6<HFG97Y
M]ALVM@?ZW8L(SR7O^YX1X2:B$1D+C&P?V,22:\>92@*?HQ)T=X$+9-JPM_VD
M, ]>-NLZIIJOJLANP/7>($^B[U4X>7*SQXVGHA\H]V6S*:)#F?K26?5&H8L2
MV25!,$42=4#!X ZTH54%SJ3H6:5"-P%Y+#DR(!P-QG8S&%JQ5G#AJ%#KMR9G
M1P'ND*IY*W)#*U%B;R;M^K"]A LRCZC!#QX)J]R:PM*KK"[3&6LIQST1;B1G
M\';!X45%M\-9?V?"^OAHR%A_VHSU\=&0LMZ#E/67M>G_ZI.>)&S@PQ8[+?(Y
M*/VZLB:]L6E#:[=08SM[6O4BF3OVTUUV+E)*]AA0H<DMT*,HJ!]E?1UB=UK&
M'1?B+L-X/$H*POI1OC 5X!]:+K$L4J"M38X$*FX>J8_4EN%D+%C)!=APHOEF
M2SR00BC; H+!O>.!.J32&G\H<1S;1E!',B<TTD#=*.E3#:\')YQ3VS:"2J(V
MHWDB9A,^ .E>"J'N3,7%RKG= 4=20AL"XW<%NEB;F3JSQ$:R'T75(5X,@4J(
MMV68=M:59K9 ^PFCQKA,%5TAEAO^G%K/RI+"29,G'#+#S/"C),T:'<74623+
M-TKIGSA6F;*QSA@%-).8\$0+AV['R<L6]B\:@OH9N1C99GML<P;S*$XY!IBH
M66W?.5.D,_GI1"&#,IC+&(YUE\2)6GN_IN"<O1>]&]OHL'!"LEO7UW5R<!H;
MO7UE&TB0MN0@XIVO"V_'[42I >V<8J9.'+!5F-EUVD(CV"*H%(G5PA8Y\7J1
M-=A"((Y-Q@SK31;I5N DIQH*BBX&6^*L F-*-)8F\0<OP:8ZN&JN0<<8!'51
M@+;,J3UOY@<[^I>WM1IZQA/;)G>N$G9:<@I+UV[2DKT-_,;.IL(FKO1R@@>^
MF[O>S#/MR^F-'+%4ZZA&G"'W925>$3;[E:@H!1<Q T-JXH%A<QC7EF*'P3W9
M@TE/%%LJ+RF>#1>"O5*9&)[1!-UX9%J1I+F%>\4,:UMEQ])=PN V0OLF-$$P
M)UN9$#-!R <*)03E'*P++A7 %MX,/=>Q=N;AEO.!SUI7/X@&D2T=\GZ&\Z&(
MG21*L$6'Z._'(^FJNR6V]:'6VQ9T0AC8<!JGL"B-QJ\#H5:ROGV]W)\</NEK
M*4L*PM[%ZR]C*DJDIK^/W#G4>2(;QZ'^NQK7Y<2-_-H*PG]0DDU2W'Z[;P>I
MIC^B'\@].**6:_5'ASG^!)8T=RA2I&IKM@DE1'/C318>^1(35"]ZITU:'M6E
M+# ER$K5KC^EPF^)2MO)MH\'"N)4N[N1=P]5-S\UJ-B[(T#'0P3H$T> CH<(
MT! !&NRJCVM7S=FN.M=1EDYPY1DX7-::L0:6&WZ!DZF=0K0Y*P?.B1A..DN[
MN2(A6_&.[#XKA.(Q,_T\N*>/&@T9+LI/XIQD;O&B(8-%?50KW(]0K5C<5U2"
M*W+,(IYNIV6),[6=N3A94-U5WLY@]\#1RGSHR(.^@;N)>43#ES<*,;/%BNF]
M6Z_-!^K62 B^BMY3*>R=_6%,OR77!MP2#M3+T1WCNE3KJ!2! ?-')3P,5PJY
M@G7%[>+(^0=3"HUC'TU8^B0>?C</3:,^4S'VR&%D$5%*Y<%_XZI\%P8G1R?'
M& 703C@-Q-JBH;733 RIDL^TD5JQO8C8!DZUV:R[:\S5NE2[2VU&*]0_^_$H
MK9R1;VM<HN%%\%+7XM# *F-T3V.#N Q:M]PS=R0(GJS>EO7W?DT1!^?6^+NF
M4CU6O(4W\1;JUI++F-<&$B56.';N @%#@7?6TD%)%65H.I2]RXM;D*"%:@4Z
M0M)9]1)CD"KO>[XGF" #\PZ. >-'G:B+\QRY$0R&@=THR^UEZ+/]W=U#/6F>
MG#R9S X.@VEM'8X=;X12YAA/M"(I(@B:K27LH:Y,[I<]OI=7N^RTR'[P\_5.
M11UK8NORV79Z+7F5=^]HAMZD23=V+W16-*PFK\M&G"3>0\1G99X[CV+VT1$:
MAU4#M0[P^Y>T7#&Z3%((*44.+'H&KJ @ 0[9/+<RU^((X>6#6D<Q?\9KTQ*4
MGD6EG==1,^:-&C%Q[B*A5W,3_Q[F-=TB@H#VI:"P^R3 O,O@3WB5&-?MO,O.
MJPSN]29;%]C71*\MX>YH.]Y7: IT,LPGF%J;M 0C!2/I6 O"JM@$>^%D0N0Q
M^NMAZWW[)R NO?L"Y>8V:-#>>..1W7D*!I0*$P&J70HP7#UZW(F(;;MP]PF"
M6&NE>"'<A)KW/B4"W^*>B18+K&BIE69EN$%7F6P)^QPF5P0W-^E:$ 5VFM35
M"$E3ZM.EOE49G &3XY.# "R1>EDQ@XB< ,XOPTY=X4^" SJW36F#\\/GAU^;
MX RNW9XY!/OI!2W8"SIEZU?"O];7B;W/.]!'H\1<LIVTNKN0U;,LQ<"F\VB+
MA4UU#[!/=*O13(*+!5HGZ(!@?CB8SE%=,.O+/4;:-<%!0:%E*6[;IN44P!D0
M<P'.JJCP'(RYG(9M]34L<9&DL7#>.!KE[+U0M9#Q[8 S_<VN;!=(1+5BGK[8
M**5+!]<N.+\OR^Y>%ZRS**]:.(+MRXN!8WE<Y8Z*?=/V@UHC,\6$]$QV=UL3
M@Z,+$U=BW7Z%]1QVJOY0SD"C@H[D$]*65&K^3=]D4__&FS@,7A>!9!+PW9L\
M.=YZGI9TWWE389["5EB.1W1-:"]=$V@A79M4*I<JN$685)=A+E,F@+X5FB&&
M=F\D0)?.THI$.D^H80/Z7=R!&;E/I3D<V^@K@"OBEK:*'(:ZGAQ1 =2HJ[?>
M%,VR&+:KE,Z J5\;XX<V&,@C3) LAJBN"G5#B02#'@VY@$.//31(AM+#J+-\
MU2D!-PE/;T5,$Q8I>?>Z59C&2O#9NM&B8,6@KW VBNG YZS6-EU5LKO<*?WM
MP6H0-!46@#+Y9G5"'YS YBNN]D(9?/S]T KDES+.E; IG-.&F9&2"Z*$:YEP
ME%LGLWU[EMWR9G\$K&&U F*;>HM4&C-7WJNZ8VYF#ML'SIK6L;.HSF)C\H<3
M1Q63OV#XLP\>1,G0OU&<YQ8N<D6K,:_A7&MRTA;8A5:1^\]@G,H[+$)'NX9&
MR@4) D/GCL*:[%=&M?''-!X)_L@_+!P+=;/[=7S4]2*A[2[8+F' Q7%]77!/
M26'[6":+_0XM[$V/9<M6A*7Y2'LQV+(5<:QJA<S2YMUTYLLL<>V-I2]("E59
M6 FI)MH#T1H.+C"7V%<QFE.2GVL0%#!(^5K=&9'/<!R^0P7L'6GC$5[C7>)1
M1=R3!\&SSKIA]/"A46(G(F9BT[#.:[ '36R:@E%WP8E"'3VWFZ9G2FZDP"N,
M%AWH<#+8A?]09@8P5$QUD62I:?U=R 9'<_2KYW*A795&@@YTRY0T.. >P%.2
M/[MWW!(ET/)&=. M%EQ*[TF3*&:-,+3?[6!OM9!1/U#?!RQ##P1Y,QCP93C6
MM\=$9PK<:<5"#4?(PD5B[BK'&GSD/9CT9"D$.?88>Q:\-+7?)@K5@\%"OX)]
M$F;?ES.PBI<JP2!ZB'L.B\2<8)LMVS(X9A=:0S%7OF?K4-X9PNKZH=8%[T,N
M'3\FVNTR.'XZ20X$^C,/M8Z @=P6P49%)>6M8F5\>3<2,)&3"Y1F0<AL]LPT
MIX ;^G-S#*"%!4LFR04<&"41Z&8ZBGD03&@DB&A8%$02*]]T @SJ_3*=I6Y*
M"H-I9GD]?I#9QE+;F,@GC&"AZ*68Q(4?HV9/>0M:B^-[+@J)'R%!=(F&RZI8
M:)(C<%[-?+>"'U:+LYRQ@MMC\%H*'*FMA,:3T>KIX*H$5G$A'"G51?;.HWUB
M8O5^G9;>24?7F^> *:#MM;1$=)RA_D#!D(B$>W<^HR67W!L[?T!JLU_4V5,V
M"7;_@.\8J)3?IN4(G6X@?0F4'5%W ?&V ^\@K _,H-PW-!\\*#)/TGKOT+Q)
M63IX=,K/'3]Y@GC(;8KG&0;.>U6@57*899=-VUX6H^2L3K(*26;HJ[36:W:B
MY59'/?E6PN4\1\/A0>0NM>IU.%B9L(SVRN^.'CEL>%IT!^(E&DX2>_(LD@M;
MYG[9U9:M9%/MR#C#9"&M= KO^$/03 2OU.>7,VVW2YT&(_1 /'Q^;8>&/$87
M$-^TG:-;T;SFC4[J"_'':44];UB%N2^+3@F<R0W6.2..WBK%GZ;3"U<;F@+K
MR!3T6F(#J3/F:51;YRUV+^P!Y1\1<FMR+YL\@@.EQN'TW@0?[J7IT-DHBIKO
MZIYO. 560O,H+3-R%BJ!=&Q)'[J2&JR+*C4FO^='4:Z*PF&$F22UXM$>21.C
MW!K[I);U^6[T9R\W#H-PH@I6,2MN*VL+Z!=6H^HD5OE0ZPJCF'2QA%E&9^W(
M0L\1FYW!]2L]_Y ,C$>*:#.P+,BI11HL[[N!N2<#,/<3 W-/!F#N ,P=W.V/
MWW_0H0\+3LG" Y_[;9ZD59P1X//LA@^.5RG3BDB8_84"[ZI8.^[X52I^G)<V
MQ#1;50?Z*.H]T+75Q\".OEBVNF?,6XJ&J+M(95H8$5@PU+U&<JXO3NP$V.S
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MQU7/7275J)-1'>J4'DM%SE1!1G7O.1[1OVB'<)[*CG1;RH<'R@56K>/9,FN
M80J#930HU<IC$J>?+D8>R51]O AZ^;>-F]\736W+Q/'F>B^V+0*G1I-R8%,\
MG-EP>Z--L8CNX(I^);@K&K7[*PZ@;$V0M0,I1AN$QE"E))L@CBAORQ7+V/=
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MZE^N,@!6S-B*%$[ASXP<O[2U*8S42.<UUZ7JI8< =GP<1VKM_2AW]*6>OEQ
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M61OW:%X5>7TC7+@Q*?&&;;G-/&>P"/$]N2Q1TH8P68ZU$/W4HK26[EU16]=
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MX=;@F:BGMM^!2Q=M7[+&01"?WTR!!^IA_!:* _!%8^X>9DF'44'1928'PJ.
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M>#/.//HH&)Q4Z7S43ZXK.)^P @@.)')R"6(TF8SGDV2:U_)J+BM':[,#[2&
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MQ!#/MV0<_,J:B ;G=2._48T@*J5B5@%P*W.F%BMPGXY*\LR-+FM*)\J2BM9
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M_$XJ$C>5.E240[7MDC;W!!]5=IU6(V=E@RM2#/.9,&&I7#C]  ]4P).006D
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M-"UZA3@\1MH(%\D<.^QI%GE&@4)\?[K.;L)B04(*DZK7.AY':IHOVI-06(J
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M;$[4/MTE:N\T4?MTEZC=)6H?I=9^HZX40N?/U;*XCK+@KE UST!9QX]%63^
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MF^<[D,V=@FR>[T V.Y#-XS0(-2_YNA>DN[;$Y>L.MWA/=O+BY#B0X)7E'B=
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M9-Q[8QDE#&OXT^Z9CD4,^6:$>=WHG 5_PC?[Q'6$P7SB0@:#Z[CSVN[AI/Z
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M>=1DM;:_9"FH1KC2D >?G]4E>R+[ [51QG:8MUQA,%OS^L)ZL#7CKAX'M,!
M*FNWE:APY;9-7.$Y:PL)B8;-[.+2\;HXJX824&DA&(\LSW;%/&D*=DO0?LUL
MR++\Z<B7)R"IVPI-"')ET.;1YAUQFI!>.)G7R$\%CF!:BR](X;+?W/T2Y I;
M4A+?MV+KG9NJD]L8I1D^C_.15>&L !GKOK@3)RZ;ZR![2#4]4YC\;++$B>86
MI4L7-U-$\Z6IY^#MHY"@NIFD>]2]JA5$-'%&WE9(;$?0<-J0DF57.:QVK.#
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M71"]CGW?$0A'.&9GM&Y>(,R=4&7?,^%W:M"/WAPH-T)@)-W+ABP#2;TDS1!
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M"VN=WM1$SP2= J^OA3B66BKFB'9H^K8!^T)S.,ZCE,]].JT,)5I?8$S*&;&
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M:BW@E^6JP:.[6L,)OD1V;%7?%.6'"BM<RP2K'3'(/:_Y7[#[(S=2*5HKTO$
M!Q,>P^H72Z+S,M6B&&A"#86?CD?7S*EE\.?U(BT3!LWP3:DY7T2$,SVM(=(:
MN;I^:]*51L(YDYMHZBT$$GG\:_#2>:Z<A('GN,D"CF$@X*0-D28CQ(]F7BOK
MR7/'2?17YUY;PS9=7P#.:R[D8)K=U.%+LD5*1,G5RX 4^NG@#1(DN>Z>.;_H
M\'CV3S+"B+D%*FW/9# !8$F%?]3'1',D_=HP_I&"4PG)Q6 += XC-"6MDPZ
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MB$1SI\V^GKL*M$0#$3H%]CT6O]BF B8<&BEM$"Z\V3[2@ ?*Y38M[ !\(0(
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M<X#_.3Y^=XXJ^LU_PN"7Z7_&(UX"N.MKFCW,Z.+=&YKMR=EE</;^_.+]%%[
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M!?/IC\8Z>.RTK)_-KQ+&XD6[]?GN-O+I:2O4;KU@7^.O\!^Q4L ^ (7J8AM
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M:2%=-:TO4ELG'N@P#AQ*;WV"6'R_M\&H+5@-V)=;-MRU&U-"GR:)L+[=6"N
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M%I<IHW9#%9 YC9"$>TJ5 J@I;12DBH31R<(H,(^0:VQ:/,[+J()EPG\1V3H
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M,8H>#5P;^:B7KKM"K :->44#C*H I2K0MUO12E='(\V$\Q/*Q[."$LU% /"
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M\-7!-O9')J/5^-5.]]-'.Z=[HT[WTT<[I_MN.=U_X^GY6=D(YEY_?W!V:"[
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M].$'(!RXHQ=A4&91$<'#U9::@S+VIGX!4L\"CQ_'?Y-LI3,C[_@+D5@CI%I
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MM[-;3XZF_4;O](3<C:[;L/UN5R8$4_I?#QYX/T5A/'WFO?>OPN?P@'^5F'J
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M(!<:_UM;-AW*O5.WC[V*;D<: 8KA->#:FEZ$] (96%WZ;>KU)E@#]@66'SF
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MPGV(K-MO+C]IB'C@_3=3L)PDXFQV@BW&IBG=A&2(82O04 AXE!R?-OAY'%%
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M,.NK@>ZDAB :>25XGN%;RW(21X'<+79H7Z<$VB/]=JX B\K(UH4)Q#Z,A#<
M/W04P6+[<=QPK=)E-<&^R;3$729K^EE#(BHT&9/(!&LAN>EMRQ^)#R8ACR1-
MXI5&$/&FAM+1&I8+E>)4Q:.YKS9;4]',*%4>I$F@#0<Y$1Q8KXS]&S9J5(=Q
M"M@J]48?S\>V8=+.M86RFG"#<YI F<08RT7GTEIE,Q.RA?Y5PKDEF"CU+\<W
MB)5FY?UXU+2RU8Q07>7K9P;\ UM 83]U9H>#PSF&!% V0SXHO>+=\2G]SE>F
M)1U<3,IE\5>()";590[HF8+<P?$<VY:DR@.)P#F%JZ(HZD*OI!Q.=!F#]1JF
M98YU9"8D(ZQQ"_\C*FET6Z_5\2[P)),Z4>8*FNAI(M1S*G5C3R[$0064%(<5
M2:=(H@>'?:9ZSG_0<_9^ RMZ"9_)[(=CF%[!%ZNSK!S\5JM'ZZ5R\J>,W1HB
M:,CK2)R,&<<K["77S>N;]XD":[19MI'DS,H*@-'EQ 0M\#?VX31_ I,*6J$P
M.MMF>;OR?8[:9ODX]OX(>>JPE;B8RT@]V;T7C$J1=6^^H'%TI =M+VJA]B41
M4T)%T'Q\X:KI=?"A$)TTD^#SZ=IQMAZ6QSB1*,)'>G&'@\FJ=B'SQ?;#2>O%
M]C4$7M:DNAX]]]XQC/<9ONF"0P1]6_2MMD4_Z;NB[U97]/NCH?["!@SQ4M]M
M@OW%*T53_6JK%-5?=(]@4FJ;]I=U&R9Q 2<?3OUP</'+Z8<SZ<>TYW.Z[XVY
MSS"B:]N%; U:N:W0T!S/_2S4(3Q*JF$J<IF%UQ&9[^ 'YB7;7VW?&XL=BU_$
M3XN]Q_&.YB^4RY3\U2R(<FV,W1"JK "G^R>T.<7XIAR:B7]PJ$9E/>AUV!B>
MGX$CH!?1OWD5T+/'9:!XC[P!";-U3N2]T%"_!U-#^P,7^BFO>2TO]$/^D(=(
M_L3S)^#LDT6,ZZ><>)V740^J[$J$_CC9DZF@>]OW!?.NN'WV ]$A$A>LQ@=^
MC(X=(M*4UY3>)/"<>;2D<3C#<MTLY9"8A6H=%-GKG-/@9 UL$$P;MBL+Q8/!
M%Y()7;*')][DTD<J\V*.-;.KT,_ZW,2N3XF42D'G>A+&Z0TXFX+\:%$D($;L
M+[8?W4F8@*M..7);/+T.Z9Q@, '].QVKK+^; XAY&*0PA@ CN8DU6JO@NN45
M>E28;KM)6&/22QO>-@:'D?*."+J$5VPZ$5<7^?0!U4=J[)T\/#FAA@ E^?%M
M:M*;ASKP#4JN:1\H<0HN, ;2QRW1;CNH;2GE_E#N^I3X4,ZCK$'.6Z6[9@JX
M 90.ZZ"7AQV?$F+XFA@%X59>"&[<20>04Y=;R .#^FNTV:JR<@6J,B,]2=F.
MW(H*4V*'GE0N[(3>6O6[WMA4(>F-C#=*J'=;;],P#[)H B\E.XX^0SDQ@L/X
MGZ(%3&&C<=/UV&38#@=D$86VSI^&N"T4J?8I,T5F6EDHU(?1\C=P5O43*:X]
M*Y%&1(,:50.6*:(@%XMP&A%_&]KP0:BO6[P"2%WDKA10 HFWGU L8'/3GLZB
M6/(^'/$\>SWF:_"V+[;"X9S/G2%HCV=O,K&8@;1CZ%,\-#0L8OA-KZ.I24?4
MQ=A(\8;7'&U+NP-R20UB2BSD$-W*$-#<0<7::5,E%^N]K&H>%3,3?<'4GDSI
M=P-+T7K5=9C\IEW7N3$M<HXE)_H.1HX2SR Z]<&;M 0S+_"QE9&P!#79H45Z
MQ<P:=&2)Y7H&9QB/I.#I"I/"H\HLREZG-8L7)K!6W7'6B4>&=4D@\4^.?_SQ
M6\I;_XA_(ZO6'/TQ4824Y(TFCIZK9/E43R9G#:C"2M)?Z-+""5JF.8^+/NCJ
M$QXTW4$;*FEZB-&X-#OMWU)N7BM@U@VU%1+-)'X'KC>K#_3Z47_DWC2EIRGT
M+FEBHY24V]*@+S1T&W9H[.4I0U,20DOK-E_6*")10_"@8Y!C<U4V-9\[EGOP
MH [IYV2P3OIDU5:358_[9-5N):N:#^:=G<$7O^N)WGE[R[N<1-/P#[M;WCJE
MUMR/[M;3/,%95D?$+X6%W\6*0VZFV]A$EY:P'_/6QHRWB6;^U9@A8Q55)M/,
MZ;+$%%)RI2699%C>=[MND"??WBU3SOHCUWQ0/N?8/?VV);GZ_G,VSTFRUU/L
MVQ8+,KMY^3;]S_9B&L_ -O_;AT5\+6G1V\R+XV?O,!_2KR&LX7L$%-YNZN!J
MOQ.W[*O37E^7EOJ-H\:W$X^W*J+0GR]80A7"N<V\*EB-?AUA'1&%<YLY34+O
M @M4WE=K?0QMT5>GO+9G>CUI4VIW92,Y$5PG%497N7<Z0V*'QFOI'KDJ-WG>
MW3-5?K6,F?T*]2MT%RO4JX^O=NO[%>I7J%<?_=;W*]2OT!=7'ULG0&\JCOO2
M\(7'/7QAJ_"%)SU\8;?@"U];'6=CR>W6\0VZZ/;UUUET.\%@YXY6J<K3B>$3
MBZB>>>5R&6;(UO[-R[,$CG$4# >OHC0/(E1.\*#S)%B'(-[;&6\$)M[EV7WS
M4H ,PX%-'ODV+;"K)T)&_U&&.8(R$S_*PKV>Z0$BOZG<BIDYX;6(\:\4,-90
MTI6^*A^D:@$1R(9 QNZO@D^0@^W5SC4BR]^$L7_C9U3AG2U3J8"HO$<8YMS&
M+8925+AD;2XZY'KD>@\A]J9/I?0SNZNMZ4X+PJJ(C+C&1CI/U(<BOW&FZ;>5
MH+2L&'WJ0GW*>92J<+8?R'Q"4AQM\>4]>?2TA=A6M<7Q/J\KCCRT>8/'W$&D
MJS#+_C+-]0.79IWJTJRNA:E^V%D?V$7%GHB5)M,T*#7=&][\"&@_M?B4U@W$
MH8G3-'-*D A8CZQRH,<\$3)_.LV0[$ZW1AD.J(88WAO'7N OHP(.\K^QZHO6
M T'RNOVGIO-BCGG,9L&7")I?&+IB;/$B15S$F46$I>LGTQ?;[/B47C/7XG 0
MAU>@98,TR<410ZX*% ^20*YJ3?P%%]-9!3C6-=LD$%JE&"(V*=2S*K+@N./1
MA>?%*SC+=HE[K82=N$ ;M0!Q0_C3:ZKA0\9_F$L9*[Y_++MQF2>Q,0',-JX4
MS=M+0+4<]MRI*J2XX^4X#!_A (S)M^\NSU^?[?44#E!EK;<2:W9%C1"Q:A*V
M:!3AE@VQG"QGDFXLD@NKM@BV'# M+A2E151TZX"OX')<$U)]\K4%4OOV7?N\
MD'?1ONO^[N@O<AG<J>(7]2S<!4P<8.J;;5XDJ?Y63A0[KTML%*1ZH9A"<73=
MJ5K9?@ Z90&H>%#=SWK[;$>,FW_\?G9Q>?[N[=O3\P^':*8==A'DK0=\%[D9
M[*#J0G*WE&_'&^M.1X[IU+L:_!TH[UU''UD&P!8EX"Z>JS>G:K/LS%K>I=1L
M=7.V-] C?[0?Y_"G,HYY=+]2Q _5B%,!;#O)NWI8OT(!N[.!?H6Z?@]VY0N)
MSZ;/;X[&6+&87I:^>EGJ55$O/HVFTF3/3:4/IAW>+YSJ.XIFE!=DYDKXE(\M
MID?,=SK2??08)M"1O42ZZ6>]L.Z0L/:ZKA>?WNSJ96E_9*E71;WX-)I=P9Z;
M76_]HLS@WZ_A"UD:>^^YC^J1].<,_0216(E\2KJLWLQ3;QIE85 @]3*"LO2_
M_)CX?87.F?"0.>%TE^D--PVZ3@M%D9=AZU)D1&YHXJPZ$:MF#P[&?-3;<[MT
M"GHEVHM/;\_=;_5N"P!MC[#9CZ*D,OH'C[:>T#TY'@Y.!<F/-1=<M42PPX;D
MS+.[K),TR[GU!W\EX 8W\=^5!.[6 9_!@;9ER=P/E7??M^6];&F_C?TV]MOX
M5[?Q2VS391B'RSGXE\_ZK=KQK3I[\)L?Q?T^[?H^8=C'#PH>"\=^]GS3MN]W
M]0Z5[5 ]!H?J599^A(U]$_IQF%'I59G?I>MT+Q-KYUXY;*?JU@.^ZR*WOQ:H
MNJM!;@N+NLTQG68225^EI>=[$SZ64SJ6_]6'./MA]:'O;6S [A!&-DSUGZK=
MQ-_^X\<?GCQY[KU-U5_7&$CV_;RVNT,E=-E5?_STN?=N20V+G^$\+L( _]'S
M/&Z5Y_&DYWG<+9['>W<:>JO4=0;_FI(G_.P=)*[/9Z*=F3AC%>;"D,$9*%*-
MWF,P+L?>-)J2(8==Z*/K$/^>M>):$2"Q6(9)[M,39H3"N ZE]_S$3SX2<TZ8
M74NZBX=AU6O_UPY: -O9R^U7!ZIK>T>+ _?3-=LOLVJM7?7EQ6!'-_ZK'%8O
M%_<ZK+=IL4%6Z+Y'5;G\D[3Q[I_ W2_WLI"._BW+\6,Y,HS.9@2?1(AE0)QV
M1*6"=D(^3\L8B;J\"(.BT2P2XKR$R4-OP%;0C'D\D'646;W@]L/J%=HN#&M;
MP/*["S<G'NBF*(Y B2!\NP\_[\P^[<VP>KDXO/!S[R?UP^I5P*YNP-&TVZQH
MK##XDJX3F1I(0=YM;HR]:4J?#5 B9BOC)2W++  'BBGVV\*IPBA,=.E^MD(2
M\XRKTB9E'B5ACMT0<#A(:BG] 8IHH>O6U$NZ.RJ@VS=!<O(\C:=C&MW<GWI)
MZOF*VC_'HCC3\P)[!(SM4CL>A:FW&W.='=)O2FU>@:5Y\.YH4A8U2F5K,+V!
MU@^KU\Z]@=9O=3^L7@7LS :L#V3OG(G6'=V>[FAT>^LX<0-2[JS0W39R>?\1
MY4\046ZZC;RCCD3S:,D$JJ8#R,QAFW^G&H)P6[1:*>_QX>+1MX51PCS\G?,M
MO#A_>?8I")?%<.!;S=0\ZJ7&QS?*O7,XJ]X3UA1V,X(HUQ1P=D.:3/KF$4.(
M;F*(8I&W"@QQD:!^28:#"M<(Z*62W"/PX^!O2:%:&[Q7?IW=>^U\[S=$B59]
M)CVH;'_Q- ==ZH!H6!.".5VD94+M+_E46V?9J D,F*RY)'H:H7Y8>^4!/?>6
M_A3#@AH43W#X'=V7W1GMUDI6>X'H!>(0R*3NW 5=4R3T?5\/M-5ZH,=]/= N
MUP-M.6)P"&&?I\?#P0?LTXR5@O-HF9L&\^*R'S"EP+Y%#-I#.&,O"2,)K;BQ
MFR3-*"0#7EJ$_2!5^A[>E,+? _B@RFVG&26^EUF4!-'2CSW07U&Q\E33\B/3
MIOSIM]0_? $Z2D5XY,/UT(\UFA'%F;$5 "?+TSRB,'&:R6#P;_01GS_!CN4"
MQIMAR"FS))4$E8-(*KATA/57,,EE%D[#(,QSF9&9],B;PNBD'?K2SS&HE86A
MMPK]+#_PJ-+=G=FMQSXH;0!R#GL:DLSCGE-/U.UU*+UO3?2UUH]NNF"-/LF6
MPFL'ZI#L\,;U6[7WON/]4B9O^PJI==0F=!^A_Y89V N(Y$M202E:^2E.8&F+
M(TJX-W9 !DWF!7,_N3)81;N/MO3JYM[=]'N_@ >MP%+"1WAY.<G)(]2)K2G"
M*/'3^-:"7ES K+"94NRB!MUD.MA!"S^"&S&<S3#%?PV.G'K[F-];-0/SN8^M
M!S"-1^!',-8P:P<#:5\$-5<9;5(N)ISBLVP\LN70?+-C_/:+Q20S)MCQ08G9
M 9Z<5R"QN'EH)HMS4=W4 ,PQPLDJ08[R($[STG@#]L& 3Q<@KN9DX/]1;_K\
M!OT)> AFGG/OD6XG]A033&S<@S,2ESEY";.&YO5)USG!+!7^FOP&>#\<DGP)
M)Z;,&4,,0N[#!Z<:])N7RV4L&&!T/<(B!0?YLC)] PW.^;35AG43Q3$?M!@1
M,^42?C9Q#UE$"Y,(1$=[W>"[+'V9"+HN:GCD;]WU5 ]*C@_P:)Z_'0[^.+]\
M>W9QX?WQR]F'LW<_5<_F&.7,+XMYFJ$[/BWAGKN"&P(>CHYUX)>,PH]R8>$G
M\7#ZN@A"/OP$:AY%"3\P!4'F5C <9Q@.0'X%[ ["!._$$TUODY?_F^Y<!_IU
M"%OPM;IQ]YT!?@-:[-EP\#]K_J.1-KH*K]_A7KS]SV].;KWP6[U--1*"AT;
MNF?>[J:V1>:>8M1^W>K3?UL"T#S]=F?3I3+")W<]Q%T2A!W=C.T:NKM'5L)+
MU?:_NRLL=ZXGM@KOQ[3MCF[][F[QP>N#RZB(]TPN=CNL>"_)U[M/JKUZ^?[7
ML].+L^'@[+?3\U^]4^_X_9N?P,!\_T\/'+#+7\#R?_<;?.;R[(UW^O:-=_9_
MSE[_CO]X^^[R_/49_>P?OY]=7)Z_>_OV]/S#F7?Y[DZ;G-W'FK3N[!K,T0\6
M,?&OF('M@4=_'7CTY'.!1_M/P4NC_>[5NS?_1#7XW2^7O_WZ\O\#4$L#!!0
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M02(V@4J'HWV(QBJ/3\<JAH'$";S@$[\5%:Y)6LZMV(:&:@RE]T SL<ZRI3$
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M\*.63=!9>Q@O2JP +"E>'>-O""';7O#&"2("8,0[INM5N7LUS%"F!1N/T^*
MWJ7;PN_O +K%I!<_P*0[,&&?K=SJWM1^0?N]2S?>T*FW_?!%V^[KUM%F:B5:
MK" 8*RN"O[0F5Y38Z"OGAVIWMB9P:#79<..75@:'C@T&3FA0O\/9W&.=. !&
MH-25<#-3Z]<!0]+HV=O\)H^R8EHLM;5J_0I1;#C/0Z*E5]OG?N_2C<;>ZM3E
MS6%[J>K5X0>N0[<P1=&!2:)*AJ$U29HB\0%E]8^P\"0;8U,4<:MTP T]?(S
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M^:2M:;2WN7.\99C=8\;CA!04]K+TRBXCKHR;,U90-\$)R;HC[=JQX91MR.$
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M[SZ\N:5%J0EME*1YBV[_?90RUUV<?,:07#"NBC%Q"R^#NB+5;!Q+HD@T80*
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MK$99Z\[ IEZGR#/D<4;BE,$XJBZ!KG\N*R0ZT.<R <TC+J/K'!DM"CX!'\(
M0*@:1AQ%^9=^;YYG256Q=0_OTS_T@F=E,4[B.8SC3,^0;PQ6<P(D0T?#[5:P
M!3^#![]L%G 0@>.S?J]EF=J:+$$3@_4"V?-"T1O/P#2)X:\XF8MYA/1,$F)S
M,C"">C&C[YG?P:_ _HC*]-]TQHCY\3MZ;,M/9PV+LZVO@84K9#)D$'@)&?I"
M&2YR-L<@G\JH7+2P!]H]UB?QC=GEHD*%),,#6Y:)-J<->WAG7CD^]+=!EFF9
M!O85C"/'V>.OZ J./>V%=A5HMXYZ%+\U2A+C^.'3@HX4D7_I^!+9)&E9GKN
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M4%&2,[(#>1HD<]GRI3\Y'GVR1X_/WBFJV%5%& ^GQ&76,?/M/. XXR=5OL[
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MY(=?M%%?]T<U4RO12(2;K;*"[G-K<ECO!+/EAVIWMN:066CM;LC12KK0X;S
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MK'RZ=W#)>64O2>MSXGUNV6DJI_(JC1RO(297FO$X'Q O?%EZ9=>:5\;=&RL
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M 4>AXP;8&6ETG,R63I:[_<W@\,AE.DI%)^16;=U?Y\F9SUIK,#-4EY"D.*H
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M^OO9X/A8_7WC2=Q$07&%C^[_\,(;I5D09KOC-([]>0Z24?WI$2DC+R_/-Q\
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M<<KU= H66X,\=38AG7@PG1G^LDC''\%2@,_I!<-9C$-\)DU"GE3Y!8]F 9,
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M\?$J9/X\7(#Z(0_# GPXU=_3#/D0/ UKN0!^$041\"%D']W.S54TOG(6 PN
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MZ_ MVY0O@@M^JYF-Z[O!8,C<7Y+8H@J**LTQ<@B1,N4U(*H7S7/G4Z\N>,1
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MJ]@Z;"EL=O*470CLN4@"JPS4GGGF;*6AEL9E<- 7U4#J[Z$%4ZOS;!2!GI&
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M!\0)YSQIH@+C.&4C]W,F!G=Y[7W%N40U?&<CCE)Q:32XPJK;MN)HOH0-K=U
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M!6R5))ZE-5\7*;#:#\B9E+I.$_=:^'?*VX _GJ<Y567J+&<>$+YL9X1O[TY
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MDWSIJ?2^8S$\)C%\!@+I' 72L6U92NW$,7<OUT?3"F[5-7DKN$A,%P%:,IF
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M8\ZVVUG@!_[+G7&>_O0C%P,3 H7R F(/KS3K661@@RK8!J2Y1)^WE]U.(X]
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MQJ$THCCZB+@4%!!/ G&Z<[:T +R9)1'KB:-P45U;RR&_8V["3O +OUAD6-$
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M5O;$+7V;&S8L5=9IVT,OYVR9'%',L<+T=L.?^ER@B4GQDF:'-V^I.@X$"+N
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MA(5Y7=<)7$?\,DT"+06M]L'Y^=N3(^H*+Y;UVMN#WR[W2]L(/U/Z.BSY>_H
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MXA'$/73"XZNPP FZA--LA"[A;D<#VAB\V>H+(D5UL[=HN[F6"IHHY@&PX"A
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MBN0P-:US=>:;GJ3"$=LHJ,%QD.=,G"->SB6FE#OQPV 6(?J1.UKV(I#KPW&
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M.*X%_JD=@M>NHT$DNBV7@<06JP1>V"!<?'-G\-; 3+==_*?R :N6Q/,J[5"
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MX\'AV?$_\&P_>'/U[NVK_P]02P,$%     @ \XGZ5*#X(BS\"P  3T,   D
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MQ#%<P=2?<BLMK;"J6[0Y;'MDK61-=A<0)I/[-%O!\&IBT6XM&>B*[E?,\HY
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MW?CX[FR^MTV_$,/^A@SZ11K_ U!+ P04    " #SB?I4<LCLL7P0  !Q30
M"@   &5X.3DM,2YH=&WM7.MST\86_^X9_P][F5XFS-@FCX9 DC(U26BY#9"2
ME#O]N);6]C:25F@E&_>OO[]S=O6P+0SMA= PX0/8TN[9L^?],L<_7[T\?]KM
M'/]\-CS%OX+^'%^]N#H_>WK\T/V+MP_]Z^-GKT]_%Y=7OY^?_7!O;)+\4.QL
MI[FXTK&RXI6:BS<FEDG//>B)2Y7I\3ULQ-:+O[KO2,0RF^CD4&P?B5R]S_LR
MTA-\#522J^S>T^/GKU]=-:'VQS+6T>+P8W!YK=5_*H?&O:?WDY%-CXX?$D#<
M^^)S8YSIR33_G @?/WMZ]GZJ1SKO=IX\&>P</WSV]+.AW\]-RE?P7T<FSTW\
M#;#A\V-,?$AF>!ET.\^TL8%620 (PR0Q!7_Z[K%XJ:-(FT2\41-M@8 *Q:G.
M5)"+U^,Q]B83(9-07&1Z)G,E+B(9J!BH]NA1@-4R%Q*?5:R+6.1&O)39M<K%
M;TFH,O%*VE"^$V^*2-G/*@8W0[Z2YU\2\3\*F^OQXG-B?B+C4:;#B>IU.R^'
M@Y[X3Q$MQ.Y^3^QN[^Z*^TDH[?1(>.$0#=GHB1=),!!;KX:7I\-?#\79J[?/
M'HBM^U'XKC!'?L/]C+\)DXE\JH1_>6+B5"8+__)!#U*1J"(K0??')BBL"KN=
MD3:Y"J:)B<QD(0*W381JIB*3DKPE1)V)2E0F<XAF3Z1V$4Q5J"(=]'5B4TU2
M2D(H(S%5,LJG^!;J0"=T@]R$<@&A=4(> D>(J,[%5%K!0H)G.LE-MR-QZE@G
M.M<S)>0D4RS98JX!4"98!,[D!>& @S0N;W/<>>SOG199 )B*]</*2 DS%GL'
M^[WM[6UAIS(#S_"$EE:TL40;2Y>.H7, %UQW.UL F&:@4 &="<5<9IE,<HL3
M1:1501 R9<8@*9Y(D=6:&CI--:6FIJ5*]K&G'SM-+)J:F)$F#L!E(<-0,WF[
MG0:*3"4F14C*K*TM%'V@)14%@ 9]WX!(D31>XFYX[,A.$)C()J7#K=AJB%"U
ML-M97UD*%F%3D;Y(Z6M)]/)*X-:GTW\@KIK,9!(RCTVBNAV&0V":6T0[QQZP
M)&#;IALOH4]KVT_09)P'V]N,7;>SD8132>*;"/5>98&N[@"0WQT,#AZ+%.SG
M4WH0[2@2([ R)H6!08==\-OD*,("N@$O4N])S<285<-=JS^5T;C;62B963'.
M3,RT#<DMX"P2%0F%&]PJ4_FEO?J7L.XF"0K(0I)'BVZ'C=5F;>PU=6#)!+;:
M/^L,8+OULZWF#WKB[=^CW57[]PF*LV[J6.0V"OVZ%?!'>YW])-UW!C7UL4U:
MQC:?;D?734>WXVW'!Q3[!DU'M\/H?6W3T>V4MD/<F8ZOB_+/@Q-(Q7^E3N:<
M]8G[,DZ/H"(#DAH9Y!SN6V:.>A]$A24>UGHA)_1W:0%*^V+O^/:%4>888()8
MVD)!38#@S)9!66G6*Z6JN"+(.$ 7X0I<, ?E1<(7NX2OAZ]@))10A85C_!J?
M%9!DNT1FN0+<[1#0Q.)E*A>D^V*T:.+BS&*)&/R,2AR^B/]Y7:+R^AXMB).
MS4UV34@%,M44YQ,>+B>(8.ZRU" YH,"HP$=;FN(@,I8V>=-?0X1T-REA GA0
MF%!*8>3(%+G/D!ZY#*DG;#'Z@URH)[)%(F+'I!^T!_86+ ;CLD5Y8K<3F,0%
MGW?:<"/:4(J7C*Q92EHHVPM4EL/(@><(B4@@JD!C/6R ]Y,3[)UX9[0#_F^(
M8):C"LJ=<-X<40LYVIDVA84@<=H4KN9-ME>EEBW^=O=@L+]=.UP6>/:DG 17
MOO*Y&F4%2=Z.2^</G&=&6HTM4%X**A3D/N"@KDB-R]4^J!G6.)+1TW)_12UV
MYRY&0'P).T' /Q8J(*_^6!)1!@(FBLR<T-J$XIT^W80^M8M[KS5:YX)'NWIP
MD!PM2IZV[=X:P=YR=!&6RRI@9$<;T'P6L ;".3.O9;X:L1[%T^[\8Q%PN6CU
M/J#(!R[T05@/@)03X#%G6,M>\1.J)J3VRR!@JR@TSF%G8*G*.HF=JFA<5N$<
M/&\E; X2.)P2\=QDL;CL[XFMYQI.^A6BO+V]O?[N_L&C)]L/FO9JC/>AJ%+)
M2P7W"&?FW?_9>]C+9,(WB4%T3=1IUFTNSTZJZ@S.=;Z4K=..2PM"%40R6[),
MGCC86FUYXK8X5UX1Q9N##7*!)+B11WZ$QH@$8AE2_H03@42L9,)LISS06(H1
M"DN5ME(^F\\1%Z1IY.O?B%)BOT!F.0LOQ\W5%=LY,Q!#T)MRZE:X?#<9^+*H
M*^I5RS(52?9G95Q2,VI);J@LX+*U5<Z>G0S$601HF4ET *JFNDZ5_RY:L5S0
M669$3E>%\$A3!:\ZDSKBU) RP/+X*@^?JY'5T%?XGFF>IX</'\[G\P%N-)B8
MV8#/([CLWQO B6>(M7*?K%!&(]H2FIXX/S\AX-_O;8L+9/!B.%-)0<CL9:%X
M'AF3]=A(_HY(L_X$F\@1((Y)IY1D \36[L[N _%X_U%__V!GAX)&*@KHB-Y5
MYL;^. WF@1F 1-^ QP+2_^KWQ7.MHO 0])NH(P!X5U I'QM%O^\;LL>G+]Z6
M:*RTY!ZE^9$8F0P&M'KV#.0"C0?[H( UD0YQDZOAL_,S<7)V?GXQ/#U]\>JG
M'^YMW^/OEQ?#D_*[/\/#"Q ZR-0"E_+3$:0\S*=TJ^U_M[5SKMZ4,&8(#W4@
MHY*HN4F7J1RI,>\X+7<T0-<$NSJE-O0;^HMN@']!BQ:RC#(EK_LNW3J$L2!:
M-IN9CQQZWR(5&C+TD(3(R<V7T8@2H=N@<Q\OZC<3E4^+R-JBF"II<>&$*V&V
M1DNPBY*,,MR&+P!M1,^YFSK/J>O#'W+!^% 7I-<C':[$PEDFUJ79W4YB<@)K
MHIGWLL4H@LLRS;8TYR:T<*3@<1IGUC=M!#-##@3$SI.]O1[=LLQWEF*9I>55
M-Q,N+!,2WA :0Q4/=N=-_QO)N85KAX?,*&R(%E1U-W9I#?DSAZR@*K>[..""
M92:J MG?$DW$NJ03J&P1*$CN<B"8?#3*X,I&TL08>5OLRLA5Q65I:P;K#D:Y
M#H /"%9HQW%_$4P;8"E,;J/$[?> _VR4>;R".MC+/*08R*ZVLE=J$$LYB2WY
MSEI,T:*0'Q*I9A0)^S)S:IB3*8,$^P;0LA5JC=S_?NKX27F?JS]LL(9_(:5;
M.Q%QS+0N3;B"#A[O[(M0+KP=YD(G%61L3GIJ,H<YVZHUM:O)VY(D2:[W0FV1
MJ_!GLHUPV:Y/)L>P=2[!(NM)O;U9R2<\^-[AQ);+/SKP:'K2N>6<^XP+&'Y*
M""&!=6IVI\9?/ [0E@,!R\F=(F\/J04OR$\@SW$]6.[1L=21(%ERTF3?.8(.
M="[+NG1SU:A@-BYYH![ 9OX %B$2;A(<TEX(RGAM1RE9SLI39Y-[ 7_@M0VU
M*XACR7RJX1;8-S "O174,C<@,S<%_!S.+!)X"<@<::_)RG2VJ1@LMN\*D'X,
MB6<HM4]?\3;NZ@MW_@9,[\2Y!66D:$C))ID!>2FA,-DAL3-7GWF6;DA]EFZG
M9>CL1N;K;NJ:-S@R>"-7:IL@;9\2I YRZ\B?2.&'8WCGPCFO_W/DK]M9G?D;
MB&HRT1>7,C,"C42J4T"@28DB3=D/AUDQ*0]FKUL%PP$60BYABBA8H!X'J/VG
MLSP2-&+'/E516G90+1O,%"N4+STFU("2S \&.3=91!%SF;'P676CT$\F<J41
MY],$1-;G$A\G3;"$< L]<7%U>>K*8293 ZKJ-@?==$)U2.DG^5+G0F;::L0!
M\_E .<+<3%7J1@3R&S.+8"?"V[!_;LPU-Y(ORX#PSB[^DZ_4%KEQ71K6BEH#
MS-3(,;4.\EV&L/JZH<-EI$[F@UH3O@/2K#RLUARN*&3S>;@[P]D03NB*O,A\
MH&\I*/(/4I7QD31T)8:(!AN[7=P$VY0L/1T+W!@9))MPFH4HR_XKMUG"A(>%
MJ\L-Q$]N@H.J(Q^A49,F_B =XBW"P;JU1@,E0&P5%-*B6+OY<F##!0M;S1A'
M,K$]7]?QS_QLB&T,MOLWH0&9*11W*\I]]<"RH>F3</5Y8]RD?-7M^'>C(IRH
MW*YNL>3NBF@=%K)('5,I:/4%E9,#:==!^8F;U<?(H.$N4P)5X=1RTWI9;YT>
M([A3")-MOIK)3$OGT, +)C<<7^C8F$XS: ;T" N7F>;6T#2D6]+M^"2"X_>E
M,0Y7$0206HZA=T64<TFM![U#6M%SV06?%',OR$_Y9)SD!%-"/&3_^2&YHWP+
M,LY^G4B10E60>3?DOEZ\U"(L$Z12_2:2BX""R37&6B=U7BBDOPTK1TXR3;2K
M=W$KCO5T '= ]-RD*Y3$28JR?(_-GTDDAG[+B6_?U;5=:6T1^_(&MT)'BS6-
MJP:,ZRX>5QYKB%3KS)&>59Q@)B!LX?R3!!92$4758)KQ]E'%J0MPO#1LNIKE
M6A2!YQJ.DX9NAXP/5[(J#O0$S100RR(=:S?DU6N=W.)(KY[>:L1BIFT(Y<.-
MY+K*M%: .O)EKP1TCF7SY*IP=-0ZFNP4EZK73D4VS,A!\PJ:7=.1SA?,FDRQ
MKM#CR$\]>8GP(\LG?I+._4#+8> !-$IU')E3D:$($.E;J@M!N!&D]W&VT,1H
MF238EQ@=DBS!EBW!<A5JIV[\?":C J SY45K50CHMT"L7(VPW(/40,?5['EL
MT. ]#?\A\)WIK+!BZ^3UVQ>G_9TG/'>PD@10UWEBRDX!:2"UCUV83R4TDD]_
MSD292293V!\J7%#D[\:O@*N)D134>)0'MIQ7$9-3B(2F*HE>W0Y2$<I2G$',
M),U.E5.-WM-[K\QM<THB5'@$:D2^5+<1]<:A\!105&VGSGJFAFV+Z^@3-D"%
M1T+'5%$):/3#%6;&BD^!>)<'X/&G'T;V%I+'TL=MR)')2G_@KM?,M_R8!*C-
MZ2!)4ZAIN&W]"-?RI]@';I9\#)=U$D5R2=H[H1)TXG\'QJL@:JS)?F)_G0+K
MDNH/\1R@@C-G:CBH@74#@AMS;QE.K6&Q"RPAL<27^214"6I@(;\4R5&88H^J
MDDB;','>%F2].&9S&#0H1L!E [RP 5?A^1=:*ZSPQ7N=A3RNHHG>;JRG+ <C
M5$)\RW=)))_H"N>IRC79VS7^>(MSK?B' $%!)6L_'$8% !A>(GAI)AL;.83U
M$X[D= (E(GB_R/<OJ)W@S /6KA*GY$/3_U*PPK_:H!\6ND!S2 DT#+VMK:__
MI9X+;]=]" ZWUPY]^MT@^QHBD_^)#?Q0ZB>"/4H]JGC _)&P\.]EUG =X\8T
M8_D7!JO$UN79R8,F6BV.HML9)@GYWC>*JAK5K-?.=O\7Y\HAI[\68#/U.?PJ
MVUSV:U4R83I%4L=65-/:9<W60,$GLOSI"74'K"L7;PCY>?B'2;SBOA.D5LUB
MQ7INPIR9XXQ>V?64C?847 7RG;LBQM<J1R.'?^&;B#1]S1-8-U.BN+V5B,^)
M^5L9Y=3RO: ?[MTJS'\YN1Q278M^L3&!Q2%K5R2^JV-OU55V=W8'CY\\&NSL
M[G]_JQ"?L?3\>!U82;7@6X7[[326+^E7DG>6\BM@/HR0EU '^=+8VV5>ODE+
M^>C@5B&.],S:;\A0;I[DWCT2KUTM\%"<2YO?#7;_DT::O[0/?4C_99K[/]3H
MOUK['U!+ P04    " #SB?I4!"SJ3$0;   HY@  "P   &9O<FTX+6LN:'1M
M[5UK5QK+TO[N6OZ'?CE[GZ7G<!U 0(UG*6(VWB-J3+ZXFIE&)@XSD[DHY->_
M5=USA0'1@!$E>\?(3%^JNJJ?KJJN;K;_U^]IY(%9MFKHGU*%;#Y%F"X;BJK?
M?4JY3B=33?UO9W5EN^M .2BKVY]27<<Q-W.YQ\?'[&,Q:UAWN4*M5LOUL4Q*
M%-KL)Y:3\OE"[N;DN"5W68]F5-UVJ"ZSH)*FZO?CV\>W0=&VI:FQHOC$[Z28
M&VD:WBIAA6CAC9QX&2OJ)!8MBZ*.7U2UC9)4J$RB0Y0(*O3'E2T@S< AN]F[
M. Z+.\GEPZ(YQZ*ZW3&L'G5 AMA2.9.7,M)&I)&,S>180_ Y>V<\/-E.-5,L
M^.V,""?.*;YN4SL8<84-#;??)[R &I+D%[189VRS&SEXZQ=T[<P=I690N$/M
M-B_HO8BU"L\L0V-V8FG^)E9<-ES=L0;)%'LO8Q5LRQEM&A[&"C5.K_>"4DR'
M>:;*6=GH\4+Y"A3D<XM1!?XE^&?;41V-[6SGQ+_PML<<2K")#/OIJ@^?4G5#
M=YCN9"X')@RV+#Y]2CFL[^3$%,QAO9S7[/;_93+D0&6:LDE:S-DBI[3'-DE?
MZ6^1YC[_Y38O[=U>M?Z6]C_O[I[#/T@>R62FK5W,WR*GMQ$.;WT.G]%,J134
M>DGU\OXM ]T"\N'_A@X#.*C#R%A4:^H*ZQ^QP6T>_E1K^:I4>$Z[M4B[NSVF
M*_#7.=#HW6V':C9[1E,;.,S[MX5;#Q9$F_#H.6U(MZTNM9A]*]UR%!2-V/S9
M<]K91UK.O;:*(R2-;;QM* -B.P.-?4IU0/LV22%O.N12[4&14_9(+HP>U=/B
M01H(L-0.UW-%??#K*:IM:G2P271#9_REVM]$A646S@3^2544IO-Y@1^AX*G;
M0_42*M]W+A W#BRCA[J2R5<RDN08X>\IH@/7T!53-Q.U(;43JL-V+M;%;'J-
MZ4IJARM+8D>Y&+O8+Z >LV A9K8H@>"Z:?-5$P@@?"G<['+DA$G7SOC3)=NW
ME93WV@%\^)2RU9ZI,8$)7E?QQD5WMN%:?F]0C,M^TV.9J,I$EGWL\JLQ/MK!
MT^"YJN";CLHLPEEAB4M2O7D4E\QPY;"[7&)_7F\FC*^AC%(!=H'E[%.'[80L
M^"V%[T:J@2C'5/+?#),5(\!_Z UI?)Q=716##--N9#1[C-JNQ7:\^;D)9?S&
M_%?Q+K"U,>V+R3ZV"V\0>*$7]Q&"RD@_   @QM&QQ;I\0E#'L"*OGS\&PS0F
MM1KI=)_I1D_5G^KVZ7$9[C>I8?]];!1&!M2;H9'Y*.#!Q\;M'-2'?_&_;?.Y
M.+Q%4/LR5%/O]$TBP\QAUA;I4>M.U3..86X2:")XT#8<Q^CQ9ZF=?_^KL)'?
MVLZ9.Z_>==!I9%V[<#66.:=W?/F-+BV/JN)TD:#\WZG8B[9AP1"*KO8T*M^3
M$M!L&YJJ;!'OI=^M>%_(EL,2R&?&5G_!0EJ(C@>*P_L9(2\7H^_U1\PVJ1[M
M+].A/56#!?>)'J-<QL2.#>[\CO0%F9P^DD]B;4945SG_[9VKT^9E8W]UI76Y
M>]EH;>?:.PO(1*M1O[IH7C8;K=65W=-]TKBI_[-[^KE!ZF<G)\U6JWEVNF"<
M21YG7ZG=5?4[Q]#3JRO[V7J62/ERJ;9@W"SV%#DXNS@!2GF3N'2C7U#+Y[F[
MD\GL&[*+UBOZF;=RX)F%/MJO^[-KNURK?6Y5BM#>[YK+T?Y2.]7,T;"M'(SP
M4D5>AVI0D;IK@:O@K*Y<,-.PG$4<>^#BW+5LER(;C@'E9(QPD4*1&!8IE->4
M=6)TB--E"\H=,.1:JJ,R>W6ET9>[5 >K8U=VD*M"K5A:1+86=L*@*[BZ B,O
M)@Q9PP<H"4;!SF>V0]@#]$LL_IHIZYMD&( K0P!\SAW)AG SDY'X[/R,'G8+
M/[JGI1<CL8C]?DJI?6=3@9YZ4*^KT,$ *&=Z$E+'"$OM'+K:@$A2FF"K2_#^
M\^O[L&+M>8HEPF$7[$ZU,>KO8'@P6:_*W\Z+'>>\U.NS&:SP2?VF=AHB:KRZ
MLJ<:MJSRP%2:-'4Y^XYT"*2QUNA3&98@' _" <(?!T)M8IM,QO"60E00F6,3
MP'' !VM]$;E-GC$.;6L,>M,T>"[S'<9\BG\VJ:+XGY_-6<3A#_QXV= T:MI
MD/^;"$9M.];S.P#U=%29:OYX@>OMA[:V'>7WVQ.>>\!(4?K[%;1Q&!L:,6R
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M)S$D_P]02P$"% ,4    " #SB?I49+ONZ2H#  "H"P  $0
M@ $     96YV8BTR,#(R,#<R,BYX<V102P$"% ,4    " #SB?I4R@L$%/X*
M  " A@  %0              @ %9 P  96YV8BTR,#(R,#<R,E]L86(N>&UL
M4$L! A0#%     @ \XGZ5%G)"<]5!P  TU<  !4              ( !B@X
M &5N=F(M,C R,C W,C)?<')E+GAM;%!+ 0(4 Q0    ( /.)^E0HS18L?+
M &9R!  *              "  1(6  !E>#$P+3$N:'1M4$L! A0#%     @
M\XGZ5&W/NSN0K@  !CL$  H              ( !ML8  &5X,3 M,BYH=&U0
M2P$"% ,4    " #SB?I4<!XH.5)>  "2!@, "@              @ %N=0$
M97@Q,"TS+FAT;5!+ 0(4 Q0    ( /.)^E3?#":VCP<  / S   *
M      "  >C3 0!E>#$P+30N:'1M4$L! A0#%     @ \XGZ5*M%\7S?0
M4+<!  D              ( !G]L! &5X-"TQ+FAT;5!+ 0(4 Q0    ( /.)
M^E3#])I='D0  (6] 0 )              "  :4< @!E>#0M,BYH=&U02P$"
M% ,4    " #SB?I4F$N@;#I(  "VO@$ "0              @ 'J8 ( 97@T
M+3,N:'1M4$L! A0#%     @ \XGZ5%;OI8DZ2   MKX!  D
M ( !2ZD" &5X-"TT+FAT;5!+ 0(4 Q0    ( /.)^E2!.]#YTDD  !CE 0 )
M              "  :SQ @!E>#0M-2YH=&U02P$"% ,4    " #SB?I4H/@B
M+/P+  !/0P  "0              @ &E.P, 97@U+3$N:'1M4$L! A0#%
M  @ \XGZ5'+([+%\$   <4T   H              ( !R$<# &5X.3DM,2YH
M=&U02P$"% ,4    " #SB?I4!"SJ3$0;   HY@  "P              @ %L
D6 , 9F]R;3@M:RYH=&U02P4&      \ #P!@ P  V7,#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
